



Tuesday – Saturday, November 18-22, 2025

VEITH
VASCULAR ENDOVASCULAR ISSUES TECHNIQUES HORIZONS



Symposium Chairman
Frank J. Veith, MD

Executive Co-Chairman
Enrico Ascher, MD

Symposium Co-Chairmen
Kenneth Ouriel, MD, MBA
Sean P. Lyden, MD

Sponsored by



www.VEITHsymposium.org

PROGRAM OUTLINE AT A GLANCE

TUESDAY PROGRAMS

PROGRAM A (SESSIONS 1-8)

7:04 A.M. - 5:56 P.M.

Progress In The Treatment Of Diseases Of Heart Valves And The Thoracic And Abdominal Aorta

Location: Grand Ballroom East, 3rd Floor

PROGRAM B (SESSIONS 9-16)

6:47 A.M. - 5:56 P.M.

Progress In Wearable Remote Measurement Devices, Vascular Robotics, Guidance Systems, Laparoscopy, Simulation And COVID; New Developments In Carotid Disease And Acute Stroke Treatment; Abdominal Aortic Branch Treatment; New Technology Concepts And Artificial Intelligence (AI); Vascular Surgery Identity, Training, Manpower And Mentorship; Updates On Open Vascular Surgery And Treatment Of Aortic Coarctation

Location: Grand Ballroom West, 3rd Floor

PROGRAM C-1 (SESSIONS 17-18)

7:00 A.M. - 12:00 P.M.

Management Of Pulmonary Embolism: The Ultimate Approach

Location: Trianon Ballroom, 3rd Floor

PROGRAM C-2 (SESSIONS 19-22)

1:00 P.M. - 5:59 P.M.

Interesting Topics Related To Lower Extremity Occlusive Disease And Its Treatments

Location: Trianon Ballroom, 3rd Floor

WEDNESDAY PROGRAMS

PROGRAM D (SESSIONS 23-30)

6:52 A.M. - 5:49 P.M.

Progress In Lower Extremity Occlusive Disease And Its Treatment

Location: Grand Ballroom East, 3rd Floor

PROGRAM E (SESSIONS 31-38)

6:52 A.M. - 5:46 P.M.

New Developments In Medical Treatments And New Drugs; Progress In Anti-Atherogenic And Anti-Hypertensive Treatments; Management Of Endoleaks; Recorded Live Cases From Leading Centers In The US AND EU; Issues Of Interest; Outpatient And Office-Based Vascular Treatment; Topics Related To Government, Reimbursement, The SVS, VQI, FDA, Guidelines, Trials And Evidence-Based Medicine

Location: Grand Ballroom West, 3rd Floor

PROGRAM F (SESSIONS 39-46)

6:50 A.M. - 5:59 P.M.

More New Developments In Thoracic Aortic Disease, TEVAR, Aortic Dissections, TAAAs, Juxta- And Pararenal AAAs, Parallel Grafts, Fenestrated And Branched EVAR (F/B/ EVAR), Multilayer Bare Stents, Infrarenal AAAs And Standard EVAR, And Hot New Aortic Topics

Location: Trianon Ballroom, 3rd Floor

THURSDAY PROGRAMS

PROGRAM G (SESSIONS 47-54)

6:50 A.M. - 5:55 P.M.

Exciting New Or Rediscovered Techniques, Concepts Or Devices; Progress IN F/B/EVAR And Parallel Grafts For Complex AAAs; Tribute To Our Military; Progress In The Treatment Of Ruptured AAAs; More About New Devices, Techniques Or Concepts; Progress In Radiation Safety

Location: Grand Ballroom East, 3rd Floor

PROGRAM H (SESSIONS 55-63)

7:00 A.M. - 5:59 P.M.

New Or Improved Devices For: Standard EVAR And More Complex AAAs; Repairs OF TAAAs, The Ascending Aorta, The Aortic Arch, And The Descending Aorta (TEVAR); New Devices For Treating Lower Extremity Lesions By Endo Or Open Techniques; Update On Endoanchors And Fixation Devices And New Or Improved Devices For Endovascularly Removing Clot And Occluding Blood Vessels

Location: Grand Ballroom West, 3rd Floor

PROGRAM I (SESSIONS 64-73)

6:50 A.M. - 6:00 P.M.

Superficial Venous Disease And Venous Ulcers

Location: Trianon Ballroom, 3rd Floor

PROGRAM J (SESSIONS 74-78)

7:45 A.M. - 12:15 P.M.

Multidisciplinary Stroke Prevention And Treatment

Location: Americas Hall 1 North, 3rd Floor

PROGRAM K (SESSIONS 79-84)

7:40 A.M. - 6:00 P.M.

AIMSsymposium At VEITHSymposium: Topics Of Interest To Interventional Radiologists

Location: Americas Hall 1 South, 3rd Floor

FRIDAY PROGRAMS

PROGRAM L (SESSIONS 85-92)

6:40 A.M. - 5:25 P.M.

Progress In The Prevention And Treatment Of Spinal Cord Ischemia (SCI) With TAAAs And Complex Aortic Aneurysm Repairs; New Developments In Carotid Artery Disease And Its Treatment: Mesh Covered Stents And TCAR, Cognitive Changes, Timing Of Treatment, Medical Treatment, Update On Carotid Trials, Treatment Of Asymptomatic Carotid Stenosis (ACs), String Sign, Carotid Clot, Significance Of MRI Lesions, Carotid Controversies And More Carotid Topics; Other New Endovascular Treatment Concepts, Techniques; Update On Percutaneous Access Closure Devices And Wound Care

Location: Grand Ballroom East, 3rd Floor

PROGRAM M (SESSIONS 93-100)

6:58 A.M. - 5:00 P.M.

New Developments In The Treatment Of Popliteal Disease; Advances In Treating Arterial And Graft Infections; Advances In Vascular Imaging And Guidance; Augmented Reality And Artificial Intelligence; Recorded Live Complex Endovascular Cases From Münster, Germany; New Developments In Thoracic Outlet Syndrome Management; Advances In Medical, Drug, Anticoagulant And Rare Vascular Disease Treatment; And Advances In The Treatment Of Vascular Trauma

Location: Grand Ballroom West, 3rd Floor

PROGRAM N (SESSIONS 101-111)

7:30 A.M. - 5:39 P.M.

Deep Venous Disease

Location: Trianon Ballroom, 3rd Floor

SATURDAY PROGRAMS

PROGRAM O (SESSIONS 112-115)

7:00 A.M. - 12:10 P.M.

Topics Too Important To Miss In General And In The Treatment Of Lower Extremity, Aortic Or Carotid Disease

Location: Grand Ballroom East, 3rd Floor

PROGRAM P (SESSIONS 116-121)

8:00 A.M. - 3:55 P.M.

Improving Outcomes In Hemodialysis Access

Location: Grand Ballroom West, 3rd Floor



SYMPOSIUM CHAIRMAN

Frank J. Veith, MD

EXECUTIVE CO-CHAIRMAN

Enrico Ascher, MD

SYMPOSIUM CO-CHAIRMAN

Kenneth Ouriel, MD, MBA

Sean P. Lyden, MD

SYMPOSIUM MANAGING DIRECTOR

Jacqueline M. Simpson, BBA

SYMPOSIUM ASSOCIATE MANAGING DIRECTORS

Steven J. Feld, MSW

Mel Loftis, BBA

ASSOCIATE PROGRAM DIRECTORS

Enrico Ascher, MD

Mark A. Adelman, MD

Jacob Cynamon, MD

Sean P. Lyden, MD

Kenneth Ouriel, MD, MBA

EXPERT PROGRAM ADVISORS

Gustavo S. Oderich, MD – Aorta

Brian G. DeRubertis, MD – Lower Extremity

Marc L. Schermerhorn, MD – Carotid

Caron B. Rockman, MD – Medical

ADVISORY COMMITTEE

Ali F. AbuRahma, MD

Mark A. Adelman, MD

Keith D. Calligaro, MD

Timur P. Sarac, MD

Jacqueline M. Simpson, BBA

Carol La Mantia Veith, RN, BA, MA

COMPONENT MEETING LEADERS

Jose I. Almeida, MD

Allan L. Brook, MD

Jacob Cynamon, MD

Steve Elias, MD

Peter Gloviczki, MD

Lowell S. Kabnick, MD

Larry A. Scher, MD

Anton N. Sidawy, MD, MPH

Thomas W. Wakefield, MD

Haimanot (Monnie) Wasse, MD, MPH

LIAISON COMMITTEE

Evan C. Lipsitz, MD, MBA – Virtual Library

Mark A. Adelman, MD – Virtual Library

Chang Shu, MD – China

Wayne W. Zhang, MD – China

Zhong Chen, MD – China

Wei Guo, MD - China

Weiguo Fu, MD - China

CONTENTS

Program Outline At A Glance.....	Inside Front Cover
Acknowledgments.....	4
Fellows & Residents Career Development Program	6-7
Special Non-CME & Other Industry Events.....	8-10
General Information	11-13
Accreditation	12
Faculty Disclosure	13
Hotel and Travel	13
Agenda	15-115
Faculty Listing	116-126
Registration	127

ACKNOWLEDGMENTS

The Cleveland Clinic Foundation Center for Continuing Education and VEITHsymposium acknowledge educational and in-kind grants* in support of this activity from:

Abbott
BD
Bentley InnoMed GmbH
Boston Scientific Corporation
Contego Medical
Cook Medical, LLC
Cordis
Gore & Associates
Shockwave Medical, Inc.
Siemens Medical Solutions USA, Inc.
Terumo Medical Corporation
Terumo Medical Corporation*



**ASSOCIATE FACULTY PODIUM
PRESENTATIONS COMMITTEE**

Enrico Ascher, MD
Zach AbuRahma, DO
Sateesh C. Babu, MD
Venita Chandra, MD
Zhong Chen, MD
Anahita Dua, MD, MS, MBA
Alex Fairman, MD
Daniel K. Han, MD
Jan M.M. Heyligers, MD, PhD
Anil P. Hingorani, MD
Paulo Eduardo Ocke Reis, MD, PhD
Caron B. Rockman, MD
Jessica P. Simons, MD, MPH
Sherif A.H. Sultan, MD, PhD
Wayne W. Zhang, MD

LATAM COMMITTEE

Tulio Navarro, MD
Rebeca Reachi Lugo, MD
Jorge H. Ulloa, MD

**CENTER FOR CONTINUING
MEDICAL EDUCATION**

Steven M. Kawczak, PhD

SPECIAL CME, NON-CME, AND INDUSTRY SPONSORED EVENTS

(PLEASE VISIT WWW.VEITHSYMPOSIUM.ORG FOR AN
UPDATED LISTING OF THESE ACTIVITIES.)

TUESDAY, NOVEMBER 18, 2025

GORE & ASSOCIATES

Lunch Symposium: 2026 PAD CPT Code Changes Outlook Lower
Extremity Revascularization, How to Prepare

Date: Tuesday, November 18, 2025

Time: 12:00 P.M.

Location: Mercury Rotunda & Ballroom, 3rd Floor

WEDNESDAY, NOVEMBER 19, 2025

GORE & ASSOCIATES

Lunch Symposium: Expanded Possibilities in Thoracic Branched
Technology

Date: Wednesday, November 19, 2025

Time: 12:00 P.M.

Location: Mercury Rotunda & Ballroom, 3rd Floor

INTERNATIONAL SOCIETY FOR WOMEN VASCULAR SURGEONS

Date: Wednesday, November 19, 2025

Time: 7:00 A.M. – 9:00 A.M.

Location: Murray Hill Suite East, 2nd Floor

MEDTRONIC

Lunch Symposium: Deep-Dive on DCBs in PAD: Expert Insights on
Sustained Efficacy, Safety, and Future Directions

Date: 12:00 P.M. – 1:00 P.M.

Location: Petit Trianon, 3rd Floor

POINT - COUNTERPOINT: CONTROVERSIES IN MODERN VENOUS DISEASE MANAGEMENT

Date: Wednesday, November 19, 2025

Time: 10:00 A.M. – 12:00 P.M.

Location: Americas Hall 1 South, 3rd Floor

PHYSICIANS AS INDUSTRY EMPLOYEES

Date: Wednesday, November 19, 2025

Time: 1:00 P.M. – 3:00 P.M.

Location: Americas Hall 1 North, 3rd Floor

SHOCKWAVE MEDICAL

Lunch Symposium: Data & Debate: Cracking Solutions for All Your
PAD Challenges

Date: Wednesday, November 19, 2025

Time: 12:00 P.M. – 1:00 P.M.

Location: Sutton Parlor Center, 2nd Floor

WORLD FEDERATION OF VASCULAR SURGERY at VEITHsymposium



Moderators: Palma M. Shaw, MD, MBA, RVPI, Wei Zhou, MD and
Enrico Ascher, MD

The World Federation of Vascular Societies (WFVS) exists to improve
the quality of care of vascular patients worldwide, by providing a forum
for the international exchange of scientific and educational knowledge
related to the diagnosis, treatment and prevention of vascular diseases.
The WFVS is composed of 8 member societies consisting of federated,
national and affiliate vascular societies.

Date: Wednesday, November 19, 2025

Time: 9:15 A.M. – 10:55 A.M.

Location: Murray Hill Suites East, 2nd Floor

SPECIAL CME, NON-CME, AND INDUSTRY SPONSORED EVENTS

VVV@Vs - Venous Venous and More Venous® WORKSHOP at VEITHsymposium®

Workshop will include Video Case Presentations, Lectures and Demonstration on vein management by experts, plus hands-on opportunities where participants can rotate through multiple training stations staffed by professionals to assist with your experience.

Date: Wednesday, November 19, 2025

Time: 1:00 P.M. – 6:00 P.M.

Location: Americas Hall 1 South, 3rd Floor

THURSDAY, NOVEMBER 20, 2025

GORE & ASSOCIATES

Lunch Symposium: Complex Aortic Repair: Integrating Evidence-Based Techniques and Clinical Experience

Date: Thursday, November 20, 2025

Time: 12:00 P.M.

Location: Mercury Rotunda & Ballroom, 3rd Floor

J. LEONEL VILLAVICENCIO LATIN-AMERICAN PROGRAM at VEITHsymposium



Course Leaders: Enrico Ascher, MD (USA), Jorge H. Ulloa, MD (COL), Rebeca Reachi, MD (MEX), Tulio P. Navarro, MD, PhD (BRA) and Frank J. Veith, MD (USA)

Five-minute presentations in English, Spanish, or Portuguese. Best Presentation Award will be given.

Date: Thursday, November 20, 2025

Time: 1:00 P.M. – 5:00 P.M.

Location: Murray Hill Suite East, 2nd Floor

MEDTRONIC

Lunch Symposium: A Legacy of Proven Durability

Date: Thursday, November 20, 2025

Time: 12:00 PM – 1:00 P.M.

Location: Petit Trianon, 3rd Floor

FRIDAY, NOVEMBER 21, 2025

FELLOWS & RESIDENTS CAREER DEVELOPMENT PROGRAM

Date: Friday, November 21, 2025

Time: 8:00 A.M. – 4:30 P.M.

Location: Americas Hall 1 North, 3rd Floor

J. LEONEL VILLAVICENCIO LATIN-AMERICAN PROGRAM at VEITHsymposium



Course Leaders: Enrico Ascher, MD (USA), Jorge H. Ulloa, MD (COL), Rebeca Reachi, MD (MEX), Tulio P. Navarro, MD, PhD (BRA) and Frank J. Veith, MD (USA)

Five-minute presentations in English, Spanish, or Portuguese. Best Presentation Award will be given.

Date: Friday, November 21, 2025

Time: 8:00 A.M. – 6:30 P.M.

Location: Murray Hill Suite East, 2nd Floor

SPECIAL CME, NON-CME, AND INDUSTRY SPONSORED EVENTS

MEDTRONIC

Lunch Symposium: TBA

Date: Friday, November 21, 2025

Time: 12:00 P.M. – 1:00 P.M.

Location: Petit Trianon, 3rd Floor

SATURDAY, NOVEMBER 22, 2025

GORE & ASSOCIATES

Lunch Symposium: 50 Years of Gore Innovation: Driving Dialysis
Excellence with KDOQI

Date: Saturday, November 22, 2025

Time: 12:00 P.M.

Location: Mercury Rotunda & Ballroom, 3rd Floor

THE VASCULAR WORLD
IS COMING TOGETHER IN NEW YORK
IN NOVEMBER 2025 . . .
AND YOU'RE INVITED!



VASCULAR FELLOWS & RESIDENTS CAREER DEVELOPMENT PROGRAM

An Interactive Symposium for Vascular Surgery Fellows and
Residents Preparing to Enter the Job Market!

Friday, November 21, 2025 • 8:00 a.m. - 4:30 p.m. • New York Hilton-Midtown, New York City
Americas Hall 1, 3rd Floor | This is a Non-CME activity.

VEITHsymposium provides vascular surgeons and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques.

We are pleased to offer the 10th VEITHsymposium Fellows & Residents Career Development Program this year. This Program is dedicated to bringing together the June 2026 graduating vascular trainee and their potential employers right at the time that the trainees are looking for their first post-training position. The Career Development Program will also provide an environment for career counseling and easy interaction between vascular trainees, senior vascular specialists, and potential employers.

WHO SHOULD ATTEND:

- Graduating Fellows and Residents in Vascular Surgery
- Attending Vascular Specialists seeking new opportunity
- Potential Employers and Vascular Career Recruiters of Vascular Specialists

ACKNOWLEDGMENTS

The Cleveland Clinic Foundation Center for Continuing Education and VEITHsymposium acknowledge educational grants in support of this activity from:
W.L. Gore & Associates, Inc. and Medtronic.

Join us in New York City this November.
Register online for VEITH at: www.VEITHsymposium.org

Program Director:
James F. McKinsey, MD
Program Co-Director:
Anahita Dua, MD, MS, MBA

Vascular Fellows & Residents Career Development Curriculum

8:00 – 8:05	Welcome <i>James F. McKinsey, MD</i> <i>Venita R. Chandra, MD</i>	11:21-11:29	What Societies Should You Join Early In Your Career And How To Move Up In Them <i>Rabih A. Chaer, MD</i>
SESSION 1	SELECTING YOUR FIRST JOB	11:30-11:38	Balancing Your Practice With Industry Relationships – From A Physician's Viewpoint <i>Peter A. Schneider, MD</i>
Moderators:	<i>James F. McKinsey, MD</i> <i>Anahita Dua, MD, MS, MBA</i>	11:39-11:47	Building Collaboration Between Specialties <i>Robert A. Lookstein, MD, MHCDL</i>
8:05 – 8:13	What Does A Vascular Practice Look Like In The 21st Century; Academic, Hybrid Or Community Practice? <i>Caron B. Rockman, MD</i>	11:48-12:00	Panel Discussion
14 – 8:22	What To Prioritize In Your First Practice? <i>Karan Garg, MD</i>	12:00-12:15	Buffet Lunch Available
23 – 8:31	Things I Wish I Had Known When I Was Selecting My First Job <i>Nicole Ilanzo, MD</i>	LUNCHEON PROGRAM	NEW INNOVATIONS IN VASCULAR SURGERY
32 – 8:40	How Much Should I Get Paid? How Do I Know If I Am Getting Paid Fairly? <i>Anahita Dua, MD, MS, MBA</i>	12:15 – 1:00	Industry Sponsored Lunch Program
8:41 – 8:49	Do I Need To Do An Added Fellowship In Advanced Aortic Interventions Before Starting My First Job? <i>Adam Beck, MD</i>	1:00 – 1:15	Panel Discussion
8:50 – 9:05	Panel Discussion	SESSION 4	LONG-TERM PRACTICE MANAGEMENT
SESSION 2	UNDERSTANDING OPTIONS AND INTERVIEWING FOR YOUR FIRST JOB	Moderators:	<i>James F. McKinsey, MD</i> <i>Anahita Dua, MD, MS, MBA</i>
Moderators:	<i>James F. McKinsey, MD</i> <i>Anahita Dua, MD, MS, MBA</i>	1:16 – 1:24	Opportunities And Resources For Your Career Available To You From The Society for Vascular Surgery <i>Keith D. Calligaro, MD</i>
9:06 – 9:14	Interviewing 101: The Right Questions To Ask When Interviewing <i>Jeffrey J. Siracuse, MD, MBA</i>	1:25 – 1:33	Incorporating Social-Media Into Your Vascular Practice <i>Caitlin W. Hicks, MD, MS</i>
9:15 – 9:23	How To Find Out What The Practice Is Really Like And Understand The Options Within The Practice <i>Joann M. Lohr, MD</i>	1:34 – 1:42	Opportunities And Resources For Your Career Available To You From Your Regional Vascular Societies <i>Audra A. Duncan, MD</i>
9:24 – 9:48	Vascular Procedure Billing And Coding – What Do You Absolutely Need To Know Going Into Your First Job? <i>Sean P. Roddy, MD</i>	1:43 – 1:51	Tips And Tricks For Managing Family, Wellness And Career Development <i>Vincent L. Rowe, MD</i>
9:49-10:04	Panel Discussion	1:52 – 2:00	Balancing Between Academia/ Research And Finance: Financial Mistakes For Early/ Mid-Career Vascular Surgeons <i>Ali F. AbuRahma, MD</i>
SESSION 3	FIRST YEAR IN PRACTICE	2:01 – 2:09	Medical Malpractice – How To Avoid A Lawsuit <i>Margaret Tracci, MD, JD</i>
Moderators:	<i>James F. McKinsey, MD</i> <i>Anahita Dua, MD, MS, MBA</i>	2:10 – 2:18	Tips And Tricks For Managing Malignant Settings, Toxic Leadership, Difficult Partners And Turf Wars <i>Shang Loh, MD</i>
10:05-10:29	Setting Up Dedicated Vascular Programs Within A Vascular Practice	2:19 – 2:27	Career Options Throughout Your Career <i>Kenneth Ouriel, MD, MBA</i>
10:05-10:13	PERT Programs <i>Rachel Rosovsky, MD, MPH</i>	2:28 – 2:38	The Role Of Surgeons In International Health Care <i>Michael L. Marin, MD</i>
10:13-10:21	Wound Care <i>John C. Lantis, MD</i>	2:54 – 3:09	Advances In Arterial And Venous Thrombectomy <i>TBD</i>
10:21-10:29	Aortic Center <i>Jason T. Lee, MD</i>	3:10 – 3:25	Panel Discussion
10:30-10:38	What Hospital Or Medical School Committees Should You Become Involved With Early In Your Career <i>Dawn M. Coleman, MD</i>	3:25 – 4:45	Interactive Cocktail Reception With Faculty, Fellows/Residents, Potential Employers And Industry
10:39-10:47	Building Your Practice: Research Considerations <i>Marc L. Schermerhorn, MD</i>		
10:48-10:56	Keys To Building A Successful Practice <i>Venita R. Chandra, MD</i>		
10:57-11:20	How To Negotiate Your First Contract <i>James F. McKinsey, MD</i>		

NEEDS ASSESSMENT

Vascular disease in all of its manifestations is a leading cause of death and disability affecting a large percentage of Americans over the age of 50. There is a critical need for physicians who diagnose, treat and manage patients with vascular disease to receive continuing medical education in this area. The latest pharmacologic, radiologic, surgical and endovascular techniques and technologies will be presented, along with discussions of when these treatments are justified and indicated and when they are not. Updates on clinical trials and opportunities for dialogue with experts in the field provide insight along with the latest data on the results of the various treatment modalities.

There is an enormous gap between actual practice and the current state of knowledge. This gap is filled imperfectly with material in books and published articles. These sources are also often negatively influenced by the biases of authors, reviewers and editors. VEITHsymposium attempts to fill this gap more perfectly and more currently by enlisting speakers with up-to-date information and data, and also those on both sides of controversial issues. In this way, the audience gets a current view of the state-of-the-art in vascular disease management as of the date of the meeting. All important topics are covered.

In addition, by having numerous short (5-6 minutes) talks followed by panel discussions and capturing the entire meeting on the web-based library, the meeting will provide an electronic reference source to help vascular specialists in their practice decisions throughout the year. It will also provide the most up-to-date unbiased information possible to help with these decisions.

FOCUS

The VEITHsymposium provides Vascular Surgeons and other Vascular Specialists with a five-day conference on the most current information about new developments in clinical practice and relevant research. Beginning Tuesday, the symposium offers over 1,300 fast-paced presentations on what is new and important in the treatment of vascular disease. Important updates and reevaluations, as well as the latest significant advances, changing concepts in diagnosis and management, pressing controversies and new techniques, agents and diagnostic modalities will be presented. Video case presentations will also be included.

OBJECTIVES

Upon completion of the VEITHsymposium, the participants will, after learning about a wide array of topics, be able to:

- Explain the practical implications of clinical trial data on new technologies and techniques for endovascular repair of abdominal aortic aneurysm and thoracic aortic disease
- Summarize the impact of data on therapeutic advances for stroke and carotid disease management
- Compare the safety, efficacy, and therapeutic indications of pharmacologic agents to the management of vascular disease
- Assess data on the latest state-of-the-art for the treatment of superficial femoral and tibial artery disease and describe potential implications for clinical care
- Summarize recent data on treatment advances for venous disease and explain their clinical implications
- Provide new information about the latest developments in hemodialysis access and vascular malformations and tumors
- Incorporate the Vascular Laboratory into the management of patients with vascular disease
- Identify and compare noninvasive tests that are available to aid in the diagnosis of vascular disease

GENERAL INFORMATION

TARGET AUDIENCE

Vascular Surgeons, Interventional Radiologists, Interventional Cardiologists, Vascular Medicine Specialists, Cardiac Surgeons, Vascular Technologists, Sonographers and all others interested in the management of vascular disease.

ASSOCIATE FACULTY GLOBAL PODIUM PRESENTATIONS

Wednesday – Friday, November 19-21, 2025

Location: Concourse A, Concourse Level

In order to have more younger and less familiar vascular surgeons and vascular specialists play an active role as Associate Faculty at our meeting, we have initiated programs whereby they can present their scientific work at the podium. Vascular surgeons and vascular specialists participating in these programs will have submitted abstracts for a podium presentation, and these abstracts will be posted on our website. The best three abstracts will receive cash prizes of \$1,000 (1st place), \$500 (2nd place) and \$250 (3rd place). Please visit www.veithsymposium.org for additional information about the Associate Faculty Global Podium Presentations component of VEITHsymposium.

ONE-DAY COMPONENT SESSIONS WILL BE HELD AS FOLLOWS:

Multidisciplinary Stroke Prevention and Treatment

Thursday, November 20, 2025

Location: Americas Hall 1 North, 3rd Floor

Improving Outcomes in Hemodialysis Access

Saturday, November 22, 2025

Location: Grand Ballroom West, 3rd Floor

ACCREDITATION STATEMENT

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

American Medical Association (AMA)

Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 45.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

American Nurses Credentialing Center (ANCC)

Cleveland Clinic Center for Continuing Education designates this live activity for a maximum of 45.75 ANCC contact hours.

Certificate of Participation

A certificate of participation will be provided to other healthcare professionals for requesting credits in accordance with their professional boards and/or associations.

GENERAL INFORMATION

ABS CONTINUOUS CERTIFICATION

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to the ACCME for the purpose of granting ABS credit.

ETHICAL MEDTECH COMPLIANCE

VEITHsymposium is Compliant with the MedTech Europe Code of Ethical Business Practice.

CME CERTIFICATES AND COURSE EVALUATION FORMS

Your CME certificate will be available online within two weeks after the meeting. An e-mail with instructions on how to obtain the certificate and complete a brief course evaluation will be sent to all registered attendees. The e-mail will be sent to the e-mail address that was used to register the attendee. Please note that CME Certificates must be claimed by **February 28, 2026**.

FACULTY DISCLOSURE

The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Integrity and Independence requiring mitigation of all faculty conflicts of interest. Faculty declaring a relevant financial relationship will be identified in the activity syllabus.

ADA STATEMENT

The Cleveland Clinic Foundation Center for Continuing Education complies with the legal requirements of the Americans with Disability Act. If any participant of the VEITHsymposium requires special assistance, please send written request to VEITHsymposium by e-mail to admin@veithsymposium.org at least one month prior to the activity.

ONLINE ACCESS TO ABSTRACTS

Presentation slides will be used as abstracts and will be available on the program page of the VEITHsymposium website at www.veithsymposium.org after the meeting. Abstracts will be available on the website for one full year.

ONLINE CONFERENCE LIBRARY

The entire program with almost all the talks, slides, audio and videos - fully synchronized - and the panels, will be available in an Online Conference Library, which can be obtained at a nominal cost. For more information on how to obtain the VEITHsymposium Online Library, please visit www.veithondemand.com or call (800) 987-9314, select option 3.

HOTEL AND TRAVEL

A block of rooms has been reserved at the conference rate of \$379 plus taxes per night. This rate is available until the block is filled or until October 17, 2025. *Please request the VEITH rate when reserving your accommodations.*

New York Hilton-Midtown (Symposium Venue)

1335 Avenue of the Americas

New York, NY 10019

(212) 586-7000 or 1-800-HILTONS (toll free U.S. only)


American Express Global Business Travel at The Cleveland Clinic

Phone: (216) 444-2564, Extension 62134971

E-mail: VEITHtravel@amexgbt.com



TO GET THE MOST OUT OF YOUR VEITHsymposium EXPERIENCE, WE INVITE YOU TO DOWNLOAD THE VEITH 2025 MOBILE APP



With the App, you can:

- Access the Full VEITHsymposium 2025 Agenda
- Explore Event Programs, Faculty, Exhibitors & More
- View the Interactive Floorplan for Guidance
- Create a Personal Daily Schedule (with Reminders!)
- Download & Print Topical Course Materials
- Make Plans to Attend Non-CME Activities
- Receive the Latest News and Updates

To download the app, please visit the Google Play Store or the Apple App Store and search for VEITH 2025. Or scan the QR Code to download the app to your Android, iPhone, iPad or Tablet.



This QR Code works for both Android and iOS devices.

TUESDAY, NOVEMBER 18, 2025

6:00 A.M. General Registration — Rhinelander Gallery, 2nd Floor
6:00 A.M. Faculty Registration — Gramercy Suite West, 2nd Floor
6:15 A.M. Continental Breakfast — Rhinelander Gallery, 2nd Floor

CONCURRENT TUESDAY PROGRAMS

PROGRAM A (SESSIONS 1-8)

Progress In The Treatment Of Diseases Of Heart Valves And The Thoracic And Abdominal Aorta

Location: Grand Ballroom East, 3rd Floor

PROGRAM B (SESSIONS 9-16)

Progress In Wearable Remote Measurement Devices, Vascular Robotics, Guidance Systems, Laparoscopy, Simulation And COVID; New Developments In Carotid Disease And Acute Stroke Treatment; Abdominal Aortic Branch Treatment; New Technology Concepts And Artificial Intelligence (AI); Vascular Surgery Identity, Training, Manpower And Mentorship; Updates On Open Vascular Surgery And Treatment Of Aortic Coarctation

Location: Grand Ballroom West, 3rd Floor

PROGRAM C-1 (SESSIONS 17-18)

Management Of Pulmonary Embolism: The Ultimate Approach

Location: Trianon Ballroom, 3rd Floor

PROGRAM C-2 (SESSIONS 19-22)

Interesting Topics Related To Lower Extremity Occlusive Disease And Its Treatments

Location: Trianon Ballroom, 3rd Floor

PROGRAM A (SESSIONS 1-8)

PROGRESS IN THE TREATMENT OF DISEASES OF HEART VALVES AND THE THORACIC AND ABDOMINAL AORTA

Grand Ballroom East, 3rd Floor

SESSION 1 (Grand Ballroom East, 3rd Floor)

PROGRESS IN TRANSCATHETER VALVE REPLACEMENT AND TREATMENT OF ASCENDING AORTIC DISEASE

Moderators: *Hazim J. Safi, MD*
Sahil A. Parikh, MD
Rodney A. White, MD

7:04 – 7:07 Opening Remarks
Frank J. Veith, MD

TRANSCATHETER HEART VALVES

7:08 – 7:13 Update On Improvements In Transcatheter Aortic Valve Replacement (TAVR) Including Alternate Access And When Is Open Surgical Valve Replacement Currently Indicated

Ali B. Khoynezhad, MD, PhD

7:14 – 7:19 Update On The Status Of Transcatheter Mitral And Tricuspid Valve Replacement/Repair

Mahesh V. Madhavan, MD, MS

Sahil A. Parikh, MD

7:20 – 7:25 Prevention Of Cerebral Embolization During Aortic Valve And Arch Instrumentation By Promoting Aortic Flow Caudally From An Aortic Sheath Into A Femoral Venous Sheath: Experimental And Clinical Experience

Juan C. Parodi, MD

Jason N. MacTaggart, MD (Presenter)

THE ASCENDING AORTA AND ARCH

- 7:26 – 7:31** Challenges And Successes With Endografts In The Treatment Of Ascending Aortic Dissections (TAADs), Penetrating Ulcers And Pseudoaneurysms
Rodney A. White, MD
- 7:32 – 7:37** Progress In Endovascular Treatment Of Type A Aortic Dissections (TAADs) In 2025: What Is Here And What Is Coming: Experience With Ascending Aortic Endografting Including The Gore Device In The ARISE Clinical Trials
Ali Azizzadeh, MD
Eric E. Roselli, MD
- 7:38 – 7:43** Advances In Endograft Repair Of The Ascending Aorta Without And With Involvement Of The Aortic Valve (Endo-Bentall): What Lesions Are Or Will Be Suitable: World Clinical Experience With Endo-Bentall To Date
Ali B. Khoynezhad, MD, PhD
- 7:44 – 7:49** **DEBATE:** Update On Endo-Bentall Procedures For Combined Ascending Aorta And Valve Disease: Devices And Results To Date: Open Surgery Is Destined To Be Replaced
Stephan Haulon, MD
- 7:50 – 7:55** **DEBATE:** Not So: Combined Ascending Aorta And Valve Disease Is Still And Will Be Best Treated By Open Surgery
Anthony L. Estrera, MD
- 7:56 – 8:02** **Panel Discussion**

SESSION 2 (Grand Ballroom East, 3rd Floor)

PROGRESS IN THE TREATMENT OF AORTIC ARCH LESIONS AND AORTIC DISSECTIONS

Moderators: *Ali B. Khoynezhad, MD, PhD*
Alan B. Lumsden, MD
Mark A. Farber, MD

- 8:02 – 8:07** Issues And Experience With Three Types Of Branch Devices To Treat Aortic Arch Diseases (Terumo Relay, Endospan Nexus, Gore Single Branched Thoracic Endograft (TBE) Compared To Debranching TEVAR
Toru Kuratani, MD, PhD
- 8:08 – 8:13** Total Endovascular Treatment Of Aortic Arch Lesions Is Possible: What Are The Best Devices And Techniques: Open Surgery Is No Longer Needed: Is There Any Role For Chimney Grafts
Nicola Mangialardi, MD
- 8:14 – 8:19** Percutaneous Endovascular Repair Of Aortic Arch Lesions With A Double Fenestrated Endograft (Valiant Captiva From Medtronic)
Ludovic Canaud, MD, PhD
- 8:20 – 8:25** Total Endovascular Repair Of Aortic Arch Aneurysms Entirely From The Femoral Approach And Without Cervical Access: Devices, Technique And Initial Results In Patients
Marcelo Ferreira, MD
- 8:26 – 8:31** Endovascular Arch Repair With Retrograde In Situ Fenestration For Branches: How To Do It And How Durable Are The Results
Jean M. Panneton, MD
- 8:32 – 8:37** Open Repair Of The Aortic Arch And Frozen Elephant Trunk (FET) With The ThoraFlex Hybrid (Terumo Aortic) Device Is Often Necessary And Best; It Can Easily Be Combined With TEVAR: Indications And Results
Joseph S. Coselli, MD

- 8:38 – 8:43** Multibranched Arch Endografts Are Not Harmless And Can Have Several Complications: What Are They And How Can They Be Minimized
Nikolaos Tsilimparis, MD, PhD
- 8:44 – 8:49** Triple-Branch Graft For Endovascular Repair Of Aortic Arch Aneurysms And Dissections: How Does It Work, What Makes It Different: Advantages And Challenges
Qingsheng Lu, MD
- 8:50 – 8:55** Status Of Fenestrated Aortic Arch Repair: What Devices Are Best And How To Avoid Strokes Beside CO2 Device Flushing
Tilo Kölbel, MD, PhD
- 8:56 – 9:02** **Panel Discussion**

SESSION 3 (Grand Ballroom East, 3rd Floor)

PROGRESS IN THE ENDOVASCULAR TREATMENT OF THE ASCENDING AORTA, AORTIC ARCH, AORTIC DISSECTIONS, STABILISE, THORACIC AORTA AND MORE

Moderators: *Christoph A. Nienaber, MD, PhD*
Joseph V. Lombardi, MD, MBA
Michael D. Dake, MD

- 9:02 – 9:07** How And Why The Aortic Arch Is An Unhospitable Location For Endovascular Graft Treatments
Piotr M. Kasprzak, MD
- 9:08 – 9:13** Percutaneous Femoral Access To All Supra Aortic Branches During Total Endo Arch Repair: Totally Femoral Insertion Of Branched Stent-Grafts Can Be Done Safely: Technical Tips And Results
Timothy A. Resch, MD, PhD
- 9:14 – 9:19** Retrograde Branches For Arch Endovascular Repairs: How To Do Them Safely Totally Via Transfemoral Access Using Specialized Reinforced Variable Sheaths: Indications And Results
Stephan Haulon, MD
- 9:20 – 9:25** Results From Multicenter Experience Of Endovascular Arch Repair With Exclusively Retrograde Branches (Femoral Access) Placed Through Orifices In The Aortic Graft: Which Devices, Value Of The Steerable Sheath And Technical Tips
Nuno V. Dias, MD, PhD
- 9:26 – 9:31** A Critical Look At Asymmetrical Saccular Aneurysms Of The Thoracic Aorta: How To Best Measure And Define Diameter: Do They Rupture When Small: Should They All Be Considered Ticking Time Bombs Regardless Of Size
Frank J. Criado, MD
- 9:32 – 9:37** What Is The STABILISE Technique For Treating Acute And Chronic TBADs By Disrupting The Intimal Flap And Overdilating The Distal Bare Stent: Updated Results, And When Should It Be The Treatment Of Choice
Jean-Marc Alsac, MD, PhD
- 9:38 – 9:43** New Developments With The STABILISE Technique For Acute And Subacute TBADs: How Is The STABILISE Registry Helping: Technical Tips And Precautions
Germano C.G. Melissano, MD
Andrea Kahlberg, MD (Presenter)
Roberto L.V. Chiesa, MD
- 9:44 – 9:49** Technical Aspects To Enhance Successful Distal Dissection Stents In Petticoat And STABILISE Configurations To Treat Aortic Dissections: How To Assure Precise Stent Deployment, Avoid Aortic Injury, And Maximize Late Remodeling
Rodney A. White, MD

- 9:50 – 9:55** Comparison Of Indication And Results For Treatment Of Aortic Arch Lesions With Branched Endografts, Fenestrated Endografts, Parallel Stent Grafts, Hybrid Repairs, Or Open Repairs
Chang Shu, MD
- 9:56–10:01** Update On Total And Partial Aortic Arch Lesion Repairs With The Gore TAG Thoracic Branch Endograft (TBE): An Off-The-Shelf (OTS) Device For Revascularizing Arch Branches: Experience To Date Across Zones 0 And 1: Advantages And Limitations
Michael D. Dake, MD
Joseph E. Bavaria, MD
- 10:02–10:07** The Terumo Relay Aortic Ascending Aorta Endovascular Graft: What Makes It Different And Current Status
Vicente Riambau, MD, PhD
- 10:08–10:14** **Panel Discussion**
- 10:14–10:24** **Break — Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 4 (Grand Ballroom East, 3rd Floor)

MORE NEW DEVELOPMENTS IN THE TREATMENT OF AORTIC DISSECTIONS, THORACIC AORTIC DISEASE AND THORACOABDOMINAL ANEURYSMS (TAAAs)

Moderators: *Jean M. Panneton, MD*
Eric L.G. Verhoeven, MD, PhD
Joseph V. Lombardi, MD, MBA

UNCOVERED STENT TREATMENTS

- 10:24–10:29** Use Of A Bare Stent (AMDS – Artivion) In The Aortic Arch After Open Ascending Aortic Repair Of DeBakey Type 1 Dissection To Alleviate End Organ Malperfusion: How Does It Work And Promising Mid-Term Results
Wilson Y. Szeto, MD
- 10:30–10:35** The Multilayered Uncovered Allay Aortic Stent (Intressa Vascular) To Treat TBADs: Indications For Use, Advantages, Precautions And Results
Claude D. Vaislic, MD
- 10:36–10:41** Value Of Multilayer Uncovered Stents To Treat Aortic Dissections (Type A And B): Indications And Limitations, Long-Term Results And When Are They The Easiest And Best Treatment
Victor S. Costache, MD, PhD
- 10:42–10:47** Proximal Aortic Coverage With TBADs: Should Proximal Deployment Of TEVAR Be Focused On The Entry Tear To Limit Supra Aortic Trunks And Arch Coverage
Jean-Marc Alsac, MD, PhD
- 10:48–10:53** How Best To Treat TBADs Extending Into The Arch, Its Branches Or Ascending Aorta; When Open, When Endo, When Hybrid
I-Hui Wu, MD, PhD
- 10:54–10:59** Updated Experience With Endovascular Thermal Septotomy Of The Dissection Flap With An Electrocautery Activated Guidewire To Treat Subacute And Chronic TBADs: How Does It Optimize Landing Zones: Technical Tips And How To Avoid Pitfalls And Complications
Carlos H. Timaran, MD
Gustavo S. Oderich, MD

- 11:00–11:05** Current Status Of A Catheter Aortic Septotomy Device For Treating Aortic Dissections By Cutting The Septum From Below: How Does It Work And Advantages: Limitations To Other Septotomies That Cut The Septum From Above
Ramon Berguer, MD, PhD
- 11:06–11:12** **Panel Discussion**
- 11:12–11:17** With Post-Dissection TAAAs When Is Open Repair The Best Treatment Option And Why: What Qualifications Will Be Needed To Do These Procedures, And How To Attain Them: Will There Be Qualified Surgeons In The Future
Hazim J. Safi, MD
- 11:18–11:23** Open Repair Of TAAAs Following TEVAR Treatment Of TBADs: How Common Are They And Technical Tips: Will This Procedure Survive In The Endovascular Era
Geert Willem H. Schurink, MD, PhD
Barend M.E. Mees, MD, PhD
Michael J. Jacobs, MD
- 11:24–11:29** Updated Experience With F/B/EVAR For Post TBAD TAAAs: Technical Tips And The Value Of Inner Branched Devices: Value Of The BeBack Catheter (Bentley) To Cross The Dissection Flap
Eric L.G. Verhoeven, MD, PhD
Athanasios Katsargyris, MD
- 11:30–11:35** When And How Best To Treat Persistent Patent False Lumens After TEVAR Treatment Of Aortic Dissections: Update On The FLIRT Procedure: What Is It And How To Do It
Christoph A. Nienaber, MD, PhD
- 11:36–11:41** The European Aortic Data Collection (EADC) Study Shows That F/B/EVAR Is The Best Treatment For Most Complex AAAs And TAAAs: When Is It Not And The Value Of A New Bridging Stent (BeFlared – Bentley) Which Flares More Easily
Stephan Haulon, MD
- 11:42–11:47** Off-The-Shelf Endovascular Aortic Devices For TAAA Repair And Their Impact On The Need For Physician Modified Endografts (PMEGs): Which Devices And When
Steven Maximus, MD
- 11:48–11:53** The SVS-STS Aortic Dissection Reporting Standards And Classification System: What Is It; What Are Its Advantages And Limitations; How Is It Helping To Understand The Disease Process And Improve Treatment
Joseph V. Lombardi, MD, MBA
- 11:54–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break - Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 5 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN ABDOMINAL AORTIC ANEURYSM (AAA) ETIOLOGY, DETECTION, TREATMENT AND EVAR

Moderators: *Ronald L. Dalman, MD*
Michael L. Marin, MD
Grace J. Wang, MD, MSCE

- 1:00 – 1:05** Are We Overtreating Patients With AAA: Which Patients Should NOT Be Treated Invasively Based On Frailty, Comorbidities, Anatomy And Aneurysm Size
Alun H. Davies, MA, DM, DSC

- 1:06 – 1:11** Should We Reconsider AAA Size Threshold For Infrarenal AAA: Why Many Patients With AAAs >5cm In Diameter Should NOT Have Any Invasive Treatment: Should The Guidelines Be Changed
Grace J. Wang, MD, MSCE
Nicos Labropoulos, PhD
- 1:12 – 1:17** Size Thresholds For Repair Of AAAs Are Wrong On The Low Side: Data From Medicare And The VQI Indicate That Rupture Risk Only Increases With AAAs Over 6-6.9 cm
David H. Stone, MD
Salvatore Scali, MD
Bjoern D. Suckow, MD
- 1:18 – 1:23** Are We Overtreating AAAs: The Current Diameter Thresholds For AAA Repair (5.5 cm For Men; 5.0 cm For Women) Are No Longer Relevant: Based On New Scrutiny Of Old Trials And A Meta-Analysis Of AAA Rupture Risk
Timothy A. Resch, MD, PhD
- 1:24 – 1:29** Update On Medical Treatment Trials To Slow AAA Growth: What Treatments Or Drugs Show Promise And Why: What About Metformin And The MAAAGI And MAT Trials
Ronald L. Dalman, MD
Anders Wanhainen, MD, PhD
- 1:30 – 1:35** If Type 2 Endoleaks, Which Are Common After EVAR, Are So Dangerous, Where Are All The Post EVAR Rupture From Them: Maybe They Aren't So Dangerous: When Must They Be Treated
Jan D. Blankensteijn, MD
- 1:36 – 1:41** **Panel Discussion**
- 1:42 – 1:47** When Is EVAR An Effective Treatment For Infected AAAs: Incidence, Pattern, And Prevention Of Recurrent Infection After EVAR For Infected AAAs: From A 20-Year Experience With >180 Cases
Boonprasit Kritpracha, MD
- 1:48 – 1:53** Computer Analysis Of CT Factors Determining AAA Wall Weakness/Strength Of Areas In AAAs Predicts Rupture Risk Independent Of Size And Post EVAR Neck Behavior: The ViTAA System
Adam Beck, MD
Randy D. Moore, MD
- 1:54 – 1:59** High Dose Statin Therapy Has A Profound Influence On The Clinical Course Of AAA Disease: From Two Prospective Screening Trials
Jes S. Lindholt, MD
- 2:00 – 2:05** New Endovascular Technology (Nectero — Intra-Sac Drug After AAA Balloon Isolation) To Slow AAA Growth: Updated Clinical Results Of The First-In-Human (FIH) Trial And The stAAAbles RCT
Andrew Holden, MBChB
Ramon L. Varcoe, MBBS, MS, PhD, MMed
Daniel G. Clair, MD
Venkatesh G. Ramaiah, MD
- 2:06 – 2:11** Unexpected Small Bowel Necrosis When Performing EVAR In Patients With Visceral Artery (SMA) Occlusive Disease: How To Predict It And How To Avoid It
Karan Garg, MD
Neal S. Cayne, MD
Carlos H. Timaran, MD
Frank J. Veith, MD
- 2:12 – 2:17** Comparison Of Long-Term Survival After Open And Endo AAA Repairs: Does It Help To Build A Case For Raising The Size Threshold For AAA Repair
Andrew Holden, MBChB

- 2:18 – 2:23** AAA Treatment And Outcomes For Women: There Are Dramatic Differences Compared To Men
Jon S. Matsumura, MD
- 2:24 – 2:30** **Panel Discussion**
- 2:30 – 2:40** **Break — Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 6 (Grand Ballroom East, 3rd Floor)

MORE ABOUT AAAs AND EVAR, STANDARD AND COMPLEX: UPDATES ON PHYSICIAN MODIFIED ENDOGRAFTS (PMEGs) AND GUIDELINES

Moderators: *Michel S. Makaroun, MD*
Maarit Venermo, MD, PhD
Dittmar Böckler, MD

- 2:40 – 2:45** Are Re-Intervention Rates After EVAR Influenced By Device Type And Manufacturer: What Is The Mechanism Responsible For Differences
Jonathan R. Boyle, MD, MA (Cantab)
- 2:46 – 2:51** Colonic Ischemia Following EVAR Repair: Current Concepts About Etiology, Diagnosis, Prevention, Treatment And Outcomes
Jean Pierre Becquemin, MD (Presentation With Synched Audio)
- 2:52 – 2:57** EVAR 2 Is No Longer A Relevant RCT: Outcomes Of EVAR In Over 18,000 High-Risk Patients Ineligible For Open Repair Shows That EVAR Is Justified In Some: When Is This So
George A. Antoniou, MD, PhD, MSc
- 2:58 – 3:03** Inflammatory AAAs: When Can Medical Treatment Be Effective As Endo Or Open Invasive Treatment: From Results Of A 5-Year Study
Julien G. Sfeir, MD
- 3:04 – 3:09** Update On How Best To Manage The Celiac Artery During Endo Repairs Of Complex AAAs: Let It Be Covered And Occluded Or Not; Fenestrate It With Or Without A Stent: How Does A Pre-Op CTA Help
Ian Loftus, MD
- 3:10 – 3:15** **Panel Discussion**
- 3:16 – 3:21** What Are The New ESVS Guidelines For Surveillance After EVAR And Do They Lead To Unsafe Practices
Hence J.M. Verhagen, MD, PhD
- 3:22 – 3:27** Failure Rates Are High For Endo Repairs Of Juxtarenal And Complex AAAs In A 7-Year Follow-Up From The UK-COMPASS Trial: Would A Wider Use Of Open Repair Remedy This
S. Rao Vallabhaneni, MD
- 3:28 – 3:33** Aortic Dissection In Pregnancy: Why Is The Mortality So High: Why Is Its Diagnosis Delayed: How Should Its Treatment Differ From Non-Pregnant Patients
Richard G.J. Gibbs, FRCS
- 3:34 – 3:39** Why The Open Retroperitoneal Approach Should Be Used More Often To Treat Complex AAAs And Failed EVARs: Training, Techniques, Indications, Advantages And Limitations: Have We Gone Too Far In The Endo vs. Open Transformation
Gabriele Maritati, MD
- 3:40 – 3:45** What Is The LEAF Initiative For Assessing Long-Term Outcomes For EVAR Devices From Various Manufacturers: What Are Some Of The Interesting Findings To Date And How Might They Influence Clinical Practice
Philip P. Goodney, MD, MS
Robert E. Lee, MD
- 3:46 – 3:56** **Panel Discussion**

SESSION 7 (Grand Ballroom East, 3rd Floor)

MORE NEW DEVELOPMENTS IN THE TREATMENT OF THORACIC AORTIC PATHOLOGY INCLUDING CORAL REEF AORTA

Moderators: *Thomas L. Forbes, MD*
Manju Kalra, MBBS
Mark A. Farber, MD

- 3:56 – 4:01** Open Repair Of Chronic Type B Dissection: What Is The Role For Open Repair; Technical Tips
Yamume Tshomba, MD
- 4:02 – 4:07** The Importance Of Aortic Dissection Entry Tear Size And Morphology: How Should They Influence Treatment And Predict Remodeling Behavior After TEVAR
Shang Loh, MD
- 4:08 – 4:13** Long-Term Outcomes Of Endovascular Treatment For TBADs: Failure Modes: What Secondary Interventions Are Required: Is Late Graft Migration An Issue
Dittmar Böckler, MD
- 4:14 – 4:19** Stenting (Open vs. Covered) Of Visceral Branches For TEVAR In Uncomplicated Type B Aortic Dissections (uTBADs): When Is It Necessary And How Does It Improve Results (From The EARNEST Trial)
Colin D. Bicknell, MD
- 4:20 – 4:25** Transposition vs. Bypass vs. Endo: What Is The Best Option For Revascularization Of The Left Subclavian Artery (LSA) During TEVAR
Thomas L. Forbes, MD

UPDATES ON CORAL REEF AORTA TREATMENT

- 4:26 – 4:31** Open Endarterectomy To Treat Coral Reef Lesions Of The Visceral Aorta And Its Branches: Technique, Pitfalls And Results: Is There Ever A Role For Endovascular Treatment
Frederic Cochenne, MD, PhD
- 4:32 – 4:37** Open Surgery Should Still Be The Treatment Of Choice For Coral Reef Aorta With Visceral Involvement: Why Is Endovascular Treatment Inappropriate
Jean-Baptiste Ricco, MD, PhD
- 4:38 – 4:43** The Value Of Endovascular Treatment Of Thoracoabdominal Coral Reef Aorta: Technical Tips, Results And When And How Can It Be Used
Giovanni B. Torsello, MD
- 4:44 – 4:49** Coral Reef Aorta: Indications For Invasive Treatment; When Open Surgery, When Endo: Technical Tips
Francesco Speziale, MD
Pasqualino Sirignano, MD, PhD
- 4:50 – 4:56** **Panel Discussion**

SESSION 8 (Grand Ballroom East, 3rd Floor)

MORE NEW DEVELOPMENTS REGARDING TBADs AND TEVAR: NEED FOR AND TIMING OF TEVAR FOR ACUTE UNCOMPLICATED TYPE B AORTIC DISSECTION (uTBADs)

Moderators: *Jon S. Matsumura, MD*
William D. Jordan Jr., MD
Jean M. Panneton, MD

- 4:56 – 5:01** With Acute Type A Dissections And Severe SMA Malperfusion, What Is The Optimal Treatment Sequence: When Should Descending Aortic TEVAR To Restore SMA Flow Precede Open Repair Of The Ascending Aorta
Martin R. Back, MD

- 5:02 – 5:07** Aortic Geometry Can Be Predictive Of TBAD Behavior And Treatment Failure After TEVAR: How To Assess It And How Should It Change Treatment
Ross Milner, MD
- 5:08 – 5:13** Re-Entry Specific Endovascular Therapy (RESET) For TBAD Features Treatment Of Reentry Tears And Improves Remodeling And Outcomes With TBADs: When And How To Do It
Jean M. Panneton, MD
- 5:14 – 5:19** **DEBATE ROUND 3:** With Acute Uncomplicated TBADs, The Case For Early TEVAR With Extensive Aortic Coverage In Most Patients: New Data Supports It
William D. Jordan Jr., MD
- 5:20 – 5:25** **DEBATE ROUND 3:** With Acute Uncomplicated TBADs, The Case For Waiting 2-6 Weeks From Onset For TEVAR And Then Limiting Aortic Coverage: The Facts Support It
Mark A. Farber, MD
- DO WE NEED AN RCT COMPARING TEVAR VERSUS MEDICAL TREATMENT FOR uTBADs**
- 5:26 – 5:31** The Science Behind The High Risk Features Of Uncomplicated Acute Type B Dissections (uTBADs) Is Shaky At Best: They Should Not Be Used As An Excuse To Treat These Patients Invasively (As Some Guidelines Suggest) Until We Have Better Evidence: Until Then An RCT Will Be Difficult Or Impossible
Hence J.M. Verhagen, MD, PhD
- 5:32 – 5:37** Progress With The IMPROVE-AD And SUNDAY RCTs Comparing TEVAR vs. Best Medical Treatment Of Acute And Subacute uTBADs: Recruitment To Date And Estimated Time To Completion
Firas F. Mussa, MD
Jacob Budtz-Lilly, MD, PhD
Panos Kougias, MD, MSc
- 5:38 – 5:43** How Important Is The Conformability Of Thoracic Endografts: The Real-Life Performance Of A More Conformable Device
Vicente Rimbau, MD, PhD
- 5:44 – 5:49** With Aortic Dissections: How Should Visceral Malperfusion Be Diagnosed And What Strategies Are Available To Treat It Before Or After TEVAR
Thomas F. Lindsay, MDCM
- 5:50 – 5:56** **Panel Discussion**
End of Program A

PROGRAM B (SESSIONS 9-16)

PROGRESS IN WEARABLE REMOTE MEASUREMENT DEVICES, VASCULAR ROBOTICS, GUIDANCE SYSTEMS, LAPAROSCOPY, SIMULATION AND COVID; NEW DEVELOPMENTS IN CAROTID DISEASE AND ACUTE STROKE TREATMENT; ABDOMINAL AORTIC BRANCH TREATMENT; NEW TECHNOLOGY CONCEPTS AND ARTIFICIAL INTELLIGENCE (AI); VASCULAR SURGERY IDENTITY, TRAINING, MANPOWER AND MENTORSHIP; UPDATES ON OPEN VASCULAR SURGERY AND TREATMENT OF AORTIC COARCTATION
Grand Ballroom West, 3rd Floor

SESSION 9 (Grand Ballroom West, 3rd Floor)

PROGRESS IN VASCULAR ROBOTICS AND IMAGING AND GUIDANCE SYSTEMS WITH LESS RADIATION AND CONTRAST

Moderators: *Robert A. Lookstein, MD, MHCDL*
Matthew J. Eagleton, MD
Willem Wisselink, MD

6:50 – 6:55 Opening Remarks
Enrico Ascher, MD

VASCULAR ROBOTICS CURRENT AND FUTURE

6:56 – 7:01 How Can Current Robotic Techniques With The Da Vinci System (Intuitive) Facilitate Open Aortic Procedures: Benefits And Drawbacks
Alan B. Lumsden, MD

7:02 – 7:07 A Decade's Retrospective Look At Vascular Robotics: Lessons Learned, Challenges And Future Possibilities
Celia Riga, MD

7:08 – 7:13 What Is The Future For Vascular Robotics: What Clinical Benefits Are Needed To Make It Successful And What Improved Techniques Are On The Horizon: How Can They Help In Training
Barry T. Katzen, MD
Gary M. Ansel, MD

7:14 – 7:19 What New Developments In Vascular Robotics Will Lead To Their Comeback: How Can Single Port Robotic Surgery Help: What Does The Future Hold
Willem Wisselink, MD

7:20 – 7:25 The Sentante Robotic System Allows For Remote Endovascular Procedures: How Does It Work: Other Advantages And Limitations
Gary M. Ansel, MD
Dainis K. Krievins, MD

IMPROVED IMAGING GUIDANCE SYSTEMS

7:26 – 7:31 The Cydar System And Its AI Modifications Allows Image Fusion For F/B/EVAR Even With Mobile C-Arms And Enhances Fusion Accuracy As Intravascular Hardware Modifies Vascular Anatomy: How Does The System Work: Advantages And Limitations
Murray L. Shames, MD
Ross Milner, MD

7:32 – 7:37 Improved Fiberoptic-Based Radiation-Free Imaging With The FORS Lumiguide System (Philips): Fiberoptic Sensors Within A Guidewire And A Special 3D Hub Allow Imaging Guidance With Any Catheter: How Does It Work And Experience
Carlos H. Timaran, MD

7:38 – 7:43 Status Of The 3D Radiation-Free Electromagnetic Intraoperative Positioning System (IOPS From Centerline) For Endovascular Guidance: How Does It Work, Advantages And Limitations: How Widespread Is Its Usage
Matthew J. Eagleton, MD
Francis Caputo, MD

7:44 – 7:50 **Panel Discussion**

SESSION 10 (Grand Ballroom West, 3rd Floor)

NEW DEVELOPMENTS IN CAROTID DISEASE AND ITS TREATMENT: A NEW LOOK AT THE TREATMENT OF ASYMPTOMATIC CAROTID STENOSIS (ACS) AND OTHER CAROTID TOPICS

Moderators: *Bruce A. Perler, MD, MBA*
Colin P. Derdeyn, MD

A NEW LOOK AT THE ASYMPTOMATIC CAROTID STENOSIS (ACS) CONTROVERSY

- 7:50 – 7:55** What Facts Would Be Needed To Change My View That All ACS Patients Are Best Treated Medically: Why The CMS Decision To Reimburse Carotid Stenting (CAS) For ACS Patients Was Based On The Wrong Comparative Data (CAS vs. CEA When It Should Have Been CAS vs. Medical Treatment)
Anne L. Abbott, MD, PhD
- 7:56 – 8:01** Transfemoral CAS (TFCAS) For ACS Is Being Overused Since CMS Expanded Its Reimbursement Without Limits
Sean P. Lyden, MD
- 8:02 – 8:07** How AI Analysis Of Plaque Features On CT, Ultrasound And MRI Can Predict Stroke Risk More Accurately To Eliminate Unnecessary Invasive Procedures For ACS: While Medical Treatment Is Improving, A Few ACS Patients May Benefit From CAS Or CEA: When Will We Know
Robert W. Chang, MD
- 8:08 – 8:13** A Neuroradiologist's View Of Current Interventions For Extracranial Carotid Disease: Do They Represent Exuberant Enthusiasm, Financial Opportunity For Industry, Doctors And Institutions, Or A Path To Excessive Risk: Impact Of The Recent Expanded Medicare Reimbursement For CAS
Colin P. Derdeyn, MD

VALUE OF CAROTID SCREENING

- 8:14 – 8:19** New Developments In Carotid Plaque Imaging (Duplex, CT, MRI): Can It Predict Stroke Risk Reliably In ACS Patients To Facilitate Highly Selective Invasive Treatment
Stavros K. Kakkos, MD, PhD
Andrew N. Nicolaides, MS
- 8:20 – 8:25** Should The Amount Of Calcium Play A Role In Decision Making Of Carotid Interventions For ACS: How To Quantitate It And How Does It Influence Outcomes
Clark J. Zeebregts, MD, PhD
- 8:26 – 8:32** **Panel Discussion**
- 8:32 – 8:37** What Is The Best Medical Therapy For Patients With Carotid Stenosis: Diet (What Should And Shouldn't Be Eaten) Is Very Important: What Drugs And Dosage Should They Be On And Should They Be Titrated Against LDL Levels: When And How Should Homocysteine Levels Be Reduced
Anne L. Abbott, MD, PhD

CORONARY DISEASE IN CAROTID STENOSIS (CS) PATIENTS

- 8:38 – 8:43** All Patients With Carotid Stenosis (Whether Invasively Treated Or Not) Have A High Incidence Of Coronary Artery Disease Which May Be Lethal: A 5-Year RCT Shows That Coronary CT Angiography With Fractional Flow Reserve (FFRCT) Can Lead To Treatment Which Lowers Mortality
Dainis K. Krievins, MD
Christopher K. Zarins, MD
- 8:44 – 8:49** Screening For ACS: Its Main Value Is In Guiding Lipid Treatment: How Low Should LDL-Cholesterol (LDL-C) Be Pushed And What Will It Do To Carotid Plaques
Stavros K. Kakkos, MD, PhD
Andrew N. Nicolaides, MS

- 8:50 – 8:55** If Optimal Skills For Performing CEA, CAS And TCAR Are Available And Invasive Treatment Is Justified, How To Select The Optimal Procedure: This Algorithm Helps
Adnan H. Siddiqui, MD, PhD
Andrew N. Nicolaides, MS
- 8:56 – 9:01** How Should The Presence Of Severe Renal Dysfunction Or ESRD Influence The Treatment Of Symptomatic Or Asymptomatic Carotid Stenosis
Rabih A. Chaer, MD
- 9:02 – 9:07** Optimal Current Treatment Of Tandem Extracranial Carotid Lesions: Techniques And Sequence Of Treatment To Include Flow Reversal Cerebral Protection
Christopher J. Smolock, MD
- 9:08 – 9:14** **Panel Discussion**
- 9:15 – 9:27** **Break - Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 11 (Grand Ballroom West, 3rd Floor)
UPDATES ON TREATMENTS FOR INTRACRANIAL ARTERIAL DISEASE; INVASIVE ENDOVASCULAR TREATMENT FOR ACUTE STROKES; COMBINED CAROTID STENOSIS AND INTRACRANIAL CLOT OR DISEASE; CAROTID DISSECTIONS

Moderators: *Allan L. Brook, MD*
Hernan A. Bazan, MD

- 9:28 – 9:33** Current Status Of Intracranial Angioplasty And Stenting And EC - IC Bypasses: Indications And Results
Colin P. Derdeyn, MD
- 9:34 – 9:39** Frailty Scores And Other Variables Impact The Outcomes Of Urgent Carotid Interventions In Acute Stroke Patients: A Comprehensive Analysis Of Risk And Prognosis Shows That Stroke Severity Is The Most Important Determining Factor
Hernan A. Bazan, MD
- 9:40 – 9:45** With Acute Strokes, What Is New With Endovascular Intracranial Techniques And Indications For Arterial Clot Removal: Do The Recent Trials Expand Treatment Options: They Do Not For More Distal Clot Removal Or Intracranial Thrombolysis: Why Must Stroke Patients Be Kept Flat
Adnan H. Siddiqui, MD, PhD

CERVICAL CAROTID STENOSIS AND INTRACRANIAL DISEASE OR CLOT

- 9:46 – 9:51** Current Optimal Treatment When Carotid Stenosis In The Neck Coexists With Intracranial Disease Or Clot
Klaus D. Mathias, MD (PowerPoint Presentation With Synched Audio)
- 9:52 – 9:57** Optimal Current Management Of Acute Embolic Stroke From Carotid Bifurcation Disease: Approach And Sequence Of The Treatment With Removal Of Intracranial Clot And Stenting Of The Carotid Lesion: Equipment And Training Needed
Adnan H. Siddiqui, MD, PhD
- 9:58–10:03** Are The Guidelines For Managing Acute Strokes In Patients With Carotid Bifurcation And Intracranial Clot Wrong: What Is The Best System For Current Management And Who Should Do The Procedures
Laura Capoccia, MD, PhD
- 10:04–10:09** With Asymptomatic Carotid Stenosis (ACS) Are There Gender Specific Differences In Treatment Outcomes Or Are Any Observed Differences Related To Vessel Size: Gender Should Never Preclude Treatment
Martin Storck, MD, PhD

CAROTID ARTERY DISSECTIONS

- 10:10-10:15** Current Optimal Treatment Of Carotid Artery Dissections: When Anticoagulation And When Antiplatelet Drugs; When CAS And When Open Surgery: Technical Tips
Klaus D. Mathias, MD (PowerPoint Presentation With Synched Audio)

10:16-10:23 Panel Discussion

SESSION 12 (Grand Ballroom West, 3rd Floor)

PROGRESS IN THE TREATMENT OF AORTIC AND AORTO-ILIAC OCCLUSIVE DISEASE (AIOD)

Moderators: *Daniel G. Clair, MD*
Wayne W. Zhang, MD
Zhong Chen, MD

- 10:24-10:29** A New Endograft System With And Without Branches Or Fenestrations For Treating Aneurysms At All Levels Of The Aorta: It Is Fully Repositionable Even After Deployment - How Does It Work And Clinical Experience
Arno von Ristow, MD, PhD
- 10:30-10:35** New Developments In The Treatment Of External Iliac Artery Endofibrosis In Committed Cyclists: Pathogenesis And Why There Is No Role For Endovascular Therapy
Margaret Tracci, MD, JD
- 10:36-10:41** Can Mesh Covered Stents Replace Stent-Grafts For The Treatment Of Complex Iliac Occlusive Lesions: Which Device; Advantages And Disadvantages; Results
Piotr Myrcha, MD
- 10:42-10:47** Chronic Flush Juxtarenal Aortic Occlusions Endovascularly With Safety: How To Do It And What Is The Role Of Lysis; Is There Ever A Need For Open Surgery
David J. Minion, MD
- 10:48-10:53** The VORTEC Technique To Eliminate The Need For Aortic Circumferential Dissection, Clamping And Suturing In An Aortofemoral Bypass: What Is It And How To Do It: Why It Is Especially Valuable For Heavily Calcified And Scarred Aortas
Mario L. Lachat, MD
- 10:54-10:59** Intravascular Lithotripsy (IVL - Shockwave-J&J) Improves The Endovascular Treatment Of Aorto-Iliac Lesions: Indications, New Technology (L6 And E8 IVL Catheters) And Technical Tips For Use
Daniel G. Clair, MD
- 11:00-11:05** New Large Balloon Intravascular Lithotripsy Catheter L6 (Shockwave-J&J) Facilitates The Treatment Of Isolated Aortic Lesions And Reduces The Need For Stents And Covered Stents
Maria Antonella Ruffino, MD
- 11:06-11:12 Panel Discussion**
- 11:12-11:17** For Aorto-Iliac Occlusive Disease (AIOD): A Unibody Stent-Graft (AFX From Endologix) Offers Durable Outcomes Comparable To Traditional Aortobifemoral Bypass Or Stents (Bare Or Covered)
Todd R. Vogel, MD, MPH

COVERED ENDOVASCULAR RECONSTRUCTION OF THE AORTIC BIFURCATION (CERAB) PROCEDURE

- 11:18-11:23** New Developments In CERAB (Covered Endovascular Reconstruction Of The Aortic Bifurcation): Long-Term Results, Advantages And Limitations: When Is It Optimal Treatment And When Is It Not: When Is Open Surgery Best
Michel Reijnen, MD, PhD

- 11:24–11:29** Redo AIOD Interventions After Failed Stenting Or Aorto-Bifem Procedures: How To Recanalize Native Vessels And Salvage With A CERAB Procedure
Christopher J. Smolock, MD
- 11:30–11:35** Radiation Free CERAB Procedures Are Possible Using FORS Technology (Philips) With Its 3-D Hub: How Is It Done And Technical Tips: Clinical Experience To Date
Barend M.E. Mees, MD, PhD
- NEW METHODS TO PRESERVE HYPOGASTRIC FLOW**
- 11:36–11:41** How Can The VORTEC Technique Be Used To Simplify Hypogastric Revascularization With Open Repair Of Difficult Iliac Aneurysms: How To Do It
Zoran Rancic, MD, PhD
- 11:42–11:47** Covered Endovascular Reconstruction Of The Iliac Bifurcation (CERAB) For Treatment Of Aorto-Iliac Occlusive Disease With Hypogastric Preservation: How To Do It: Advantages And Results
Joshua D. Adams, MD
- 11:48–11:53** Real-World Evaluation Of The Covered Endovascular Revascularization Of The Aortic Bifurcation (CERAB) Technique For Treating Complex AIOD: Indications, Advantages, Limitations And Stent-Graft Choice
Jean Bismuth, MD
- 11:54–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break - Rhinelander Gallery, 2nd Floor**
Visit the Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 13 (Grand Ballroom West, 3rd Floor)

NEW CONCEPTS; MACHINE LEARNING, ARTIFICIAL INTELLIGENCE (AI) TO DECREASE RADIATION PERSISTENT HIGH AMPUTATION RATES (SEE ALSO SESSION 9)

Moderators: *Barry T. Katzen, MD*
Kak Khee Yeung, MD, PhD

- 1:00 – 1:05** The Cost Of Artificial Intelligence (AI) In Medicine: Boldly Or Foolishly Going Where No One Has Gone: Will The Benefits Be Worth The Cost
Cherrie Z. Abraham, MD
- 1:06 – 1:11** Is Image Fusion Advanced Guidance For Complex And Simple Aortic Procedures: When Is It Certainly Worthwhile Because It Decreases Radiation Exposure And When Do We Need An RCT To Show Its Benefits
Rachel E. Clough, PhD
- 1:12 – 1:17** How To Develop A Robotic Vascular Surgery Practice And How It Can Benefit A Vascular Surgeon: What Is The Future Of Robotic Vascular Surgery
Lars Stangenberg, MD, PhD
- 1:18 – 1:23** How VQI Registry Data Can Optimize DRG Coding And Save Hospitals Millions: Is AI Involved
Jack L. Cronenwett, MD
- 1:24 – 1:29** Amputation Rates In The US Are Rising Even Though Interventions For Ischemia Are Increasing: Why Is This So And What Can Be Done To Fix The Problem
Joseph L. Mills, MD
- 1:30 – 1:35** **Panel Discussion**
- 1:36 – 1:41** Why Randomized Controlled Trials (RCTs) In Vascular Surgery Are Obsolete And Unethical In The Era Of Artificial Intelligence
Willem Wisselink, MD

- 1:42 – 1:47** The VASCUL-AID Platform: Using AI To Predict Cardiovascular Disease Progression In AAA Patients And Lower Extremity Arterial Occlusive Disease: What Does It Show After 6 Years Of Study And How Does It Improve Patient Care
Kak Khee Yeung, MD, PhD
- 1:48 – 1:53** Why Best Medical Therapies (BMTs) Are Not Working Well In Lower Extremity Arterial Occlusive Disease Patients Despite Excessive Healthcare Expenditure: How Can AI Remedy The Situation
Christian A. Behrendt, MD
- 1:54 – 1:59** How Can AI Improve Treatment Strategies Before And After AAA Procedures: Will It Improve Outcomes And Be Widely Available
Apostolos K. Tassiopoulos, MD
- 2:00 – 2:05** Can Microchips, Wireless Technology And AI Come Together To Alter Workflow For Peripheral Interventions And Improve Treatment Outcomes
Barry T. Katzen, MD
- 2:06 – 2:12** **Panel Discussion**

SESSION 14 (Grand Ballroom West, 3rd Floor)

ISSUES IMPORTANT TO VASCULAR SURGERY'S INDEPENDENCE, IDENTITY, WELL BEING AND TRAINING

Moderators: *James C. Stanley, MD*
Joseph L. Mills, MD

- 2:12 – 2:17** What New Initiatives Should The SVS Be Engaged In To Improve The Status Of Vascular Surgery And The Well Being Of Vascular Surgeons: Why Hasn't The SVS Been Able To Do More
Margaret Tracci, MD, JD
- 2:18 – 2:23** Why We Need A Free-Standing American Board of Vascular Surgery And Why The ABS Should Support Its Vascular Surgery Board In Becoming A New Independent ABMS Board: It's About More Than Us
James C. Stanley, MD
- 2:24 – 2:29** Leaders Have To Lead: This Is True In Vascular Surgery And Everything Else: Why Lack Of Leadership In Vascular Surgery Has Resulted In Our Remaining A Subordinate Subservient Subspecialty: Why Has It Happened And What Can Be Done About It
Jean Bismuth, MD
- 2:30 – 2:35** Why The SVS Has Been Reluctant To Support An Independent American Board Of Vascular Surgery When So Many Membership Polls Have Shown Overwhelming Support For Such A Board Over The Past Two Decades
Benjamin W. Starnes, MD
- 2:36 – 2:41** Efforts On Behalf Of The SVS Regarding An Independent ABMS Approved Board Of Vascular Surgery
Keith D. Calligaro, MD
Matthew J. Eagleton, MD
- 2:42 – 2:47** Why The ABVS, An Organization Committed To Establish An Independent ABMS Approved Board of Vascular Surgery, Has Been Unable To Make Significant Progress For The Past 6 Years
Alan M. Dietzek, MD, RPVI

TRAINING RELATED ISSUES

- 2:48 – 2:53** Recent Developments In Vascular Surgery Training Programs: Changes In Numbers And Quality Of 0+5 And 5+2 Trainees; Why We Need More Qualified Vascular Surgeons And How Are We Going To Get Them
Dawn M. Coleman, MD

- 2:54 – 2:59** Obtaining Cardiac Surgery Training After Vascular Surgery Training: I Did It, So It's Possible: Is It Worthwhile: Advantages And Disadvantages
Jennifer L. Perri, MD, MBA
- 3:00 – 3:05** Impact Of EVAR On Resident/Fellow Experience In Open AAA Repair Experience And Competence: What To Do About It
Murray L. Shames, MD
- 3:06 – 3:11** How To Handle Bad Clinical Outcomes And Other Professional And Personal Adversity: It Really Matters For A Vascular Surgeon/Specialist/Trainee
John F. Eidt, MD
- 3:12 – 3:17** What Proportion Of General Surgery Chairs Are Filled By Vascular Surgeons: Is It Helpful To Vascular Surgery Or Not: Why They Often Do Not Support Vascular Surgery
Anil P. Hingorani, MD
- 3:18 – 3:24** **Panel Discussion**
- 3:25 – 3:36** **Break — Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 15 (Grand Ballroom West, 3rd Floor)

PROGRESS IN THE TREATMENT OF RENAL AND VISCERAL ARTERY DISEASE

Moderators: *Randall DeMartino, MD*
Paulo E. Ocke Reis, MD, PhD
James C. Stanley, MD

- 3:36 – 3:41** Diagnosis And Management Of Renal Artery Stenosis With Or Without Mid-Aortic Syndrome In Pediatric Patients: Open Aortic Surgery Is Alive And Well: When Is Stenting Justified
Alex Fairman, MD
- 3:42 – 3:47** Endovascular Treatment Of Renal Artery Aneurysms: Indications, Embolic Techniques, Bare And Covered Stents: Technical Tips And Outcomes
Robert A. Morgan, MD
- 3:48 – 3:53** Current Role Of Renal Artery Angioplasty And Stenting: In View Of The RCT Data When Is It Justifiably Indicated
Robert A. Lookstein, MD
Michael R. Jaff, DO
- 3:54 – 3:59** Is Median Arcuate Ligament Syndrome (MALS) Overdiagnosed And Overtreated: Is It Real Or Just Rare: What Is The Pathogenesis And How Is It Best Treated
Peter Henke, MD
- 4:00 – 4:05** Isolated Dissection Of The Celiac Axis Or Superior Mesenteric Artery (SMA) May Be Symptomatic Or Asymptomatic: Natural History And When Is Anticoagulation Or Invasive Treatment Needed
I-Hui Wu, MD, PhD
- 4:06 – 4:11** Current Optimal Treatment Of Gastroduodenal And Pancreaticoduodenal Artery Aneurysms In Patients With Occlusion Of The Celiac Axis: Open Or Endovascular
James C. Stanley, MD
- 4:12 – 4:17** Open Surgery For The Management Of Visceral Aneurysms In The Endovascular Era: When Is It Best Especially In The Treatment Of Giant Pancreaticoduodenal Aneurysms
Domenico Valenti, DMChir, PhD

- 4:18 – 4:23** Current Optimal Treatment For Compression Of The Third Portion Of The Duodenum By The SMA (Wilke's Syndrome) With Or Without Left Renal Vein Compression (Nutcracker Syndrome): The Importance Of Hypermobility
Wilhelm Sandmann, MD
- 4:24 – 4:29** Technical Tips To Recanalize Long Complex SMA Occlusions: When Is Open Treatment Required
Armando Mansilha, MD, PhD
- 4:30 – 4:35** Current Role For Open SMA Reconstruction In The Endo-First Era: When Is Retrograde Open Mesenteric Stenting (ROMS) Indicated
W. Darrin Clouse, MD
- 4:36 – 4:42** **Panel Discussion**

SESSION 16 (Grand Ballroom West, 3rd Floor)

PROGRESS IN THE TREATMENT OF AORTIC COARCTATIONS AND EXPERT TECHNICAL SKILLS FOR OPEN VASCULAR OPERATIONS

Moderators: *R. Clement Darling III, MD*
James H. Black, III, MD
Peter Gloviczki, MD, PhD

NEW DEVELOPMENTS IN THE TREATMENT OF AORTIC COARCTATION

- 4:42 – 4:47** Long-Term Follow-Up Of Covered Stents To Treat Coarctation Of The Aorta: How To Deal With Complications
Elchanan Bruckheimer, MBBS
- 4:48 – 4:53** Experience With The Gore TBE (Thoracic Single Branched Endograft) For Treatment Of Recurrent Aortic Coarctation Or Aneurysm Formation: Technical Tips
Bernardo C. Mendes, MD

OPEN VASCULAR SURGERY

- 4:54 – 4:59** What Is The Role Of Aorto-Iliac Endarterectomy In The Endovascular Era: When And Why Is It The Best Treatment
Margaret Tracci, MD, JD
- 5:00 – 5:05** Technical Pearls To Facilitate Open Repairs Of Complex AAAs
Audra A. Duncan, MD
- 5:06 – 5:11** Open SMA Bypass After Failed Endovascular Interventions: Patient Selection, Technical Tips And Long-Term Outcomes
Salvatore Scali, MD
- 5:12 – 5:17** The Right Retroperitoneal Approach For Open AAA Repair: When To Do It, Advantages And Technical Tips
Ashraf Mansour, MD
- 5:18 – 5:23** Minimal Incisions For Open Vascular Operations Upon The Aorta And Femoral Arteries: How To Do Them: Advantages And Limitations
Robert M. Proczka, MD, PhD

IMPROVEMENTS IN VASCULAR MANAGEMENT TO ACHIEVE ANTERIOR SPINE EXPOSURE

- 5:24 – 5:29** Anterior Lumbar Spine Exposures: Variation Of Standard Approaches, Tips, Tricks, And Tools For Dealing With Difficult Circumstances: Causes And Management Of Unexpected Venous Injury
Andrew H. Schulick, MD, MBA

- 5:30 – 5:35** Technical Tips And Precautions For Safe And Effective Anterior Spine Exposure: What Hemorrhagic Complications Can Occur And How Are They Best Managed
Bernadette Aulivola, MD
- 5:36 – 5:41** Catastrophic Vascular Complications Of Anterior Spine Exposures; How To Avoid Them And How To Salvage The Situation If They Occur
William P. Robinson, MD
- 5:42 – 5:47** Technical Tips For Advanced Spine Exposure Including Bilateral Approaches: Managing Unusual Complications And Venous Anomalies
Heron E. Rodriguez, MD
- 5:48 – 5:56** **Panel Discussion**
End of Program B

PROGRAM C-1 (SESSIONS 17-18)
MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH
Trianon Ballroom, 3rd Floor

SESSION 17 (Trianon Ballroom, 3rd Floor)
MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH – PART 1

Moderator: *Peter Monteleone, MD*

- 7:00 – 7:05** Introduction To The Symposium
Frank J. Veith, MD
- 7:05 – 7:15** Welcome And Introduction
Peter Monteleone, MD
- 7:15 – 7:25** Risk Stratification Of Acute Pulmonary Embolism: Which Model Best Identifies Low- vs. High-Risk Cases
Aditya Sharma, MD
- 7:25 – 7:35** Echocardiography Is All You Need To Manage Acute Submassive PE
David M. Dudzinski, MD
- 7:35 – 7:45** CTA Is All You Need To Manage Acute Submassive PE
Brian B. Ghoshhajra, MD, MBA
- 7:45 – 7:55** Testing For Cancer And Other Hypercoagulable States In PE: Why, When, And What Tests
Rachel Rosovsky, MD, MPH
- 7:55 – 8:10** Medical Treatment Of PE: A Case Based Discussion
Ido Weinberg, MD, MSc
- 8:10 – 8:25** An Overview Of Clinical Trials For PE: Will Any Of Them Move The Needle
Stavros V. Konstantinides, MD
- 8:25 – 8:35** Intravenous Thrombolytic Therapy For PE: Why, When, And At What Dose
Jay Giri, MD, MPH
- 8:35 – 8:45** Ultrasound-Assisted Pharmacomechanical Thrombolysis: Emerging Data To Define Use In PE
Peter Monteleone, MD
- 8:45 – 8:55** Pharmacomechanical Thrombolysis With The Bashir Catheter: Unique And Differentiated Approach
Eric A. Secemsky, MD, MSc
- 8:55 – 9:05** Percutaneous Mechanical Thrombectomy Without Lytics: The FlowTrieve® System
Mitchell D. Weinberg, MD
- 9:05 – 9:15** Percutaneous Mechanical Thrombectomy Without Lytics: The Indigo System
Robert A. Lookstein, MD, MHCDL
- 9:15 – 9:25** Large Bore Aspiration Thrombectomy—Tips, Tricks And Pearls
Gary M. Ansel, MD

9:25 – 9:40 Panel Discussion

Panelists: Gary M. Ansel, MD
Brian B. Ghoshhajra, MD, MBA
Jay Giri, MD, MPH
Robert A. Lookstein, MD, MHCDL
Rachel Rosovsky, MD, MPH
Eric A. Secemsky, MD, MSc
Aditya Sharma, MD
Ido Weinberg, MD, MSc
Mitchell D. Weinberg, MD

9:40–10:10 Break — Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 18 (Trianon Ballroom, 3rd Floor)

MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH – PART 2

Moderator: **Peter Monteleone, MD**

10:10–10:20 The Angiovac Strategy For The Treatment Of PE
Christopher J. Kwolek, MD, MBA

10:20–10:30 ECMO-Assisted Pulmonary Embolectomy In Massive PE: Can It Replace Open Surgical Thromboembolectomy
Animesh Rathore, MD

10:30–10:40 How To Best Use The Direct Oral Anticoagulants — What Are The Tips
Robert M. Schainfeld, DO

10:40–10:55 Your Referring Docs Think Heparin Is All They Need To Offer For PE — How To Tell The Intervention Story
Patrick Troy, MD

10:55–11:10 Pulmonary Denervation: A New Frontier In The Treatment Of Pulmonary Hypertension
Mark G. Davies, MD

11:10–11:25 Balloon Pulmonary Angioplasty For Chronic Thromboembolic Pulmonary Hypertension: Has This Become Mainstream
Kenneth Rosenfield, MD

11:25–11:35 The Team Approach To PE Management: The National PERT Consortium
John Moriarty, MD

11:35–12:00 Challenging The Experts: Interactive Q&A

Panelists: Alun H. Davies, MA, DM, DSc
Christopher J. Kwolek, MD, MBA
Robert A. Lookstein, MD, MHCDL
John Moriarty, MD
Animesh Rathore, MD
Kenneth Rosenfield, MD
Robert M. Schainfeld, DO
Eric A. Secemsky, MD, MSc
Patrick Troy, MD

End of Program C-1

12:00– 1:00 Lunch Available - Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors)

PROGRAM C-2 (SESSIONS 19-22)

INTERESTING TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENTS

Trianon Ballroom, 3rd Floor

SESSION 19 (Trianon Ballroom, 3rd Floor)

HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENTS: “NO OPTION” FOR LIMB SALVAGE ISSUES IN CLTI

Moderators: *Richard J. Powell, MD*
Vincent L. Rowe, MD

- 1:00 – 1:05** In Octogenarians And Nonagenarians With CLTI When Is Revascularization Indicated: When Should It Be Endo And When Open And What Results Should Be Achievable
Kimihiko Komori, MD, PhD
- 1:06 – 1:11** Optimal Vessel Preparation For Drug Coated Balloon (DCB) Treatment Of Fem-Pop Lesions: Atherectomy, IVL Or POBA: Is It Lesion Or Previous Intervention Dependent
Hany M. Zayed, MD
- 1:12 – 1:17** The ArtAssist Self Applied Intermittent Compression Device To Treat CLTI Patients: How Does It Work: When Is It Indicated And When Is It Not: Results
Sherif A.H. Sultan, MD, PhD
- 1:18 – 1:23** Updates On The Value Of Stem Cell And Gene Therapies In CLTI: Are There New Developments Suggesting That They May Be Helpful For "No Option" Patients: How Many Such Patients Still Exist: What About The BioGenCell System
Richard J. Powell, MD
Yael Porat, PhD
- 1:24 – 1:29** Technical Tips Of Deep Venous Arterialization (DVA): To Make It Work What Are The Critically Important Aspects Of Care Which Start After The Procedure
Erwin Blessing, MD
- 1:30 – 1:35** Open vs. Endovascular Deep Venous Arterialization (DVA): Advantages And Limitations Of Each: How To Choose One Or The Other
Richard F. Neville, MD
- 1:36 – 1:41** Tissue Necrosis Persisting Despite A Patent Endovascular Intervention Can Be Healed By An Additional Bypass: What Is The Mechanism And The Experience
Hasan H. Dosluoglu, MD
- 1:42 – 1:47** Treatment Of Pedal Arch Occlusive And Stenotic Lesions: Thrombectomy Tools And Techniques That Work
Timothy W.I. Clark, MD
- 1:48 – 2:04** **Panel Discussion**

SESSION 20 (Trianon Ballroom, 3rd Floor)

MORE HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENT – EVALUATING ARTERIAL ANATOMY AND TREATMENT OUTCOMES WITH CLTI

Moderators: *Marianne Brodmann, MD*
Caron B. Rockman, MD

- 2:04 – 2:09** What Is The Woundosome Concept, How Is It Different And More Important Than The Angiosome Concept To Achieve Wound Healing
Lorenzo Patrone, MD
- 2:10 – 2:15** The Value Of Distal Angiography, Selective And Subselective, In The Treatment Of Lesions Causing CLTI: Technical Tips On How To Do It
Jos C. van den Berg, MD, PhD

- 2:16 – 2:21** The Impact Of Prior Endovascular Failure On Subsequent Open And Endo Treatment Outcomes In The BEST-CLI RCT: It's Not Good
Richard J. Powell, MD
- 2:22 – 2:27** What Is Optimal Medical Therapy For Patients With CLTI: Why Does It Paradoxically Improve MALE But Not MACE In The Data From The BEST-CLI Trial
Vikram S. Kashyap, MD
- 2:28 – 2:33** What Has Been The Impact Of The BEST-CLI And BASIL 2 RCTs On The Treatment Of CLTI In European Practices
Francesco Spinelli, MD
- 2:34 – 2:39** Remote Wireless Monitoring Of Stent Blood Flow Is Possible With The Vesselsens Flow System: How Does It Work And Results
Michael K. W. Lichtenberg, MD
- 2:40 – 2:45** Remote Wireless Monitoring (IntelVasc) Of Any Lower Extremity Vascular Treatment: How Does It Work And How Can It Help Patients
Jean Bismuth, MD
- 2:46 – 2:52** **Panel Discussion**
- 2:52 – 3:00** **Break — Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 21 (Trianon Ballroom, 3rd Floor)

HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENTS

Moderators: *Neal S. Cayne, MD*
Gary M. Ansel, MD

- 3:00 – 3:05** After CLTI Invasive Treatment For One Limb, Adverse Ischemic Limb Events In The Contralateral Limb Are Common Requiring Careful Observation And Often Invasive Treatment: Based On Data From The SPINACH Trial
Nobuyoshi Azuma, MD
- 3:06 – 3:11** Update On New And Innovative Techniques To Treat Buerger's Disease: What Are They And How Do They Improve Results
Kamphol Laohapensang, MD
- 3:12 – 3:17** **DEBATE:** Endovascular Treatment Of Common Femoral Artery (CFA) Bifurcation Lesions Should Be The Intervention Of Choice: What Is The Eiffel Tower Technique And What Are Its Results
Yann Gouëffic, MD, PhD
- 3:18 – 3:23** **DEBATE:** Why Endarterectomy Is Still The Best Approach For All CFA Lesions
Thomas L. Forbes, MD
- 3:24 – 3:29** Endovascular PTA And Stenting Of Deep Femoral Artery (DFA) Lesions Is Possible And Effective: How To Do It, Limitations, And Results
Pasqualino Sirignano, MD, PhD
- 3:30 – 3:35** Decreased Renal Function And Dialysis Dependent Renal Failure (ESRD) Are Negative Factors In The Outcomes Of Limb Salvage Surgery In CLTI Patients: These Must Be Acknowledged But Are Not A Contraindication To Endo Or Open Procedures
Vincent L. Rowe, MD
- 3:36 – 3:41** Comparison Of Limb Outcomes Between Bypass Surgery And Endovascular Therapy In CLTI Patients With Dialysis-Dependent And -Independent Patients
Kimihiro Komori, MD, PhD
- 3:42 – 3:47** **Panel Discussion**

- 3:48 – 3:53** Intravascular Ultrasound Guided Interventions For Fem-Pop Occlusive Disease: When And How To Make Them Work And Be Cost Effective
Michael K.W. Lichtenberg, MD
- 3:54 – 3:59** **DEBATE:** IVUS-Guided Revascularization Of Fem-Pop Lesions: Advantages, Limitations And Why It's Better Than Duplex Guided Treatment
Fabrizio Fanelli, MD
- 4:00 – 4:05** **DEBATE:** Not So: Duplex Guidance Is Better Than IVUS Guidance For Fem-Pop Revascularization: Advantages And Limitations
Enrico Ascher, MD
Natalie A. Marks-Ascher, MD, RPVI, RVT
- 4:06 – 4:11** **DEBATE:** All CLTI Patients Should Undergo Endovascular Treatment As The First Procedure: What Is The Role For Bypass Surgery
Iris Baumgartner, MD
- 4:12 – 4:17** **DEBATE:** Not So: Some Patients Should Undergo A Bypass As The First Procedure: Which Ones
Michael S. Conte, MD
- 4:18 – 4:23** **Panel Discussion**

SESSION 22 (Trianon Ballroom, 3rd Floor)

MORE HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE, CLTI AND ITS TREATMENTS

Moderators: *Brian G. DeRubertis, MD*
Caitlin W. Hicks, MD, MS

- 4:24 – 4:29** Compensatory Arterial Enlargement In Patients With Diabetes: What Is The Mechanism And How Should It Influence Treatment
Nicos Labropoulos, PhD
- 4:30 – 4:35** Value Of Index Of Microcirculatory Resistance (IMR), Optical Coherence Tomography (OCT), BTK-Flow Reserve And Fractional Flow Reserve (FFR) In BTK Lesions: How To Perform These Measurements
Lee Bouwman, MD, PhD
- 4:36 – 4:41** How Should Patient Age Impact The Choice Of Bypass vs. Endovascular Therapy For CLTI: An Analysis Of The Outcomes Of The BEST CLI Trial According To Patient Age
William P. Robinson, MD
- 4:42 – 4:47** Why Pre-Intervention Physiologic Testing Is Important In Determining Treatment Of Patients With Intermittent Claudication: When Is Invasive Treatment Justified
Caitlin W. Hicks, MD, MS
- 4:48 – 4:53** Technical Tips For Simple And Complex BTK, And Pedal And Deep Femoral Punctures And Access: When Are They Useful And How To Do Them
Lorenzo Patrone, MD
- 4:54 – 4:59** Laser And Optics Based Intravascular Lithotripsy (IVL-Bolt Medical) System For The Treatment Of Below-The-Knee (BTK) Calcified Lesions: How Does It Work And Results Of The RESTORE BTK Trial
Michael K.W. Lichtenberg, MD
- 5:00 – 5:05** Why Intravascular Lithotripsy (IVL - Shockwave-J&J) Is A Game Changer In The Treatment Of BTK Vascular Lesions: What Is The Evidence, What Are The Indications And Techniques
Palma M. Shaw, MD, MBA, RPVI
- 5:06 – 5:11** **Panel Discussion**

- 5:12 – 5:17** Update On The Advantages Of The Chocolate Wire Constrained Uncoated Balloon (From Medtronic) For Treating Popliteal And BTK Lesions: Advantages Including Prevention Of Vessel Recoil: Updated Results (From The CHOCO CABANA Trial)
Gunnar Tepe, MD
- 5:18 – 5:23** Efficacy Of Chocolate Balloon (Medtronic) Stabilization In The Management Of Dissections After Fem-Pop Balloon Angioplasty: The CHOCO-STAB Study
Felice Pecoraro, MD
- 5:24 – 5:29** 3-Year Outcomes Of The MOTIV Drug Eluting Bioresorbable Scaffold (Reva Medical) To Treat BTK Artery Lesions
Michel J. Bosiers, MD
- 5:30 – 5:35** Spinal Cord Stimulation: Another Method To Treat CLTI Patients: How Does It Work And When Might It Be Indicated: Can It Be Effective In Patients With Tissue Loss
Allan L. Brook, MD
- 5:36 – 5:41** Retrograde Recanalization Of Lower Extremity Occlusive Lesions: Technical Tips, Complications And How To Be Successful Even After Removal Of The SFA
Erwin Blessing, MD
- 5:42 – 5:47** Why Ankle Brachial Indices (ABIs), Toe Pressures, Handheld Doppler Signals And Doppler Wave Forms May Be Misleading In Diabetics With CLTI: Pulse Volume Recordings Are Always Reliable
Alun H. Davies, MA, DM, DSc
- 5:48 – 5:53** Simple, Quick And Safe Conversion Of Retrograde Arterial Access To Antegrade Femoral Access And How To Get A Guidewire Going Into The Deep Femoral Artery Into The SFA
Timothy W.I. Clark, MD
- 5:54 – 5:59** **Panel Discussion**
End of Program C-2

WEDNESDAY, NOVEMBER 19, 2025

- 6:00 A.M. General Registration** – Rhinelander Gallery, 2nd Floor
6:00 A.M. Faculty Registration – Gramercy Suite West, 2nd Floor
6:15 A.M. Continental Breakfast – Rhinelander Gallery, 2nd Floor

CONCURRENT WEDNESDAY PROGRAMS

PROGRAM D (SESSIONS 23-30)

Progress In Lower Extremity Occlusive Disease And Its Treatment

Location: Grand Ballroom East, 3rd Floor

PROGRAM E (SESSIONS 31-38)

New Developments In Medical Treatments And New Drugs; Progress In Anti-Atherogenic And Anti-Hypertensive Treatments; Management Of Endoleaks; Recorded Live Cases From Leading Centers In The US And EU; Issues Of Interest; Outpatient And Office-Based Vascular Treatment; Topics Related To Government, Reimbursement, The SVS, VQI, FDA, Guidelines, Trials And Evidence-Based Medicine

Location: Grand Ballroom West, 3rd Floor

PROGRAM F (SESSIONS 39-46)

MORE NEW DEVELOPMENTS IN THORACIC AORTIC DISEASE, TEVAR, AORTIC DISSECTIONS, TAAAs, JUXTA- AND PARARENAL AAAs, PARALLEL GRAFTS, FENESTRATED AND BRANCHED EVAR (F/B/EVAR), MULTILAYER BARE STENTS, INFRARENAL AAAs AND STANDARD EVAR, AND HOT NEW AORTIC TOPICS

Location: Trianon Ballroom, 3rd Floor

PROGRAM D (SESSIONS 23-30)

PROGRESS IN LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENT

Grand Ballroom East, 3rd Floor

SESSION 23 (Grand Ballroom East, 3rd Floor)

GENERALITIES IN THE TREATMENT OF LOWER EXTREMITY OCCLUSIVE DISEASE, CLTI AND THEIR MEDICAL TREATMENT: SOME NEW CONCEPTS

Moderators: *Enrico Ascher, MD*

Andrej Schmidt, MD

Christopher K. Zarins, MD

6:52 – 6:57 Despite Aggressive Efforts By All Vascular Specialists To Save Lower Limbs, The Incidence Of Major Amputations (BKA And AKA) Is Increasing In The US: What Is The Cause And What Can Be Done To Reverse This Trend

Panos Kougias, MD, MSc

6:58 – 7:03 How Does Early Intervention For Critical Limb Threatening Ischemia (CLTI) Save Legs And Lives: The Earlier Ischemia Is Corrected, The Better

Jonathan R. Boyle, MD, MA (Cantab)

7:04 – 7:09 An Interventional Cardiologist's Perspective On The Primary And Secondary Outcomes Of BEST-CLI: Why Does It Differ From The Perspective Of Most Vascular Surgeons

Kenneth Rosenfield, MD

7:10 – 7:15 Technical Tips For Vessel Prep Prior To The Use Of DCBs And DESs: It Is Different And Not Simple: How To Do It And Why Is It Important

Erwin Blessing, MD

7:16 – 7:21 What Are The Best Medical Adjuncts To Improve Patency Of Bypass Grafts And Endovascular Procedures

Peter Henke, MD

7:22 – 7:27 With CLTI Patients Silent Coronary Ischemia Is Deadly: Coronary CT Angiography And FFRCT (By Heartflow) Facilitates Detection And Treatment Of High Risk Coronary Plaques Which Decreases Mortality As Shown By An RCT: The Coronary Intervention Can Precede Or Follow The Lower Extremity Procedure

Dainis K. Krievins, MD

Christopher K. Zarins, MD

7:28 – 7:33 Local Anesthetic Injection Into A Lesion Site Facilitates Angioplasty (PTA) And Stent Placement By Decreasing Patient Pain And Movement: How To Do It

Andrej Schmidt, MD

7:34 – 7:39 Use Of Intraoperative Pedal Duplex To Detect Embolization During Complex Lower Extremity Revascularization: How To Do It, What Are The Causes And How To Prevent It

Peter A. Schneider, MD

7:40 – 7:45 The Retrievable "Infuse" Drug Delivery Stent-Graft: How Does It Work And Will It Render Drug Coated Balloons (DCBs) Obsolete
Bryan W. Tillman, MD, PhD

7:46 – 7:53 **Panel Discussion**

SESSION 24 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN ATHERECTOMY AND STENTS (UNCOATED AND COATED)

Moderators: *Craig M. Walker, MD*

Ramon L. Varcoe, MBBS, MS, PhD, MMed

Peter A. Schneider, MD

PROGRESS IN ATHERECTOMY

7:53 – 7:58 The Many Devices For Atherectomy: Advantages And Limitations Of Each: Which Is The Best And Why: When Is Atherectomy Solidly Indicated And When Is It Overused

Todd R. Vogel, MD, MPH

7:59 – 8:04 Management Of Atherectomy Failures: What Are The Causes: Are They More Common In OBLs And How Are They Related To Over Usage

John Blebea, MD, MBA

8:05 – 8:10 The Available Atherectomy Devices: Which One Is Best For What Lesions: What Is The Solid Evidence That Atherectomy Is Effective: From A Systematic Review And Meta-Analysis

Eric A. Secemsky, MD, MSc

8:11 – 8:16 Optimal Treatment For Calcified Fem-Pop Lesions: Why Intravascular Lithotripsy (IVL - Shockwave-J&J) And When Aperta High Pressure PTA Balloon (Braun): What About Atherectomy - Their Limitations And Advantages

Craig M. Walker, MD

UPDATE ON UNUSUAL STENTS

8:17 – 8:22 Long-Term Results With The Vasculomimetic, Interwoven Supera Stent (Abbott) To Treat Occlusive Disease In The Aorta, Iliac And Other Arteries: Advantages And Limitations: When Should It Be The Preferred Treatment

Rajiv Parakh, MBBS, MS

8:23 – 8:28 Advantages And Limitations Of Supera Vasculomimetic (VMI Stents) For Complex Fem-Pop Occlusive Lesions: They Even Work In The Subintimal Position: When Are They The Best Treatment

Erwin Blessing, MD

8:29 – 8:34 Update On The BioMimics 3D Spiral Flow Stent (From Veryan Medical): How Does It Work And Is Its Patency Equal To That Of DESs

Robert E. Beasley, MD

8:35 – 8:40 When Should Coronary Drug-Eluting Stents (DESs) Be Used To Treat Vein Bypass Stenoses And When Should They Not Be: Which Stent Is Best

Christopher J. Abularrage, MD

8:41 – 8:46 Updated Results With The Spur Spiked Temporary Stent System For Drug Delivery (Reflow Medical) With And Without DCB Angioplasty: Data From The DEEPER OUS And DEEPER REVEAL Trials

Anahita Dua, MD, MS, MBA

Thomas Zeller, MD

Michael K.W. Lichtenberg, MD

8:47 – 8:53 **Panel Discussion**

SESSION 25 (Grand Ballroom East, 3rd Floor)

**LOWER EXTREMITY TOPICS RELATED TO BTK
LESION DCBs AND STENTING – STANDARD AND
NEW BIORESORBABLE**

Moderators: *Michael S. Conte, MD*
Sahil A. Parikh, MD
Kenneth Ouriel, MD, MBA

- 8:53 – 8:58** Experience To Date With Everolimus And Other Nonabsorbable Coronary DESs To Treat Infrapopliteal BTK Lesions – Long And Short – Causing CLTI: What Are The Stents And When Do They Help: Might The Drug Eluting Resorbable Stents (DRSs) Be Better
Robert A. Lookstein, MD, MHCCL
- 8:59 – 9:04** 3-Year Results Of The Esprit (Abbott) Drug Eluting Resorbable Stent (DRS) In The LIFE-BTK RCT Comparing It With Plain Old Balloon Angioplasty (POBA): DRSs Make A Difference
Ramon L. Varcoe, MBBS, MS, PhD, MMed
Sahil A. Parikh, MD
Brian G. DeRubertis, MD
- 9:05 – 9:10** 2-Year Results Of The Magnitude Sirolimus Eluting Bioresorbable Stent (From R3 Vascular): For BTK Lesions: How Does It Compare With Other Treatments: Is Intravascular Lithotripsy (IVL-Shockwave) Feasible To Treat BTK Lesions
Marianne Brodmann, MD
- 9:11 – 9:16** Bioresorbable Magnesium Scaffold (Stent — BIOTRONIK) Has Been Improved For Lower Extremity And Coronary Lesions: Current Status, Advantages And Limitations
Ron Waksman, MD
- 9:17 – 9:22** Update On The Value Of DCBs For BTK Angioplasty Including A RCT Comparison Of A Sirolimus DCB (Magic Touch – Concept Medical) vs. A Paclitaxel DCB (Lithos – Acotec)
Dierk Scheinert, MD
- 9:23 – 9:28** With The Good Results Of The DRSs: After Their Approval What Unmet Needs In The Treatment Of BTK Disease Remain To Be Met
Brian G. DeRubertis, MD
- 9:29 – 9:34** Promising Results To Date With Bioresorbable DESs To Treat BTK Lesions: How Will They Change The Open/Endo Balance For Treating CLTI: The Need For Open Bypasses Will Be Diminished But Will Never Fade Away
Steven Kum, MD
- 9:35 – 9:40** How Does The LIFE BTK Study With Esprit Bioresorbable DRS (From Abbott) Change The BEST-CLI Conclusions For BTK Lesions
Lawrence A. Garcia, MD
- 9:41 – 9:46** Other BTK Resorbable Stent Platforms Including A Sirolimus Coated One From R3 Vascular: What Will Be The Impact Of BTK DRSs And How Will Vessel Prep Differ With BTK Bioresorbable Stent Platforms
Sahil A. Parikh, MD
- 9:47 – 9:52** The Value Of Everolimus Eluting Coronary Stents (Xience — Abbott) Bailout Stenting Of BTK Lesions After Angioplasty Causing CLTI: From A Real-World Multicenter Study
Yann Gouëffic, MD, PhD
- 9:53 – 9:59** **Panel Discussion**
- 10:00-10:12** **Break — Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 26 (Grand Ballroom East, 3rd Floor)

**NEW DEVELOPMENTS IN DRUG COATED
BALLOONS (DCBs) AND DRUG ELUTING STENTS
(DESs): UPDATES ON PACLITAXEL TOXICITY,
RANDOMIZED CONTROLLED TRIALS (RCTs) AND
BTK LESION TREATMENTS WITH DCBs AND DESs**

Moderators: *Marianne Brodmann, MD*

Dierk Scheinert, MD

Sean P. Lyden, MD

**NEW INFORMATION ON DCBs AND DESs FOR
FEMPOP LESIONS: UPDATES ON RCTs**

- 10:12-10:17** Although Paclitaxel Coated Devices Confer No Increase In Mortality Rates, They May Still Be Associated With Increased Amputation Rates When Used To Treat CLTI Patients: What Mechanism May Be Responsible
Konstantinos Katsanos, MSc, MD, PhD
- 10:18-10:23** Increased Amputation Rates From Use Of Paclitaxel Coated Devices May Be Real Or A Methodological Artifact: Other Paclitaxel Coating Effects Like Embolization Or Post Atherectomy Aneurysm Formation Deserve Further Study
Peter A. Schneider, MD
- 10:24-10:29** Comparative Long-Term Outcomes With DESs And DCBs To Treat Fem-Pop Lesions: Unique Observations After 2-12 Years In 1000 Patients: What Is The Best Technique For Vessel Preparation
Fabrizio Fanelli, MD
- 10:30-10:35** 2-Year Results Of The SPORTS RCT Comparing DESs (Eluvia – Boston Scientific) vs. Bare Metal Stents (BMSs) vs. DCBs: Which Device Is Best And In What Circumstances
Gunnar Tepe, MD
- 10:36-10:41** Long-Term Results Of An RCT Comparing Surveil DCBs (Surmodics) With In.Pact DCBs (Medtronic) For Treating FemPop Lesions: From The TRANSCEND Trial: How Do The Two Devices Differ
Peter A. Schneider, MD
- 10:42-10:47** DESs vs. Bare Stents: Data From The TRUETA Trial: What New Information Influencing Practice Comes From This Large Data Analysis
Brian G. DeRubertis, MD
- 10:48-10:53** Systematic Literature Review And Meta-Analysis Of Fempop Endovascular Treatment With DESs, Cover Stents And BMSs: When Is Each Best And What Is The Hard Evidence
Yann Gouëffic, MD, PhD
- 10:54-10:59** Directional Atherectomy As Vessel Prep For DCB Use For FemPop Lesions: For Which Lesion Characteristics Is It The Best Treatment: What Is The Evidence For Its Superiority
Brian G. DeRubertis, MD
Thomas Zeller, MD
- 11:00-11:05** **Panel Discussion**

**NEW DEVELOPMENTS IN THE ENDOVASCULAR
TREATMENT OF BTK LESIONS**

- 11:06-11:11** 12 Commandments For A Successful BTK Intervention In Patients With CLTI
Ali Amin, MD, RVT
- 11:12-11:17** What's New And What's Next For The Treatment Of BTK Lesions: When Is POBA Still Acceptable And What About Drug Eluting And Non-Drug Eluting Devices, Resorbable Or Not
Lawrence A. Garcia, MD

- 11:18–11:23** Updated 2-Year Results Of The DEBATE-BTK SHOCK RCT Evaluating The Value Of Lithotripsy (Shockwave-J&J) Prior To DCB Treatment In Diabetic Patients Undergoing BTK Revascularization
Francesco Liistro, MD
- 11:24–11:29** Patency And Wound Healing Results Of The 3-French Compatible Microstent (From Micro Medical) Compare Favorably With POBA For BTK Lesions: From The STAND RCT: Antegrade And Retrograde Insertions Are Possible
Robert E. Beasley, MD
Marco G. Manzi, MD
- 11:30–11:35** Update On The SELUTION4BTK RCT Comparing A Sirolimus-Coated DCB (From Cordis/Medalliance) With POBA For BTK Lesions
Patrick J. Geraghty, MD
Marianne Brodmann, MD
George L. Adams, MD
- 11:36–11:41** Why Some BTK DCB Trials Have Not Shown Uniformly Better Results: Technical And Balloon Factors Matter
Francesco Liistro, MD
- 11:42–11:47** Late (5-Year) Results From The AcoArt II BTK DCB RCT Show Safety With No Increased Mortality And Improved Patency vs. POBA To Treat BTK Lesions
Wei Guo, MD
Francesco Liistro, MD
- 11:48–11:53** Open vs. Endo Revascularization For Patients With Infrapopliteal Disease Causing CLTI: A Large Population Based Study Confirms The Superiority Of Saphenous Vein Bypass: Newer Technologies May Alter This Conclusion
Mahmoud B. Malas, MD, MHS
- 11:54–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break - Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 27 (Grand Ballroom East, 3rd Floor)
PROGRESS IN EXOTIC AND EXTREME NEW TREATMENTS FOR VERY DISTAL LOWER EXTREMITY DISEASE CAUSING ADVANCED CLTI: OPTIONS TO SAVE THE “NO OPTION FOR TREATMENT” LIMB AND THE “DESERT FOOT”

- Moderators:** *Patrick J. Geraghty, MD*
Marco G. Manzi, MD
Hasan H. Dosluoglu, MD
- 1:00 – 1:05** What Presently Defines A No Option Or Desert Foot Before Or After Failed Endo Or Open Treatments: Can Better Arterial Imaging Help And How To Do It
Peter A. Schneider, MD
- 1:06 – 1:11** Progress In The Treatment Of Supposed "No Option" CLTI Patients: With Better Arterial Imaging, Inframalleolar PTA Or Bypass Or Deep Vein Arterialization (DVA) May Be The Best Treatment: How To Do This Better Imaging With Direct Arterial Injection, DSA, CTA And MRA And What They Can Show
Sherif A.H. Sultan, MD, PhD
- 1:12 – 1:17** More Distal Angioplasty Can Salvage Some "No Option" Limbs: Below-The-Ankle Endo Interventions In 2025: Techniques, Devices And Should Balloons Be Drug Coated Or Not
Marianne Brodmann, MD

- 1:18 – 1:23** Extreme New Endovascular Treatments For Otherwise Untreatable "No Option" CLTI: Plantar Loop And Other Techniques: How To Do Them, Specialized Equipment And Results
Marco G. Manzi, MD
- VALUE OF PROSTHETIC (PTFE) TIBIAL BYPASSES**
- 1:24 – 1:29** Long-Term Multicenter Outcomes Show That Prosthetic (PTFE) Bypasses To Tibial And Peroneal Arteries Are Worthwhile
Hasan H. Dosluoglu, MD
Heepeel Chang, MD
Richard F. Neville, MD
Frank J. Veith, MD
- 1:30 – 1:35** **Panel Discussion**
- UPDATE ON VEIN ARTERIALIZATION FOR CLTI**
- 1:36 – 1:41** Long-Term Outcomes Of Transcatheter Arterialization Of The Deep Veins (DVA) Using The LimFlow System (Inari-Stryker): From A Multicenter UK Study: Indications, Advantages And Limitations
Hany M. Zayed, MD
- 1:42 – 1:47** Intraoperative Optimization Of DVA (LimFlow) For No Option CLTI: Flow Volume In The Lateral Plantar Vein Is A Crucial Parameter To Measure And Modulate For DVA Success: How To Do It And How To Use It
Miguel F. Montero-Baker, MD
- 1:48 – 1:53** Long-Term 5-Year Experience With LimFlow DVA For CLTI: Optimal Case Selection, Technical And Post Procedure Pearls To Improve Results: Role And Methods Of Vein Embolization
Steven Kum, MD
- 1:54 – 1:59** Results With LimFlow Deep Vein Arterialization (DVA) Are So Good That There Are Few CLTI Patients That Are Truly "No Option" For Invasive Treatment: What Are The Adjuncts To The Procedure That Contribute To Its Success – Anticoagulation, Etc.
Anahita Dua, MD, MS, MBA
- 2:00 – 2:05** Not So Fast: Results With DVA May Not Be As Good Universally As Reported In The PROMISE And Other Trials: DVA May Have Some Downsides Leaving Room For Other Treatments Of "No Option" CLTI Patients
Marc L. Schermerhorn, MD
- 2:06 – 2:11** Alternate Catheter-Based System For DVA: The Boomerang Device And Trial (Cardiva Medical) Creates An Endovascular A-V Fistula Without The Need For A Stent-Graft: How Does It Work: Advantages And Results
Brian G. DeRubertis, MD
- 2:12 – 2:17** Open Surgical Vein Arterialization: Indications, Technical Tips, Long-Term Results And Advantages Of Open vs. Endo
Pramook Mutirangura, FRCS (Edinburgh)
- 2:18 – 2:24** **Panel Discussion**

SESSION 28 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN PROSTHETIC GRAFTS; STENT GRAFTS; PERCUTANEOUS ENDOVASCULAR BYPASSES; STENT OCCLUSIONS AND TREATMENT OF IN STENT RESTENOSIS (ISR)

Moderators: *Miguel F. Montero-Baker, MD*
Richard F. Neville, MD
Anahita Dua, MD, MS, MBA

**NEW CONCEPTS RE PTFE GRAFTS AND STENT-
GRAFTS**

- 2:25 – 2:30** For Primary Treatment Of CLTI What Is The Current Role And Proportion Of Patients Needing An Open Bypass In The Endovascular Era: What Percentage Of CLTI Patients Will Need An Open Bypass At Some Time In Their Course: What Percentage Of These Bypasses Will Have To Be Done With A PTFE Graft
Niten Singh, MD
- 2:31 – 2:36** Heparin-Bonded Expanded PTFE Grafts For BTK Bypasses: What Is The Evidence That They Are Better And Are Propaten (Gore) Grafts The Best For Extensive FemPop Disease: Based On An RCT And A Systemic Review And Meta-Analysis
Yann Gouëffic, MD, PhD
- 2:37 – 2:42** Viabahn Stent-Graft For Complex Fem-Pop Lesions: When Are They The Best Treatment: Technical Tips For Making Them Work And Avoiding Intimal Hyperplasia At Their Ends: Long-Term Results And What Treatment Is Best If They Thrombose – Endo Or Open
Osamu Iida, MD, PhD (PowerPoint Presentation With Synched Audio)

PERCUTANEOUS FEMPOP BYPASSES

- 2:43 – 2:48** 4-6-Year Results With Percutaneous (PQ) Transvenous Fem-Pop PTFE Bypasses (From Endologix): How Is It Done And Updated Results From The DETOUR Trials Compare Favorably To Open Fem-Pop Bypasses: What Are The Limitations
Sean P. Lyden, MD
Dainis K. Krievins, MD
- 2:49 – 2:54** Percutaneous Extravascular FemPop PTFE Bypasses Without Traversing The Vein: Technique And 7-Year Experience In Patients: Are Others Doing The Procedure
Pierre G. Sarradon, MD
Jean Pierre Becquemin, MD

**RESTENOSIS AFTER DCBs AND TREATMENT OF
IN-STENT RESTENOSIS (ISR)**

- 2:55 – 3:00** What Are The Best Treatment Options For Restenosis After DCBs And How They Differ From Restenosis After Angioplasty And Stenting
Gunnar Tepe, MD
- 3:01 – 3:06** Atherectomy Followed By DCB To Treat Severe In-Stent Restenosis (ISR): Why Is Excimer Laser The Best Atherectomy Tool: Technical Tips And Late Results
Craig M. Walker, MD
- 3:07 – 3:12** **Panel Discussion**
- 3:13 – 3:23** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 29 (Grand Ballroom East, 3rd Floor)

**FOOT PERFUSION EVALUATION METHODS;
LOWER EXTREMITY RCTs: NEW CONCLUSIONS
PRO AND CON**

Moderators: *Matthew T. Menard, MD*
Marco G. Manzi, MD
Frank J. Veith, MD

NEW METHODS TO EVALUATE FOOT PERFUSION

- 3:24 – 3:29** iThera: A New Laser Measurement Tool To Assess Microcirculation And Foot Perfusion After Revascularization In CLTI Patients
Marianne Brodmann, MD

- 3:30 – 3:35** Pedal Pulse Acceleration Time (PAT) Is The Best Method To Assess Circulatory Improvement After Revascularizations For CLTI: How To Do It And Why It's Better Than Other Methods
Maarit Venermo, MD, PhD
- 3:36 – 3:41** Near Infrared Spectral Imaging (NIRS) Is The Best Way To Assess Foot Perfusion Before And After Revascularization Treatments: Equipment Needed And How Does It Work
Richard F. Neville, MD
- NEW FINDINGS AND INTERPRETATIONS FROM THE BIG RCTs**
- 3:42 – 3:47** Findings And Interpretations From New Sub Analysis Of The BEST-CLI RCT: When Are They Applicable And When They Are Not
Matthew T. Menard, MD
Alik Farber, MD, MBA
Kenneth Rosenfield, MD
- New Findings And Interpretations From The BASIL 2 And BASIL 3 RCTs: What They Tell Us That Is Helpful And What They Don't**
- 3:48 – 3:53** New Findings And Interpretations From The BASIL 2 And BASIL 3 RCTs: What They Tell Us That Is Helpful And What They Don't
Matthew Popplewell, MD
Andrew W. Bradbury, MD
- 3:54 – 3:59** What New Conclusions Can Be Reached By Combining The Data From BEST-CLI And BASIL Trials: When Are They Applicable And When Are They Not
Alik Farber, MD, MBA
Andrew W. Bradbury, MD
Matthew T. Menard, MD
Kenneth Rosenfield, MD
- 4:00 – 4:05** How To Use The BEST-CLI And BASIL 2 Findings Optimally In A Real World CLTI Practice In 2025 And Beyond
Kosmas I. Paraskevas, MD
Frank J. Veith, MD
- 4:06 – 4:11** How Can We Understand And Best Use The Diverging Results Of The BEST-CLI, BASIL 2, And BASIL 3 RCTs For The Treatment Of CTLI Patients
Anders Wanhainen, MD, PhD
- 4:12 – 4:17** The Reason Why The Apparently Opposite Results From BEST-CLI And BASIL 2 Are Actually Consistent And Reflect Everyday Clinical Practice: As Shown By Results From A Large Multicenter Prospective Cohort Study
Christian A. Behrendt, MD
- 4:18 – 4:23** Why CLTI Patients At Many Hospitals Could Not Be Included In The BEST-CLI Trial: Why This Weakens The Trial's Conclusions And Make Them Non-Applicable To Much Real-World Practice: What To Do About It
Niten Singh, MD
- 4:24 – 4:31** **Panel Discussion**

SESSION 30 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN THE TREATMENT OF INTERMITTENT CLAUDICATION (IC) AND ACUTE LIMB ISCHEMIA (ALI)

Moderators: *Alik Farber, MD, MBA*

Natalie A. Marks-Ascher, MD, RPVI, RVT

Thomas S. Maldonado, MD

INTERMITTENT CLAUDICATION (IC)

- 4:32 – 4:37** Perfusion Measurements To Detect Muscle Perfusion In Claudicants Are More Diagnostically Conclusive Than Walking Tests: What Techniques Should Be Used And Do They Help In Selecting Patients For Invasive Treatment
Werner Lang, MD
- 4:38 – 4:43** How Can AI Predict Rapid Disease Progression In Patients With Intermittent Claudication And How Should It Influence Treatment
Bijan Modarai, PhD
- 4:44 – 4:49** Short Chronic Occlusions (CTOs) <5cm When Treated Endovascularly For IC Are Associated With Poor Outcomes: Current Classification Systems Underestimate The Detrimental Impact Of Any CTO And Do Not Accurately Guide The Treatment Of IC: How Should They Be Changed
William P. Robinson, MD
- 4:50 – 4:55** Weight Loss Semaglutide Drugs (Ozempic, Wegovy) Increase Walking Ability And ABIs In Diabetics With IC: The STRIDE RCT
Caitlin W. Hicks, MD, MS
- 4:56 – 5:01** Why Supervised Exercise Therapy For IC Has Higher Late Mortality Than Early Revascularization (From A Systematic Review): How Can This Be And Should It Be An Indication For Wider Treatment Of IC
Jes S. Lindholt, MD
- 5:02 – 5:07** Infrapopliteal Peripheral Vascular Interventions For IC Are Performed Frequently In The US And Are Associated With Poor Long-Term Outcomes: What Specialty And Sites Of Treatment Are Most Involved And What Should Be Done About It
Caitlin W. Hicks, MD, MS
- 5:08 – 5:13** **Panel Discussion**
- ACUTE LIMB ISCHEMIA (ALI) (See Also Session 63)**
- 5:14 – 5:19** The PROMOTE-ALI Study Shows That Open Surgery Is Still The Best Treatment For ALI Because Emboli And Thrombosis Are Usually Superimposed On Underlying Arteriosclerosis
Katariina M. Noronen, MD, PhD
- 5:20 – 5:25** New Findings From The STRIDE Multicenter Trial: Mechanical Computer Assisted Suction Thrombectomy With The Indigo Aspiration System (Penumbra): Subgroups Showed Similar Outcomes For Patients With Stent Or Graft vs. Native-Vessel Thrombosis: When Was Angioplasty, Stenting Or Bypass Necessary
Thomas S. Maldonado, MD
- 5:26 – 5:31** Different Options For Thrombosuction In ALI: Which Device For Which Case And When Is Open Surgery Necessary
Athanasios Katsargyris, MD
- 5:32 – 5:37** New Developments And Devices To Treat ALI: How Do The Newer Devices Work: What Is The Current Need For Thrombolytics: When Is Open Treatment Necessary And When Is A Bypass Necessary
Patrick E. Muck, MD
- 5:38 – 5:43** What Is New With The Penumbra Indigo Clot Aspiration Systems: Improved Mechanical Catheter And Computer Based Clot Removal Indigo Systems: New Size Catheters For The Treatment Of Acute Arterial Clot: How The Systems Works And Why They Improve Clot Removal In Various Vascular Beds: Is Open Surgery Ever Needed
Frank R. Arko, MD
- 5:44 – 5:49** **Panel Discussion**

End of Program D

PROGRAM E (SESSIONS 31-38)

NEW DEVELOPMENTS IN MEDICAL TREATMENTS AND NEW DRUGS; PROGRESS IN ANTI-ATHEROGENIC AND ANTI-HYPERTENSIVE TREATMENTS; MANAGEMENT OF ENDOLEAKS; RECORDED LIVE CASES FROM LEADING CENTERS IN THE US AND EU; ISSUES OF INTEREST; OUTPATIENT AND OFFICE-BASED VASCULAR TREATMENT; TOPICS RELATED TO GOVERNMENT, REIMBURSEMENT, THE SVS, VQI, FDA, GUIDELINES, TRIALS AND EVIDENCE BASED MEDICINE
Grand Ballroom West, 3rd Floor

SESSION 31 (Grand Ballroom West, 3rd Floor)

ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND LIPID MANAGEMENT

Moderators: *Alik Farber, MD, MBA*

Natalie A. Marks-Ascher, MD, RPVI, RVT

Thomas S. Maldonado, MD

INTERMITTENT CLAUDICATION (IC)

- 6:52 – 6:57** Advances In The Use Of Anticoagulant, Antithrombotic And Antiplatelet Drugs In Vascular Patients: What Are The Next Generation Drugs And How Do They Help As Baseline Treatment And Peri-Procedurally
Elliot L. Chaikof, MD, PhD
- 6:58 – 7:03** Best Preoperative Preparation To Prevent Postoperative Myocardial Infarctions (MIs) With Vascular Surgery Or Endo Interventions: What Tests, What Drugs, What Invasive Coronary Procedures Before Or After The Vascular Procedure
Peter Henke, MD
- 7:04 – 7:09** All Acute Adverse Events From Arteriosclerosis (Stroke, MI, ALI) Depend On Thrombosis: This Explains The Positive Outcomes From The Use Of Rivaroxaban In The VOYAGER And COMPASS Trials: Recent VOYAGER Data Show That Rivaroxaban Improves Claudication Symptoms
Anthony J. Comerota, MD
- 7:10 – 7:15** The Risk Of Arteriosclerosis And Its Complications Are Increased By LDL Cholesterol (LDL-C) Levels: What Are The Best Medical Strategies To Decrease These Complications: Statins, Adjunctive LDL-C Lowering Drugs - Inclisiran, Bempedoic Acid, Ezetimibe, PCSK-9 Inhibitors, Lepodisiran, Colchicine, Olezarsen: How They Should Be Administered
Richard Bulbulia, MA, MD
- 7:16 – 7:21** The Importance Of Decreasing Inflammation (As Reflected By C-Reactive Protein Levels) With Old And New Drugs; New Information On The Effect Of Elevated Lp(a) And Elevated Triglycerides: What Drugs Can Lower Them (Mulvalapin And Zerlasiran; Vascepa)
Ron Waksman, MD
- 7:22 – 7:27** The Importance Of LDL-C Lowering During A Lifetime And In Decreasing Dementia Risk: How Low To Strive For With Intensive Drug Therapy: How Young To Start If High; How Old To Continue Statins: Why And How Often Should LDL-C Levels Be Measured
Clayton J. Brinster, MD
J. David Spence, MD

- 7:28 – 7:33** Update On The New Anti-Atherosclerosis Vaccine (AtheroVax): A Drug To Produce Lifelong LDL-C Lowering With A Single Gene Modifying Treatment: The Heart-1 Gene-Editing Trial: How Does AtheroVax Work And Results To Date
Ron Waksman, MD
Nicholas Kipshidze, MD, PhD, DSc

7:34 – 7:42 Panel Discussion

SESSION 32 (Grand Ballroom West, 3rd Floor)

CATHETER-BASED TREATMENTS FOR RESISTANT HYPERTENSION; MANAGEMENT OF CARDIAC PROBLEMS, CORONARY DESs, SMOKING AND TRANSFUSION IN VASCULAR SURGERY PATIENTS; PREVENTING VASCULAR AND CARDIAC COMPLICATIONS

Moderators: *Ron Waksman, MD*
Lindsay Machan, MD

UPDATE ON RENAL DENERVATION FOR HYPERTENSION

- 7:42 – 7:47** An Update On Renal Denervation For Resistant Hypertension: It Really Works As Shown By RCTs: What Are The Techniques And Devices: When Should They Be Used
Horst Sievert, MD
- 7:48 – 7:53** Renal Artery Denervation Is Back: New Evidence; New Devices, New Applications And Adjuncts (Sensors And Feedback Loops) To Facilitate The Treatment: Why Does It Work And When Should It Be Used
Lindsay Machan, MD
- 7:54 – 7:59** What Are The Molecular Mechanisms Underlying Carotid And Coronary Plaque Rupture: Can They Be Modified By Drugs In The Future
Hernan A. Bazan, MD

OTHER TOPICS RELATED TO VASCULAR DISEASE AND ITS TREATMENT

- 8:00 – 8:05** The Outcomes Of Major Vascular Procedures Are Better In Fat Than Thin Patients: What Is The Basis For This Obesity Paradox And Should It Influence Treatment: Thin May Be In, But Fat Is Where It's At
Bruce A. Perler, MD, MBA
- 8:06 – 8:11** Congestive Heart Failure And A Low Ejection Fraction Negatively Influence The Duration Of Patency Following Lower Extremity Bypasses: What To Do About It
Maciej L. Dryjski, MD, PhD
- 8:12 – 8:17** New Developments In Methods To Prevent Kidney Damage From Iodinated Contrast Agents: Are Any Drugs Truly Protective
Sahil A. Parikh, MD
- 8:18 – 8:23** How To Manage Patients With Recent Coronary DESs Who Require Vascular Operations Or Interventions: What To Do About Antiplatelet Medications: How Long To Wait Before Stopping Safely: What To Do With Urgent Or Emergent Cases To Avoid DES Thrombosis
Caron B. Rockman, MD
- 8:24 – 8:29** Expanding Endovascular Renal Artery Denervation To Multiorgan Arterial Denervation: What Are Its Potential Benefits In Treating Human Diseases: What Is The Supporting Evidence
Horst Sievert, MD

- 8:30 – 8:35** Managing Postoperative Anemia After Major Vascular Surgery: When Can It Be Tolerated And When Should It Be Corrected By Transfusion
Panos Kougiass, MD, MSc
- 8:36 – 8:42** **Panel Discussion**
- 8:42 – 8:54** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 33 (Grand Ballroom West, 3rd Floor)

A) PROGRESS IN MANAGING ENDOLEAKS: UNDERSTANDING THEIR CONSEQUENCES AND PREDICTING, PREVENTING AND TREATING THEM;
B) DR. CYNAMON'S GAME CHANGING INNOVATIONS

Moderators: *Luis A. Sanchez, MD*
Mark W. Mewissen, MD, RVT

A) ALL ENDOLEAKS AFTER EVAR

- 8:54 – 8:59** Improving Endoleak Detection And Accurately Defining Their Source With Contrast Enhanced Sonography: Equipment Needed And How To Do It (**This presentation will be given in-person on Thursday in Session 59 at 1:42 PM.**)
Thanila A. Macedo, MD (PowerPoint Presentation With Synched Audio)

TYPE 1 ENDOLEAKS

- 9:00 – 9:05** How To Minimize Gutter Type 1 Endoleaks With Chimney EVAR: How Does A Standard Protocol Help; How To Treat Them When They Occur
David J. Minion, MD
- 9:06 – 9:11** Major Systemic Trauma Can Cause Type 1 Endoleaks Anytime After EVAR With Or Without Fixation Elements: How Should Such Endoleaks Be Treated
Carlo Setacci, MD
- 9:12 – 9:17** How A Five Branched Endograft System (Cook) Can Be More Effective For Treating Challenging Type IA Endoleak After EVAR: How It Works, Advantage And Limitations
Piotr M. Kasprzak, MD
- 9:18 – 9:23** Update On Embolization Treatment For Type 1 Endoleaks After EVAR: Indications, Techniques, Embolic Agents And Contraindications
Robert A. Morgan, MD
- 9:24 – 9:29** How To Treat Type 1 Endoleaks After EVAR: When Cuff, When F/EVAR, When Chimney, When Open Conversion: What About Embolization
Andres Schanzer, MD

- 9:30 – 9:35** **Panel Discussion**

TYPE 2 ENDOLEAKS AFTER EVAR

- 9:36 – 9:41** Most Type 2 Endoleaks After EVAR Should Be Left Alone Because Treatments Have Poor Results, Have Complications And Do Not Improve Outcomes: What Are The Exceptions
Hence J.M. Verhagen, MD, PhD
- 9:42 – 9:47** When Do Persistent Type 2 Endoleaks After EVAR Lead To AAA Rupture: How Can Such Ruptures Be Predicted And How Should They Be Treated With Different Endografts
Naoki Fujimura, MD, PhD
- 9:48 – 9:53** The Influence Of Endograft Covering Material On The Occurrence And Behavior Of Type 2 Endoleaks And Sac Remodeling After EVAR: There Are Device Differences And They Affect Outcomes
Michel Reijnen, MD, PhD

- 9:54 – 9:59** Glue Embolization Is Effective Treatment For Most Threatening Type 2 Endoleaks: When And How To Do It: How Can Fusion Help: Limitations
Neal S. Cayne, MD
- 10:00–10:05** Transgraft Treatment Of Type 2 Endoleaks After EVAR: When And How To Do It: Advantages: How To Make And Seal The Graft Puncture Site
James F. McKinsey, MD
- 10:06–10:11** Active AAA Sac Management With Shape Memory Polymers: They Can Be Placed Prophylactically Or To Treat Endoleaks And Improve Outcomes After EVAR: Technique And Updated Results (From The shAAape Trial)
Andrew Holden, MBChB
Michel Reijnen, MD, PhD
Marc L. Schermerhorn, MD
- 10:12–10:17** Are We Taking Invasive Treatment Of Type 2A (1 Vessel) And 2B (>1 Vessel) Endoleak Too Far: Where Should We Stop
Furuzan Numan, MD
- 10:18–10:23** **Panel Discussion**
B) CYNAMON'S GAME CHANGING INNOVATIONS
- Moderators:** *Jacob Cynamon, MD*
Mark W. Mewissen, MD, RVT
- 10:24–10:29** Limb Salvage From Dotter To Stents And Beyond: Regulatory Hurdles Then And Now
Barry T. Katzen, MD
- 10:30–10:35** Embolization: The Most Transformative And Diverse Innovations Of IR
Ziv J. Haskal, MD
- 10:36–10:41** The History And Future Of Clot Management: Fogarty, Thrombolysis, Thrombectomy, Etc.
Jacob Cynamon, MD
- 10:42–10:47** How The First US EVAR Changed The Vascular World
Frank J. Veith, MD
- 10:48–10:53** Catheters, Guidewires, Balloon Innovations That Have Changed IR: Advice From A Serial Innovator
Michael G. Tal, MD, MBA
- 10:54–11:00** **Panel Discussion**

SESSION 34 (Grand Ballroom West, 3rd Floor)

ISSUES IMPORTANT TO VASCULAR SURGEONS/ SPECIALISTS

Moderators: *Thomas L. Forbes, MD*
Kim J. Hodgson, MD

VASCULAR SURGEONS IN A HEART AND VASCULAR CENTER

- 11:00–11:05** Why Heart And Vascular Centers Benefit All Stakeholders Including Vascular Surgeons: How To Assure That Vascular Surgery Has A Fair Role In Leadership And Allocation Of Resources
Vikram S. Kashyap, MD
- 11:06–11:11** In Heart And Vascular Centers, The Heart Dominates And Vascular Surgeons Are Often Undervalued And Subordinated
Richard J. Powell, MD
- 11:12–11:17** Vascular Surgery's Identity And Role Is Usually In A Subservient Position Within A Heart And Vascular Center: What Should Be Done To Correct This Inequity In The Interest Of Better Patient Care
Timur P. Sarac, MD

**UNIONIZATION FOR VASCULAR SURGEONS/
SPECIALISTS**

- 11:18–11:23** **DEBATE:** Why Vascular Surgeons And Vascular Specialists Should Unionize: It Will Solve Many Of The Problems They Currently Face Due To Hospital Administrators
Enrico Ascher, MD
- 11:24–11:29** **DEBATE:** Why Unionization Of Doctors Including Vascular Surgeons/Specialists Will Not Benefit Doctors Or Patients And May Be Harmful
Samuel R. Money, MD, MBA

**OTHER ISSUES IMPORTANT TO VASCULAR
SURGEONS/SPECIALISTS**

- 11:30–11:35** Despite What Many Organizations And Institutions Say, Most Partnerships And Close Relations Between Industry And Physicians Are Ethical, Benefit Society, Save Lives, And Improve The Healthcare System: It's Common Sense
Bruce A. Perler, MD, MBA
- 11:36–11:41** Physician And Industry Responsibility In Overuse Of Technology (Atherectomy, CAS, EVAR, Etc.): What Is Happening To Correct This Overuse Especially In View Of The Recent Media Spotlight On This Issue
Murray L. Shames, MD
- 11:42–11:47** How Human Behavior – Even With Vascular Surgeons/Specialists – Is Controlled By Biases And Rationalizations: How To Overcome These And Perform Better
Scott L. Stevens, MD
- 11:48–11:53** How Vascular Guidelines Can Be Used To Support Unjustified Malpractice Claims: What Can Be Done About It
Larry A. Scher, MD
- 11:54–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break - Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 35 (Grand Ballroom West, 3rd Floor)

**RECORDED LIVE CHALLENGING CASES AND
INNOVATIVE TECHNIQUES FROM THE PLINIO
ROSSI AND LINC COMPONENTS**

Moderators: *Fabrizio Fanelli, MD*
Andrew Holden, MBChB
Carlo Setacci, MD

THE PLINIO ROSSI COMPONENT

- 1:00 – 1:30** **PROGRAM TO BE DETERMINED**
Visit www.veithsymposium.org for updates.

THE LINC COMPONENT

Moderators: *Dierk Scheinert, MD*
Andrej Schmidt, MD
Daniela Branzan, MD

- 1:30 – 1:59** **PROGRAM TO BE DETERMINED**
Visit www.veithsymposium.org for updates.

SESSION 36 (Grand Ballroom West, 3rd Floor)

**MORE ISSUES IMPORTANT IN VASCULAR
SURGERY: HISTORY, PRACTICE PATTERNS, VALUE
OF GUIDELINES AND RCTs, MALPRACTICE,
SCIENCE, TRAINING AND HUMAN BEHAVIOR**

Moderators: *Jack L. Cronenwett, MD*
Jerry Goldstone, MD

VASCULAR HISTORY

- 2:00 – 2:05** The Sudden Death And Revealing Autopsy Of King George II In 1760: A 265-Year Perspective On Aortic Dissection And How It Influenced History
Frank J. Criado, MD
- 2:06 – 2:11** From The SVS History Collection: The Importance Of Battlefield Failures In World War II And How They Led To The Formation Of The SVS
Jerry Goldstone, MD

OTHER CHALLENGING ISSUES

- 2:12 – 2:17** How To Prevent Problems With Overlapping Surgical Procedures For A Single Surgeon With A Covering Surgeon Policy: Is It Good For Patients
Patrick A. Stone, MD
- 2:18 – 2:23** How A Vascular Surgery Service With A Large Volume Of Emergent Patients Can Handle Them Without Disrupting Elective Schedules And Clinical Practices: A Committed Surgeon Of The Day Without Other Responsibilities Is The Answer
Michael C. Stoner, MD
- 2:24 – 2:29** The Burden Of Iatrogenic Vascular Injury To The Vascular Surgery Workforce At A Tertiary Care Center: What Can And Should Be Done To Offset This Problem: An Uncommitted Surgeon Of The Day May Help: Financial Implications
Caron B. Rockman, MD
- 2:30 – 2:35** **Panel Discussion**

FLAWS IN EVIDENCE BASED STUDIES

- 2:36 – 2:41** Wishful Thinking And Confirmation Bias: The Achilles Heel Of Statistical Analysis And How They Lead To Flaws In Evidence-Based Medical Studies
Frans L. Moll, MD, PhD
- 2:42 – 2:47** Vascular Surgeons/Specialists Need To Develop High Quality Evidence To Improve Care: Why And How To Do It: How Registry-Based RCTs Can Help: What Are They, Why Are They Different From And Better Than Standard RCTs
Jens Eldrup-Jorgensen, MD
- 2:48 – 2:53** In What Circumstances Can Nonoperative Management Improve Patient-Reported Outcomes As Revascularization: Does This Apply To Intermittent Claudication, Asymptomatic Carotid Stenosis, Small AAAs, Etc.
Benjamin S. Brooke, MD, PhD
- 2:54 – 2:59** Principles Physicians Need To Consider When Innovating Medical Devices: It's More Than Securing Intellectual Property
Gary M. Ansel, MD
- 3:00 – 3:05** Legal Implications Of Performing PMEGs And Laser Fenestrations Without An IDE: When Is The Vascular Specialist Vulnerable And When Are They Not
O. William Brown, MD, JD
- 3:06 – 3:11** Artificial Intelligence Will Transform How Vascular Surgery Is Practiced: How Does It Work And How Will It Help: How Do Machine Learning, Algorithmic Learning And Enhanced Reality Fit In
Benjamin S. Brooke, MD, PhD
- 3:12 – 3:17** **Panel Discussion**
- 3:18 – 3:28** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 37 (Grand Ballroom West, 3rd Floor)

MORE ISSUE-RELATED TOPICS IMPORTANT TO VASCULAR SURGEONS AND VASCULAR SPECIALISTS; ISSUES RELATED TO OUTPATIENT CENTERS OR OFFICE-BASED LABS (OBLs) AND AMBULATORY SURGERY CENTERS (ASCs)

Moderators: *Malachi Sheahan, MD*
Krishna Jain, MD

- 3:28 – 3:33** Aortic And Lower Extremity Artery Gender Differences Exist In The Treatment And Outcomes Of Vascular Disease: Why Is This So And What Can Be Done To Remedy The Deficiencies That Exist
Linda M. Harris, MD

ISSUES RELATED TO OBLs AND ASCs

- 3:34 – 3:39** In 2026 What Will Happen With Global Reimbursement For OBLs And Component Reimbursement In ASCs: When And Where Should Surgeons Do Procedures To Gain Good Reimbursement For Their Work
Sean P. Roddy, MD
- 3:40 – 3:45** How Can OBLs Provide Good Vascular Care With Excellent Results, Be Profitable, Do Research, And Still Allow Vascular Surgeons To Work From 8 AM To 5 PM: Why Is A Hospital Affiliation Still Mandatory
Mark A. Mattos, MD
- 3:46 – 3:51** How To Make Outpatient Vascular Treatment Facilities (OBLs, ASCs) Safe, Effective And Profitable Without Doing Unjustified Procedures: How Can They Make Uniquely Important Vascular Research Contributions
Christopher J. Kwolek, MD, MBA
- 3:52 – 3:57** How Can Viable OBLs Be Maintained In The Current Environment: For What Procedures: When Is An ASC A Better Solution: What Are The Obstacles
Krishna Jain, MD
- 3:58 – 4:03** How To Build An Outpatient Center Of Excellence Committed To The Treatment Of CLTI: When Is An OBL Better And When Is An ASC Better – For Patients, For Surgeons
Miguel F. Montero-Baker, MD
- 4:04 – 4:09** Geriatric Vascular Surgery In The OBL: What Is Different, What Is Unknown
Anil P. Hingorani, MD
- 4:10 – 4:15** Academic Vascular Surgery Groups Can And Must Design, Implement, And Execute Adding An OBL To Their Practice: Do It Or Die
Francesco A. Aiello, MD, MBA
- 4:16 – 4:21** The Endovascular Revolution Is Responsible For Unnecessary And Inappropriate Treatments: Have We All Been Drinking The Kool-Aid: What Can Vascular Surgeons And Others Do About It
Russell H. Samson, MD, RVT
- 4:22 – 4:28** **Panel Discussion**

SESSION 38 (Grand Ballroom West, 3rd Floor)

UPDATES AND ISSUES IMPORTANT TO ALL VASCULAR SURGEONS AND SPECIALISTS: FUTURE REIMBURSEMENT; IMPROVING VASCULAR CARE QUALITY; FIXING FALSE TESTIMONY; FLAWED PEER REVIEW; FDA IMPROVEMENTS; LEARNING HEALTH SYSTEMS

Moderators: *Sean P. Roddy, MD*
R. Clement Darling III, MD

ESTABLISHING VASCULAR SURGERY'S REAL IDENTITY

- 4:28 – 4:33** The Importance Of Mentorship In Vascular Surgery: How Should We Be Telling Medical Students And Others What Vascular Does And Its Critical Role To Patients And Most Other Specialties
Malachi Sheahan, MD

VASCULAR REIMBURSEMENT ISSUES

- 4:34 – 4:39** What Will Happen With CPT Codes And Physician Reimbursement In Late 2025 And 2026: What's Good And What's Bad
Sean P. Roddy, MD
- 4:40 – 4:45** What Is The Merit Based Incentive Payment System (MIPS) For Value Based Reimbursement: How Does It And Other Value Based Reimbursement Systems (MVPs) Work For Vascular Surgeons: Are They Good Or Bad
Evan C. Lipsitz, MD, MBA

LEGAL ISSUES AND PUNISHING FALSE TESTIMONY

- 4:46 – 4:51** Precautions To Take With Operative And Other Records: Tips To Avoid Noxious Legal Or Governmental Audit Problems
Terry Litchfield, MPA
- 4:52 – 4:57** We Don't Hold Physicians Who Provide False Or Misleading Testimony Against Vascular Surgeons Accountable: Why Has The SVS Committee On This Topic Failed To Be Effective: A New Standard For Medical Malpractice
O. William Brown, MD, JD
- 4:58 – 5:03** Update On The SVS/ACS Vascular Verification Program (VVP) To Assure Quality Vascular Care In Outpatient And Inpatient Programs: What Is It And How Will It Help Vascular Surgery
R. Clement Darling III, MD
Anton N. Sidawy, MD, MPH
- 5:04 – 5:09** **Panel Discussion**

IMPROVING VASCULAR CARE QUALITY

- 5:10 – 5:15** Measuring Aortic Surgery Quality Of Care Has Been All Wrong: The Future Of Surgical Quality Reporting Must Incorporate Baseball Statistical Approaches And How This And AI Will Help
Douglas W. Jones, MD, MS
- 5:16 – 5:21** Leveraging The Vascular Quality Initiative To Reduce Length Of Stay Following EVAR And CEA
Ronald L. Dalman, MD

FDA RELATED ISSUES

- 5:22 – 5:27** Why Does The FDA Evaluation And Time To Market For Endografts Take So Long: How To Make The Process Faster And More Efficient: What About Breakthrough Fast Track And 510(k) Processes: Why Some IDEs Fail To Get FDA Approval
Valerie M. Merkle, PhD
- 5:28 – 5:33** Why Do We Not Have More FDA Approved Devices For F/B/EVAR In The US: Is The FDA Failing Or Doing Its Job
Murray L. Shames, MD
- 5:34 – 5:39** Different Perspectives From Industry And The FDA Regarding Factors That Influence Innovation: The Importance Of Innovation, Engineering And Financial Rewards
Dorothy B. Abel, BSBME
- 5:40 – 5:46** **Panel Discussion**
- End of Program E**

PROGRAM F (SESSIONS 39-46)

MORE NEW DEVELOPMENTS IN THORACIC AORTIC DISEASE, TEVAR, AORTIC DISSECTIONS, TAAAs, JUXTA- AND PARARENAL AAAs, PARALLEL GRAFTS, FENESTRATED AND BRANCHED EVAR (F/B/EVAR), MULTILAYER BARE STENTS, INFRARENAL AAAs AND STANDARD EVAR, AND HOT NEW AORTIC TOPICS

Trianon Ballroom, 3rd Floor

SESSION 39 (Trianon Ballroom, 3rd Floor)

MORE TOPICS RELATED TO THE THORACIC AORTA, AORTIC DISSECTIONS, INFLAMMATORY ANEURYSMS AND THEIR TREATMENT

Moderators: *Ramon Berguer, MD, PhD*

Timothy A. Resch, MD, PhD

6:50 – 6:55 TEVAR In Patients With Compromised Distal And Proximal Landing Zones: Strategies For Success: The Value Of Scallops And Endoanchors

Giovanni Tinelli, MD, PhD

6:56 – 7:01 Updated Clinical Experience With The Endopatch: A Promising Solution For Endovascular Repairs For Aortic Dissections: What Is It And How Does It Work

Wei Guo, MD

7:02 – 7:07 Options For Left Subclavian Revascularization During TEVAR: Laser Fenestration, Open Bypass, Single Branch Device (Gore), Etc.: Advantages And Limitations Of Each

Timothy A. Resch, MD, PhD

7:08 – 7:13 When A Single Branched TEVAR Is Used But Requires A Longer Proximal Seal In The Aortic Arch, How Can This Be Achieved

Jason T. Lee, MD

7:14 – 7:19 Relay Custom Made Endografts (Terumo) For TEVAR, Scalloped, Etc: When And Why Are They Advantageous Compared To Single Branch LSA TEVAR Devices

Michael P. Jenkins, MBBS, BSc, MS

Mo S. Hamady, MD

7:20 – 7:25 Chimneys And In Situ Graft Fenestrations For Endovascular Repairs Of Dissections In The Aortic Arch: When And How To Make Them Work

Ivo Petrov, MD, PhD

7:26 – 7:31 **DEBATE:** The STABILISE Technique To Eliminate The False Lumen And Relaminate The Aorta Will Change The Treatment Of Acute And Subacute TBADs And Will Replace Most False Lumen Occlusion Devices And F/B/EVAR Treatments: How To Do It And Precautions

Igor A. Laskowski, MD, PhD

Heepeel Chang, MD

7:32 – 7:37 **DEBATE:** Not So Fast: A Multimodular Approach To Treating Acute, Subacute And Chronic TBADs With TAAAs: Who Needs A F/B/EVAR; Who Needs A Candy-Plug Or Other Techniques: What Is The Role For STABILISE

Tilo Kölbel, MD, PhD

Fiona Rohlfes, MD, PhD

7:38 – 7:45 **Panel Discussion**

SESSION 40 (Trianon Ballroom, 3rd Floor)

**MORE ADVANCES RELATED TO TREATING
PATHOLOGY INVOLVING THE ASCENDING
AORTA AND THE AORTIC ARCH: INTRAMURAL
HEMATOMAS (IMHs), AORTIC DISSECTIONS AND
THEIR TREATMENT**

Moderators: *Ross Milner, MD*
Tilo Kölbel, MD, PhD

- 7:45 – 7:50** **DEBATE:** When And How To Treat Type B Aortic Intramural Hematomas (IMHs) By TEVAR: Technical Tips, Precautions And Results: Why Very Early Treatment Yields Worse Results
Jean M. Panneton, MD
- 7:51 – 7:56** **DEBATE:** Early TEVAR For Type B IMHs Is Safe And The Guidelines Should Be Changed
Ian Loftus, MD
- 7:57 – 8:02** Origins Of Intramural Hematomas (IMHs): Why So Many Prove Benign And Do Well With Medical Treatment: When And How To Treat Them With TEVAR
Frank J. Criado, MD
- 8:03 – 8:08** Expert Consensus (ESVS) On The Use Of TEVAR For Ascending Aortic Disease: Optimal Devices And Results For Complicated And Uncomplicated Aortic Dissections And Other Pathologies: When Is It Indicated And When Not
Santi Trimarchi, MD, PhD
Irene Fulgheri, MD
- 8:09 – 8:14** Updated Concepts In The Treatment Of Type A Aortic Dissections (TAADs): How Should The Distal Aorta Be Treated By TEVAR Before Repair Of The Ascending Aorta: Antegrade Insertion Of An Endograft With Open Arch Repair: Lessons Learned, Complications And Their Resolution
Ourania Preventza, MD
Joseph S. Coselli, MD
- 8:15 – 8:20** **Panel Discussion**
- 8:21 – 8:26** Full-Endo Repair Of Aortic Arch Disease: How Do Industry Made Customized Endografts Compare To PMEGs And In Situ Fenestrated Endografts
Andrea Kahlberg, MD
Germano C.G. Melissano, MD
- 8:27 – 8:32** In Situ Fenestration For Endovascular Repair Of Aortic Arch Lesions: Does It Reduce Perioperative Strokes And How To Avoid Cerebral Ischemia During The Procedure
Ralf R. Kolvenbach, MD
- 8:33 – 8:38** Long-Term Stroke Risk In Total Aortic Arch Branched Endovascular Repairs: What Are The Etiologies, Why Is It An Unresolved Problem And How Can It Be Solved
Giovanni Tinelli, MD, PhD
- 8:39 – 8:44** Updated European Experience With The Endospa Nexus Endograft (OTS) For Treating Complex Aortic Arch Lesions: Advantages And Multicenter Results
Mario L. Lachat, MD
- 8:45 – 8:50** Updated Results From The US TRIOMPHE Trial Of The Endospa Nexus Endograft (OTS) For Treating Complex Aortic Arch Lesions Including Chronic Dissections: Advantages, Limitations And Will It Have A Major Role
Ross Milner, MD

- 8:51 – 8:56** With Chronic TBADs Laser Assisted Resection Of The Dissection Septum Or Membrane Septotomy Creates A Single Lumen For A TEVAR Landing Zone: How Is This Technique Performed And Updated Results
Nuno V. Dias, MD, PhD
Björn Sonesson, MD, PhD
- 8:57 – 9:02** Complications And Challenges After Arch Repair And FET: Many Secondary Procedures Needed: What Are They
Götz M. Richter, MD, PhD
- 9:03 – 9:08** **Panel Discussion**
- 9:09 – 9:16** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 41 (Trianon Ballroom, 3rd Floor)

OPEN AND ENDO TREATMENT OF COMPLEX AAAs (JUXTA, PARA- AND SUPRA-RENAL) AND TAAAs; INTERESTING NEW DEVICES FOR THEIR TREATMENT

Moderators: *Gilbert R. Upchurch, MD*
Christopher J. Kwolek, MD, MBA

COMPLEX AAAs AND TAAAs

- 9:16 – 9:21** Endovascular Treatment Of Post-Dissection TAAAs By F/B/EVAR: Challenges, Technical Tips, Optimal Devices And Long-Term Outcomes
Carlos H. Timaran, MD
- 9:22 – 9:27** With Complex AAAs Mortality For Endo Repair Is Lower Than That Of Open Repair: What Other Factors Should Be Considered In Making An Endo vs. Open Choice For Each Patient: How Does The UK-COMPASS (Endo vs. Open) Study Help
George Geroulakos, MD, PhD
- 9:28 – 9:33** F/B/EVAR In Complex AAAs And TAAAs, Early And Long-Term Results Are Better In Fit And Young Patients In Whom F/B/EVAR Should Be The Treatment Of Choice
Piergiorgio Cao, MD
- 9:34 – 9:39** Outcomes Of F/EVAR And B/EVAR After Five Or More Years: What Risk Factors Are Associated With Early Death And The Chances Of Long-Term Survival
Thomas F. Lindsay, MDCM
- 9:40 – 9:45** With All The New Devices What Is The Role For PMEGs In The Treatment Of Complex AAAs Or TAAAs
Bernardo C. Mendes, MD
- 9:46 – 9:51** Late Complications Of F/B/EVAR: What Are The Causes And How Are They Best Treated
Athanasios Katsargyris, MD
Eric L.G. Verhoeven, MD, PhD
- 9:52 – 9:57** **Panel Discussion**
- 9:58–10:03** Optimal Volume Thresholds For Surgeons And Institutions Doing F/B/EVAR: Pros And Cons Of Regionalization
Sara L. Zettervall, MD
- 10:04–10:09** Patch Aneurysms After Open TAAA Repairs: How To Treat Them When They Occur And How To Prevent Them
Manju Kalra, MBBS
- 10:10–10:15** Hybrid Repair Of A TAAA (Proximal TEVAR With Distal Open Repair – The Upchurch Procedure): When Is It Indicated; What Are The Advantages And Updated Results
Gilbert R. Upchurch, MD
Salvatore Scali, MD
Dean Arnaoutakis, MD

- 10:16–10:21** Open TAAA Repair With The Thoracoflo (Terumo) Hybrid Graft System For Failed Open And Endovascular Aortic Repairs: Technical Tips, Advantages, Limitations And Results
Mazin Foteh, MD
- 10:22–10:27** The Gore TAMBE Device For Complex AAAs And TAAAs: Advantages, Limitations, Technical Tips And Lessons Learned
Jason T. Lee, MD
- 10:28–10:33** An Off-The-Shelf (OTS) Inner Branched Endograft (E-nside From Artivion) For The Treatment Of Juxtarenal And Pararenal Aortic Aneurysms: Advantages, Limitations, Technical Tips And Results From A Multicenter Italian Registry
Michele Antonello, MD, PhD
- 10:34–10:40** **Panel Discussion**

SESSION 42 (Trianon Ballroom, 3rd Floor)

PROGRESS IN TREATING ILIAC ANEURYSMS; ILIAC BRANCHED DEVICES (IBDs); UPDATE ON FLOW MODULATING AND BARE STENTS FOR TREATING ANEURYSMS AND DISSECTIONS

Moderators: *Thomas S. Maldonado, MD*
Rodney A. White, MD

TREATMENT OF ILIAC ANEURYSMS WITH IBDs OR PARALLEL GRAFTS

- 10:40–10:45** Surprisingly, Occlusion Of One Or Both Hypogastric Arteries During EVAR Does Not Result In Colon Ischemia Or Other Serious Consequences: From A Large VQI Study
Heepeel Chang, MD
- 10:46–10:51** Comparison Of All Iliac Branched Endovascular Devices (IBDs): Advantages And Limitations Of Each
Sonia Ronchey, MD, PhD
- 10:52–10:57** 5-Year Outcomes Of The ICEBERG Study Of The Gore IBD (IBE Device) For Revascularizing The Hypogastric Artery With Aorto-Iliac Aneurysms: Advantages And Limitations
Michel Reijnen, MD, PhD
- 10:58–11:03** Long-Term Outcomes With The Cook PRESERVE II Study Of The Cook IBD (ZBIS): Why Is It Better And Different From Other IBD Devices: When Is It Contraindicated
W. Anthony Lee, MD
Fabio Verzini, MD, PhD
- 11:04–11:09** Advantages And Current Status Of The Artivion IBD Device For Treating Common And Internal Iliac Artery Aneurysms: From The PLIANT II Multicenter Study: When Will This Device Be Available In The US
Lee Bouwman, MD, PhD
- 11:10–11:15** Long-Term Results Of The Lobato Parallel Graft Technique For Treating Iliac Artery Aneurysms: What Makes It Different: Technical Tips, Advantages And Limitations
Armando C. Lobato, MD, PhD
- 11:16–11:21** **Panel Discussion**

UPDATE ON FLOW MODULATING BARE STENTS

- 11:22–11:27** Flow Modulating Bare Stents (Allay From Intressa) Are Not Showing Long-Term Benefit For The Treatment Of Complex AAAs And TAAAs Based On An Updated Review Showing Their Limitations: However Results Show They Have Value In The Treatment Of TBAD Patients With Or At High Risk Of End Organ Malperfusion
Claude D. Vaislic, MD

- 11:28–11:33** While Flow Modulating Bare Stents (Allay From Intressa) Do Not Always Seem To Prevent Aneurysm Enlargement And Rupture With TAAAs, They May Be Effective Treatment For Visceral Aneurysms: What Are The Indications
Arno von Ristow, MD, PhD
Rodney A. White, MD
- 11:34–11:39** Treatment With 9 Years Of Follow Up Of Aortic Dissections With Multilayer Bare Stents: When Are They Effective And When Aren't They
Victor S. Costache, MD, PhD
Ivo Petrov, MD, PhD
- 11:40–11:45** Role Of Bare Metal AMDS Stents (From Artivion) For Repair Of Acute DeBakey Type 1 Dissections: How Do They Work, Indications And Advantages
Wilson Y. Szeto, MD (PowerPoint Presentation With Synched Audio)
- 11:46–11:51** Thoraflex Hybrid Graft Rescue When Treatment Of Aortic Dissection In The Arch With Bare Stents (AMDS From Artivion And Allay From Intressa) Fails: What Is The Mechanism Of Failure And What Is The Bailout Procedure
Mazin Foteh, MD
- 11:52–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break - Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 43 (Trianon Ballroom, 3rd Floor)

NEW DEVELOPMENTS IN AAA BEHAVIOR, TREATMENT AND STANDARD INFRARENAL EVAR: THE INFLUENCE OF DIABETES, BLOOD PRESSURE, AGE, ECT. ON AAA GROWTH; IMPROVED ULTRASOUND SURVEILLANCE, LOCAL ANESTHESIA FOR EVAR, 3D CTA ANALYSIS, CONSEQUENCES OF AAAs LOST TO FOLLOW-UP AND ALL AAAs ARE NOT TIME BOMBS WAITING TO EXPLODE

Moderators: *Christopher K. Zarins, MD*
Stephan Haulon, MD

- 1:00 – 1:05** Why Is It Important To Avoid "Lost To Follow Up" For Patients With AAA (Pre- Or Post-Treatment)
Matthew W. Mell, MD, MS
- 1:06 – 1:11** Diabetes Reduces The Growth Rate Of Abdominal Aortic Aneurysms: From A Large Meta-Analysis: What Is The Mechanism
George A. Antoniou, MD, PhD, MSc
- 1:12 – 1:17** How Does Patient Age At Endograft Implantation Influence The Durability Of EVAR Success: How Should This Guide The Choice Of Endo vs. Open Repair
Ronald L. Dalman, MD
- 1:18 – 1:23** How Do Arterial Blood Pressure Levels Influence AAA Growth Rates: Does Controlling The Blood Pressure Slow Growth Rates
Colin D. Bicknell, MD
- 1:24 – 1:29** Late Rescue For Renal Artery Occlusion After EVAR: How To Do It And Why There Are No Time Limits
James F. McKinsey, MD
- 1:30 – 1:35** **Panel Discussion**
- 1:36 – 1:41** What Is The Relationship Between AAAs, Inflammation (On PET/CTs), Cancer And Mortality: How Should These Variables Influence Treatment
Natzi Sakalihasan, MD, PhD
- 1:42 – 1:47** 3D Geometric Analyses Of CTAs: What Are They, How To Do Them And How Can They Help To Predict, Prevent Or Treat Endoleaks With EVAR And F/EVAR
Jean-Paul de Vries, MD, PhD

- 1:48 – 1:53** Advantages And Disadvantage Of Local Anesthesia For EVAR: How To Use It Safely And With Adjuncts: It Is Particularly Valuable In Octogenarians
Faisal Aziz, MD
- 1:54 – 1:59** The Role Of Contrast-Enhanced Ultrasound After EVAR: When Can It Replace Contrast CT For Surveillance: Advantages And Limitations
R. Eugene Zierler, MD, RPVI
- 2:00 – 2:05** Endovascular Solutions To Effectively Deal With Hostile Neck Anatomy Of AAAs Other Than F/B/ EVAR: Why They Should Be Favored
Stavros K. Kakkos, MD, PhD
- 2:06 – 2:11** **Panel Discussion**

SESSION 44 (Trianon Ballroom, 3rd Floor)

**MORE NEW DEVELOPMENTS IN AAAs:
ENDOVASCULAR TREATMENTS WITH HERITABLE
AORTIC DISEASE (CONNECTIVE TISSUE GENETIC
DISORDERS - CTDs): HOW DOES INTRASAC
THROMBUS LOAD AFFECT AAA BEHAVIOR AND
PROGNOSIS AFTER EVAR**

Moderators: *Evan C. Lipsitz, MD, MBA*
James H. Black, III, MD

**TREATMENT OF AORTIC ANEURYSMS WITH
HERITABLE AORTIC DISEASE AND CONNECTIVE TIS-
SUE DISORDERS (CTDs)**

- 2:12 – 2:17** Why And How Should AAAs And Iliac Pathology Be Treated Differently In Patients With Heritable Vascular Syndromes (Marfan, Loeys-Dietz And Ehlers-Danlos [EDS])
Sherene Shalhub, MD, MPH
- 2:18 – 2:23** Endovascular (Endograft) Treatment Of Complex Aortic Diseases In Patients With CTDs: When Is It Indicated And When Is It Not: From The Results Of An International Multicenter Study Including Marfan, Vascular EDS And Loeys-Dietz Syndromes
Anders Wanhainen, MD, PhD
- 2:24 – 2:29** The Value Of TEVAR In Patients With CTDs: When Is It Acceptable Treatment And When Is It Contraindicated
Francis Caputo, MD
- 2:30 – 2:35** Value Of F/B/EVAR In The Management Of Failed Open Repairs Of Complex AAAs In Patients With Heritable Aortic Disease: Technical Tips
Barend M.E. Mees, MD, PhD
Geert Willem H. Schurink, MD, PhD
Michael J. Jacobs, MD
- 2:36 – 2:41** Endovascular (Endograft) Therapy For Marfan And Other CTDs: When Is It Indicated As The Primary Treatment Or After Failed Open Repair And When Is It Not: Is It Time For A Guideline Change
James H. Black, III, MD
- 2:42 – 2:47** Results Of The STABILISE Technique In Patients With Connective Tissue Disorder Related TBADs: When Can It Work And When Is It Contraindicated
Jean-Marc Alsac, MD, PhD
- 2:48 – 2:53** Medical Treatment Of Patients With Vascular Ehlers Danlos Syndrome: How Does Celiprolol (A Beta Blocker) Treatment Work And How Does It Help
Anders Wanhainen, MD, PhD

THE EFFECT OF AAA SAC THROMBUS LOAD

- 2:54 – 2:59** **DEBATE:** Large Amount Of AAA Sac Thrombus Promotes Morbidity Without Rupture And With Rupture: By What Mechanisms Is Thrombus Harmful And How Can Thrombus Load Be Quantitated
David H. Deaton, MD
- 3:00 – 3:05** **DEBATE:** Large Flow Luminal Space In An AAA Sac With Minimal Mural Thrombus Is Associated With Adverse Events After EVAR: It Is More Important Than AAA Sac Size: Thrombus May Be Protective
Hence J.M. Verhagen, MD, PhD
- 3:06 – 3:12** **Panel Discussion**
- 3:12 – 3:24** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 45 (Trianon Ballroom, 3rd Floor)

MORE HOT AORTIC TOPICS, PMEGs AND IDEs, GRAFT CHOICES FOR COMPLEX AAAs AND TAAAs

Moderators: *Michel S. Makaroun, MD*
Peter Gloviczki, MD, PhD

PMEGs AND IDEs

- 3:24 – 3:29** Hospitals Without Investigational Device Exemptions (IDEs) Have Worse Outcomes After PMEGs: These Are Often Unreported And Not In The VQI
Caitlin W. Hicks, MD, MS
- 3:30 – 3:35** PMEGs Outside Of IDE Trials: What Is The FDA's Position And Will CMS Reimburse For Them: How Can A Vascular Surgeon Get An IDE For PMEGs
Bjoern D. Suckow, MD
- 3:36 – 3:41** Technical Tips For In Situ Fenestration For F/B/EVAR Using A Radiofrequency Powerwire (From Baylis) And Biplane Angiography: Advantages And Limitations
Patrick E. Muck, MD
- 3:42 – 3:47** Technical Improvements For PMEGs To Facilitate Diameter Reduction And Branch Access Covered Stent Delivery
Bjoern D. Suckow, MD
- 3:48 – 3:53** Standardized 4-Vessel Fenestrated PMEGs Using The Medtronic Captiva Endograft: Technical Tips And Advantages: From The SPHERE Registry
Michele Piazza, MD
- 3:54 – 3:59** How To Navigate The Many Choices Of Endografts For Pararenal And Type IV TAAAs: TAMBE, Zenith Fenestrated, In Situ Laser F/EVARs, PMEGs Or Parallel Grafts
Ravi K. Veeraswamy, MD
- 4:00 – 4:05** **Panel Discussion**
- 4:06 – 4:11** Ultra Low Profile, Fully Retractable And Repositionable Transaxillary Endovascular Graft Device For Infrarenal AAA Repair: How Does It Work And Advantages
Anahita Dua, MD, MS, MBA

COMPLICATIONS: PREVENTION AND TREATMENT

- 4:12 – 4:17** Use Of Endografts To Manage Access Complications During Routine And Complex Endovascular Procedures: Technical Tips And What Devices Need To Be Stocked In The OR And Angio Suite
Tal M. Hörer, MD, PhD
- 4:18 – 4:23** Use Of The Aptus Endoanchor Variable Curve Sheath As A Rescue Tool To Fix Maldeployed EVAR Endografts: When And How To Do It: Technical Tips
William D. Jordan Jr., MD
- 4:24 – 4:29** Complex Endovascular Aneurysm Repair In Cases With Compromised Iliac Access: Technical Tips
Cherrie Z. Abraham, MD

- 4:30 – 4:35** Fate Of Renal Arteries After Complex AAA Endo Repairs: What Are The Potential Obstacles Or Threats: How To Overcome Them And Maintain Renal Function
Matteo Orrico, MD
Nicola Mangialardi, MD
- 4:36 – 4:41** **Panel Discussion**

SESSION 46 (Trianon Ballroom, 3rd Floor)

MORE HOT NEW TOPICS RELATED TO AORTIC DISEASE AND ITS TREATMENT

Moderators: *Andres Schanzer, MD*
Peter F. Lawrence, MD

- 4:42 – 4:47** How To Perform F/EVAR With Full Renal Perfusion In Patients With An Early Renal Artery Bifurcation
Joshua D. Adams, MD
- 4:48 – 4:53** The Femoral Flag Concept With TBADs: How Can The Femoral Arteries On Presenting CT Indicate Vulnerable Visceral Artery Anatomy And How Should This Influence Treatment
David M. Williams, MD
- 4:54 – 4:59** Single vs. Double Antiplatelet Therapy After F/B/EVAR Based On Key Findings From A Large Multicenter Clinical Trial: What Drugs Are Best And For How Long
Tilo Kölbel, MD, PhD
Petroula Nana, MD
- 5:00 – 5:05** Ultrasonic Emulsification And Aspiration For Coral Reef Atherosclerosis As A Novel Alternative To Transaortic Endarterectomy And Thoracic Aorta-Based Bypass Grafting
Jae S. Cho, MD
- 5:06 – 5:11** **Panel Discussion**

DECREASING TYPE 2 ENDOLEAKS

- 5:12 – 5:17** AAA Sac Embolization With Shape Memory Polymer Plugs During The EVAR Procedure Can Prevent Type 2 Endoleaks If The Plugs Are Placed Near To Branch Orifices: Technique And Imaging Matters: Results
Thomas S. Malonado, MD

BRANCH EMBOLIZATION BEFORE EVAR: DOES IT HELP

- 5:18 – 5:23** **DEBATE:** Routine Inferior Mesenteric Artery (IMA) Embolization Prior To EVAR Is NOT Beneficial: Based On An Analysis Of Over 700 Patients
Maarit Venermo, MD, PhD
- 5:24 – 5:29** **DEBATE:** An RCT Shows The Advantages Of IMA And Lumbar Embolization: When Should This Be Done And When Is It Unnecessary Before EVAR
Dominique Fabre, MD, PhD
Stephan Haulon, MD
- 5:30 – 5:35** **DEBATE:** Preemptive IMA Coil Embolization Before EVAR Does NOT Improve EVAR Outcomes: From The CLARIFY IMA Trial: Is It Ever Beneficial
Naoki Fujimura, MD, PhD
- 5:36 – 5:41** Value Of Preemptive Embolization Of AAA Side Branches (IMA And Lumbar) Prior To EVAR: Objective Evidence That It Prevents Sac Enlargement: When Is It Necessary And When Not
Daniela Branzan, MD
Andrej Schmidt, MD
- 5:42 – 5:47** An Innovative New Stapling Device To Facilitate Aortic Anastomoses: How Does It Work And What Makes It Different And Limitations
Joseph S. Coselli, MD
Marek Ehrlich, MD

- 5:48 – 5:53** Mid-Term Outcomes Of Total Endovascular Repair Of The Entire Aorta From Zone 0 To 9: How To Minimize Complications: When Is It Necessary
Sukgu M. Han, MD, MS
- 5:54 – 5:59** **Panel Discussion**
End of Program F

THURSDAY, NOVEMBER 21, 2025

6:00 A.M. General Registration – Rhinelander Gallery, 2nd Floor
6:00 A.M. Faculty Registration – Gramercy Suite West, 2nd Floor
6:15 A.M. Continental Breakfast – Rhinelander Gallery, 2nd Floor

CONCURRENT THURSDAY PROGRAMS

PROGRAM G (SESSIONS 47-54)

Exciting New Or Rediscovered Techniques, Concepts Or Devices; Progress In F/B/EVAR And Parallel Grafts For Complex AAAs; Tribute To Our Military; Progress In The Treatment Of Ruptured AAAs; More About New Devices, Techniques Or Concepts; Progress In Radiation Safety

Location: Grand Ballroom East, 3rd Floor

PROGRAM H (SESSIONS 55-63)

New Or Improved Devices For: Standard EVAR And More Complex AAAs; Repairs Of TAAAs, The Ascending Aorta, The Aortic Arch, And The Descending Aorta (TEVAR); New Devices For Treating Lower Extremity Lesions By Endo Or Open Techniques; Update On Endoanchors And Fixation Devices And New Or Improved Devices For Endovascularly Removing Clot And Occluding Blood Vessels

Location: Grand Ballroom West, 3rd Floor

PROGRAM I (SESSIONS 64-73)

Superficial Venous Disease And Venous Ulcers

Location: Trianon Ballroom, 3rd Floor

PROGRAM J (SESSIONS 74-78)

Multidisciplinary Stroke Prevention And Treatment

Location: Americas Hall 1 North, 3rd Floor

PROGRAM K (SESSIONS 79-84) - AIMsymposium AT VEITHsymposium: TOPICS OF INTEREST TO INTERVENTIONAL RADIOLOGISTS

Location: Americas Hall 1 South, 3rd Floor

PROGRAM G (SESSIONS 47-54)

EXCITING NEW OR REDISCOVERED TECHNIQUES, CONCEPTS OR DEVICES; PROGRESS IN F/B/EVAR AND PARALLEL GRAFTS FOR COMPLEX AAAs; TRIBUTE TO OUR MILITARY; PROGRESS IN THE TREATMENT OF RUPTURED AAAs; MORE ABOUT NEW DEVICES, TECHNIQUES OR CONCEPTS; PROGRESS IN RADIATION SAFETY

Grand Ballroom East, 3rd Floor

SESSION 47 (Grand Ballroom East, 3rd Floor)

EXCITING NEW OR REDISCOVERED TECHNIQUES, DEVICES, CONCEPTS

Moderators: *Frank J. Veith, MD*

Michael B. Silva, Jr., MD

Richard F. Neville, MD

- 6:56 – 7:01** Progress In Remote Monitoring Of Vascular Graft Flow Rates And Other Parameters Including Hematocrit, Serum Potassium Levels, O₂ Saturation, Etc. (The Alio System): Where Is It At Present And Where Is It Going
Richard F. Neville, MD
- 7:02 – 7:07** Polymer Biodegradable Grafts To Create Autogenous Living Conduits: A New Paradigm: Where Do They Stand And What Are The Potential Benefits
Frans L. Moll, MD, PhD
- 7:08 – 7:13** New Developments In The Endo And Open Management Of Pediatric Iatrogenic And Traumatic Vascular Injuries: When An Arterial Graft Is Needed Which Ones Are Best
Erica L. Mitchell, MD, MEd
- 7:14 – 7:19** The Role Of The Vascular Surgeon In Treating Perinatal Hemorrhage: Endovascular Iliac Balloon Occlusion Can Be Life Saving: How And Where Balloons Should Be Placed
Dittmar Böckler, MD
- 7:20 – 7:25** How Can GLP1A And Other Anti-Obesity Drugs Benefit Vascular Patients And Vascular Procedures: How May They Decrease Vascular Disease Progression, Symptoms And Cardiovascular Risk
Henrik Sillesen, MD, DMSc
- 7:26 – 7:31** **Panel Discussion**
- 7:32 – 7:37** Progress With The Retrievable Rescue Stent-Graft To Control Massive Aortic Or Caval Bleeding: How Does It Work, How Is The Device Retrieved And When Will It Be Widely Available
Bryan W. Tillman, MD, PhD
- 7:38 – 7:43** Current Concepts In The Treatment Of Vascular Ehlers Danlos Syndrome (EDS): How To Make Treatment Outcomes And Operations For Complications Successful: Technical Tips
James H. Black, III, MD
- 7:44 – 7:49** Current Status And Future Potential Of Pig To Human Organ Xenografting
Robert A. Montgomery, MD, DPhil
- 7:50 – 7:55** Classification And Management Of BTAI: An Update From The Revised SVS Clinical Practice Guidelines: When Is Medical Management The Best Treatment
Ali Azizzadeh, MD
- 7:56 – 8:01** Long-Term (Up To 20 Years) Follow-Up Of 95 TEVAR Patients With Non-Compliant Endografts For Blunt Traumatic Aortic Injury (BTAI): All Major Complications Requiring Reintervention Occurred Within 18 Months: Was There A Detrimental Effect On The BP Or Heart In These Patients
Johnny Steuer, MD, PhD
- 8:02 – 8:07** **Panel Discussion**

SESSION 48 (Grand Ballroom East, 3rd Floor)

PROGRESS IN FENESTRATED AND BRANCHED EVAR (F/B/EVAR) AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; AND RELATED TOPICS

Moderators: *Gustavo S. Oderich, MD*
James F. McKinsey, MD
Jade S. Hiramoto, MD

- 8:08 – 8:13** With Complex AAAs (Juxta, Para) What Is The Best Endovascular Treatment And When: Standard F/B/ EVAR, Inner Branched B/EVAR Or Parallel Graft EVAR (Chimney Or Sandwich)
Rocco Giudice, MD

- 8:14 – 8:19** Complete Aortic Endovascular Repairs For Complex AAAs And TAAAs Using Parallel Endografts With A Docking Station: How And Why To Make Them Work Effectively Despite Doubts About Parallel Grafts: What Are The Limitations
Manish Mehta, MD, MPH

F/EVAR FOR FAILED EVAR

- 8:20 – 8:25** Late Results Of F/EVAR For Failed EVAR Are Excellent: When Should It Be The Procedure Of Choice For EVAR Failures: Technical Tips Including Use Of A F/EVAR Device With An Integrated Bifurcation To Facilitate The Procedure
Andres Schanzer, MD

- 8:26 – 8:31** F/EVAR After Failed EVAR: It Works But Long-Term Results Are Worse Than For Standard F/EVAR: Why This May Be: Technical Tips To Facilitate The Procedure
Marc L. Schermerhorn, MD

- 8:32 – 8:37** Late Results Of F/EVAR For Failed EVAR: Although Technically Successful, Late Mortality Is Disappointingly High: Why Is This So
Barend M.E. Mees, MD, PhD

- 8:38 – 8:44** **Panel Discussion**

- 8:45 – 8:50** Ch/EVAR For Juxtarenal AAAs: Results From A Single Center With The Longest Available Follow-Up Confirm Long-Term Safety And Effectiveness: Technique Is Vital And How To Do It
Joost van Herwaarden, MD, PhD

- 8:51 – 8:56** Value Of Parallel Endografts In The Management Of TAAAs And Complex AAAs: Why Do They Fail And Have A Bad Reputation: How To Make Them Work Effectively And Consistently
David J. Minion, MD

IMPORTANCE OF BRIDGING GRAFTS

- 8:57 – 9:02** Which Bridging Covered Stents Or Stent-Grafts Work Best For F/B/EVAR: A European Perspective: Why Renal Artery Bridging Stent-Grafts Are The Achilles Heel In B/EVAR And What To Do About It
Martin J. Austermann, MD

- 9:03 – 9:08** Why Balloon Expandable Bridging Stent-Grafts Are Best For F/B/EVAR: Which One Is Best And Why: A US Perspective Advantages Of The Gore VBX Stent-Graft
Mark A. Farber, MD

- 9:09 – 9:14** New Bridging Stents For F/EVAR: What Are Their Characteristics And Why They Make A Difference
Timothy A. Resch, MD, PhD

- 9:15 – 9:23** **Panel Discussion**

- 9:23 – 9:38** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 49 (Grand Ballroom East, 3rd Floor)

MORE PROGRESS IN F/B/EVAR AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; AND RELATED TOPICS

Moderators: *Manish Mehta, MD, MPH*
Jan D. Blankensteijn, MD
Weiguo Fu, MD

- 9:38 – 9:43** A Real-World Experience Of Using An Off-The-Shelf (OTS) Preloaded Inner Branched Endograft (E-nside - Artivion) For The Treatment Of Complex AAAs And TAAAs: When Is It Helpful And When Is It Not
Boonprasit Kritpracha, MD

- 9:44 – 9:49** Aortic Mural Thrombus: How To Detect And Quantitate It: What Is Its Effect On SCI Risk With Complex AAA And TAAA Repairs: How Should It Change Management
Jade S. Hiramoto, MD
Timothy A.M. Chuter, MD
- 9:50 – 9:55** Aortic Research Consortium (ARC) Quality Analysis Over Time Shows Improving F/B/EVAR Outcomes Despite Growing Disease Complexity: Key Technical Tips And Reasons For Improvement
Andres Schanzer, MD
- 9:56–10:01** Antegrade In Situ Laser Fenestration Of Visceral Branches For TAAA And Pararenal AAA Repairs: Technical Tips, How To Avoid Pitfalls And Mid-Term Results
Jean M. Panneton, MD
- 10:02–10:07** Three Parallel Graft Techniques For Repair Of Aortic And Iliac Degenerative And Post Dissection Aneurysms: What Are The Differences Between The Sandwich, Lobato And Chimney Methods And What Are Their Advantages, Limitations And Results
Armando C. Lobato, MD, PhD
- 10:08–10:13** **Panel Discussion**
- 10:14–10:19** Open TAAA Repairs: How Do The Results Of Primary Repairs Compare With Those Done For Failed TEVAR, B/EVAR And F/EVAR: What Are The Technical Challenges Of The Secondary Repairs
Germano C.G. Melissano, MD
Andrea Kahlberg, MD
- 10:20–10:25** F/EVAR And B/EVAR In Chronic Dissections Are Not Successful In All Patients; Further Interventions Are Often Needed: What Are They
Götz M. Richter, MD, PhD
- 10:26–10:31** Impact Of Aortic Remodeling On Main Graft And Bridging Stent Stability After B/EVAR And F/EVAR: How Harmful Is It, How Can It Be Prevented And How Should It Influence Treatment
Giovanni B. Torsello, MD
- 10:32–10:37** Longer-Term Outcomes Of Inner Branches To Address Visceral Target Arteries In F/EVAR And B/EVAR: What Are The Correct Indications For Them And Does The Bridging Stent-Graft Matter
Eric L.G. Verhoeven, MD, PhD
Athanasios Katsargyris, MD
- 10:38–10:43** Aneurysm Sac Changes After F/B/EVAR For TAAAs: Why They Are Important Prognostically: What Beside Endoleaks Can Cause Enlargement: When And How Should Enlargement Be Treated
Darren B. Schneider, MD
- 10:44–10:49** The BeGraft And BeGraft Plus (Bentley) As Bridging Covered Stents For F/B/EVAR: Advantages And Mid-Term Outcomes: What Is The New BeFlared Covered Stent And Why Is It Better
Eric L.G. Verhoeven, MD, PhD
Athanasios Katsargyris, MD
- 10:50–10:56** **Panel Discussion**

SESSION 50 (Grand Ballroom East, 3rd Floor)

A TRIBUTE TO OUR MILITARY AND MILITARY PHYSICIANS: SOME MILITARY HISTORY; TREATMENT OF MILITARY AND CIVILIAN VASCULAR INJURIES AND CONTROL OF HEMORRHAGE; UPDATE ON REBOA

Moderators: *Todd E. Rasmussen, MD*
Wayne F. Yakes, MD

- 10:56–11:06** How General Dan "Razin" Caine Orchestrated The Taking Out Of ISIS During Trump's First Presidential Term
Wayne F. Yakes, MD
- 11:07–11:12** What Has Been The Effect Of The Russia/Ukraine War On Ukrainian Vascular Surgery Care – Civilian And Military
Andriy O. Nykonenko, MD, PhD
Oleksandr Sokolov, MD, PhD
- 11:13–11:18** New Developments In REBOA (Resuscitative Endovascular Balloon Occlusion Of The Aorta): What Is Partial REBOA; How Does It Work And When Is It Indicated: A New Catheter (P-REBOA PRO) To Facilitate It; What Makes It Different
Todd E. Rasmussen, MD
- 11:19–11:24** Progress In Dealing With Major Civilian Vascular Injuries And Their Complications During The Ukraine War: Are The Resources Adequate And How Are The Medical And Surgical Personnel Coping
Yuliia Nahaliuk, MD
- 11:25–11:30** Progress In Dealing With Vascular Trauma – Military And Civilian – During The Gaza/Israeli War
Samy S. Nitecki, MD
- 11:31–11:36** Update On The Management Of Arterial And Venous Injuries – Civilian And Military: When Should The Treatment Be "Endovascular First" And When Should It Be Open Surgery: Equipment And Training Are Important Determinants
Charles J. Fox, MD
- 11:37–11:42** New Developments In Isolated Limb Perfusion To Enable Traumatically Amputated Limb Reimplantation
Zachary M. Arthurs, MD
- 11:43–11:48** Advances In Endovascular Resuscitation And Bleeding Control: Update On The Value Of Standard And Partial REBOA
Tal M. Hörer, MD, PhD
- 11:49–11:54** A New Hemostatic Agent (Cresilon [Trauma Gel]) Topical Application To Control Traumatic Hemorrhage
Enrico Ascher, MD
- 11:55–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break - Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 51 (Grand Ballroom East, 3rd Floor)

PROGRESS IN THE TREATMENT OF RUPTURED INFRARENAL AAAs

Moderators: *Thomas L. Forbes, MD*
Michel S. Makaroun, MD
Frank J. Veith, MD

INFRARENAL RUPTURED AAAs

- 1:00 – 1:05** Why EVAR Is Currently The Best Treatment For All Or Most Ruptured Infrarenal AAAs: Why The RCTs Comparing Open And Endo Repair Are Misleading: When In 2025 Might Open Repair Be The Best Treatment
Panos Kougias, MD, MSc
- 1:06 – 1:11** Long-Term Results Of The AJAX RCT Comparing EVAR With Open Repair For Ruptured AAAs Has Flaws: What Are They: Despite These Flaws, EVAR Wins In The End – Especially In Older Patients
Willem Wisselink, MD

- 1:12 – 1:17** A 15-Year Experience With Universal (100%) Endovascular Management Of Ruptured AAAs: Technical Tips; Insights And Updates: When May Open Surgery Be Necessary
David T. McGreevy, MD, PhD
Tal M. Hörer, MD, PhD
- 1:18 – 1:23** The Role Of Intraluminal Thrombus In AAA Growth And Rupture: What Mechanism Makes Thrombus Harmful
Marc R.H.M. van Sambeek, MD, PhD
- 1:24 – 1:29** Update On Advances In Treatment Of Abdominal Compartment Syndrome Associated With Ruptured AAAs: When And How Can It Be Treated Medically And When Must The Abdomen Be Opened
Anders Wanhainen, MD, PhD
- 1:30 – 1:35** A Novel Technique To Facilitate Quick Contralateral Gate Cannulation During Ruptured EVAR Even With Proximal Balloon Control
Ross Milner, MD
- 1:36 – 1:41** AAA Rupture After EVAR Behaves Differently From De Novo Rupture: How Should Treatment Be Modified In Patients With Ruptures After EVAR
Piotr Szopinski, MD, PhD
- 1:42 – 1:47** Selection Of Patients With Ruptured AAAs For Noninvasive (Comfort) Care Based On Scoring Systems Or Advanced Age Is NOT Appropriate And Unfair To Some Patients
Isabelle Van Herzele, MD, PhD
- 1:48 – 1:53** How Can The Turndown Rate For Invasive Treatment Of Ruptured AAAs Be Decreased: It Is Worthwhile
Matthew W. Mell, MD, MS
- 1:54 – 1:59** **Panel Discussion**

SESSION 52 (Grand Ballroom East, 3rd Floor)

PROGRESS IN ENDO AND OPEN TREATMENT TECHNIQUES FOR RUPTURED INFRARENAL AAAs, COMPLEX AAAs AND TAAAs; NEW DEVELOPMENTS IN SURVEILLANCE AND SCREENING

Moderators: *Keith D. Calligaro, MD*

Mario L. Lachat, MD

Manish Mehta, MD, MPH

- 2:00 – 2:05** For Ruptured Complex AAAs A Short Custom Made Single Fenestrated Graft Can Be Used To Revascularize The SMA Followed By A Bifurcated Graft And Laser Fenestration For The Renal Arteries: Technique And Experience
Nuno V. Dias, MD, PhD
- 2:06 – 2:11** New Developments In The Management Of Ruptured AAAs With Aorto-Enteric Fistulas: How To Improve Survival
Salvatore Scali, MD
- 2:12 – 2:17** T-Branch (Cook - OTS) Treatment Of Ruptured TAAAs: The Value Of Local Anesthesia And Why Axillary Access And The BeFlare Covered Stent Are Important Adjuncts: Advantages And Contraindications
Nikolaos Tsilimparis, MD, PhD
- 2:18 – 2:23** With Ruptured Complex AAAs And TAAAs, Parallel Grafts Are The Best Treatment: They Are Simpler, More Effective And Less Costly Than Other Treatments
Manish Mehta, MD, MPH
- 2:24 – 2:29** Open Retroperitoneal Aortic Approach For Ruptured AAAs: Technical Tips, Advantages And Limitations: When Is It Better Than EVAR And F/EVAR
R. Clement Darling III, MD

- 2:30 – 2:35 Panel Discussion**
- 2:36 – 2:41** In Situ Laser Fenestration To Facilitate Urgent F/ EVARs For Ruptured Complex AAAs: Technical Considerations And Equipment Needed
W. Anthony Lee, MD
- 2:42 – 2:47** Laser In Situ F/EVAR Is The Procedure Of Choice For Ruptured Complex AAAs Or TAAAs: Technical Tips, Endografts To Use, Advantages And Limitations
Jonathan Bath, MD
- 2:48 – 2:53** Rapid In Situ Laser Fenestration For Endovascular Treatment Of Ruptured Complex AAAs: How To Do It With Minimal SMA And Renal Ischemia And Results
Anders Wanhainen, MD, PhD
- 2:54 – 2:59** Aortic Endograft And Branch Diameter Sizing For Ruptured AAAs: How To Compensate For Size Changes Due To Hypotension: Does Patient Age Matter
Zoran Rancic, MD, PhD

NEW DEVELOPMENTS IN AAA SCREENING AND SURVEILLANCE

- 3:00 – 3:05** How AI And 3D Imaging Software Can Improve Aortic Screening And Surveillance Of AAAs Before And After Invasive Treatment: Should Screening Groups Be Expanded
Robert W. Chang, MD
- 3:06 – 3:11** Lessons Learned From 15 Years Of National Aneurysm Screening In The UK: Is It Still A Viable Service And Does It Really Save Lives: What Changes Are Needed
Ian Loftus, MD
- 3:12 – 3:18 Panel Discussion**
- 3:18 – 3:28 Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 53 (Grand Ballroom East, 3rd Floor)

EXCITING NEW OR UPDATED CONCEPTS, TECHNIQUES AND TREATMENTS

Moderators: *Fred A. Weaver, MD, MMM*

Timur P. Sarac, MD

Cynthia K. Shortell, MD

- 3:28 – 3:33** Aberrant Subclavian Artery And Dysphasia Lusoria: An Anomaly That We Should All Understand And Be Able To Treat: Treatment Of Associated Kommerell's Diverticulum
Peter F. Lawrence, MD
- 3:34 – 3:39** Technical Tips For Performing Safe And Effective Open Repair Of Degenerative And Post Dissection TAAAs
Germano C.G. Melissano, MD
- 3:40 – 3:45** What Are The Best Vascular Grafts To Treat Aortic And Aortic Branch Pathology In Infants And Children
James C. Stanley, MD
- 3:46 – 3:51** What Are The Effects Of Glucagon Like Peptide (GLP-1) Agonists: How Do They Work And How Do They Influence AAA Growth
Francis Caputo, MD
- 3:52 – 3:57** A New Device For Endo Arch Repairs Entirely From Groin Access: How Does The Device Work And Clinical Experience To Date
Wayne W. Zhang, MD
- 3:58 – 4:03** Implantable Carotid Stent-Like Device To Stimulate The Carotid Sinus Nerve (Of Hering) And Treat Intractable Heart Failure And Hypertension (The Barostim System): How Does It Work And Current Clinical Status
John F. Eidt, MD
Fred A. Weaver, MD, MMM

- 4:04 – 4:09** Fiber And Lint Contamination During Endovascular And Surgical Procedures Promotes Thrombosis: How To Reduce And Prevent It
Craig M. Walker, MD
John R. Laird, MD
- 4:10 – 4:15** **Panel Discussion**
- 4:16 – 4:21** Median Arcuate Ligament Syndrome (MALS) In The Pediatric Population: Diagnosis And Optimal Treatment
Alex Fairman, MD
- 4:22 – 4:27** Artificial Intelligence Angiographic Flow Analysis During Peripheral Angioplasty Procedures To Aid Intra-Procedural Decision Making And Prediction Of Clinical Outcomes
Konstantinos Katsanos, MSc, MD, PhD
- 4:28 – 4:33** Update On External Sirolimus Patch Around AV Fistula And AV Graft Vascular Anastomosis
Sriram S. Iyer, MD
- 4:34 – 4:39** Hyperbaric Oxygen Therapy And Its Applications In Vascular Surgery For Diabetic And Non-Diabetic Patients: What Is The Level 1 Evidence That It Works: When Is It Indicated, When Is It Not
Robert B. McLafferty, MD, MBA
- 4:40 – 4:45** Technical Tips For Removing Lost Or Malpositioned Intravascular Stents, Wires, Etc.: It Can Be Difficult And Special Techniques May Be Required
Guillermo A. Escobar, MD
- 4:46 – 4:51** Radial Access For Visceral And Lower Extremity Lesions: Equipment, Technical Tip, Limitations And Precautions
Marcelo Guimaraes, MD, MBA
- 4:52 – 4:57** **Panel Discussion**

SESSION 54 (Grand Ballroom East, 3rd Floor)

PROGRESS IN RADIATION SAFETY, DEVICES AND TECHNIQUES

Moderators: *Lindsay Machan, MD*
Jacob Cynamon, MD

- 4:58 – 5:03** New Developments In Radiation Protection: How Can AI Help: A New More Ergonomic System: It Can Overcome Imperfections In Older Protection Devices
Lindsay Machan, MD
- 5:04 – 5:09** New Strategies To Reduce Radiation Exposure During Complex Endovascular Aortic Procedures
Bijan Modarai, PhD
- 5:10 – 5:15** The Zero Radiation Project: MRI Can Replace Radiation In The Diagnosis, Treatment And Follow-Up Of EVAR Treated AAA Patients: How To Do It And Validation
Kak Khee Yeung, MD, PhD
- 5:16 – 5:21** Techniques To Minimize Radiation Exposure And Contrast Use To Reduce Nephropathy: CO2 Angiography Is Unnecessary
Ali Amin, MD, RVT
- 5:22 – 5:27** How Does The EggNest System Of Radiation Protection Help Us Prevent Eye Damage, Cancer, Osteoporosis, Etc. During Endovascular Procedures: How And How Well Does The System Work
Javairiah Fatima, MD
- 5:28 – 5:33** The Rampart IC Radiation Protection System: What Is It And How Effective Is It
Jan M.M. Heyligers, MD, PhD
- 5:34 – 5:39** How Can C-Arm System Settings Be Used To Minimize Radiation Exposure
Maarit Venermo, MD, PhD

5:40 – 5:45 New Developments In Improving Radiation Safety By Room Mitigation And Personal Protection
Ravi K. Veeraswamy, MD

5:46 – 5:55 **Panel Discussion**
End of Program G

PROGRAM H (SESSIONS 55-63)

NEW OR IMPROVED DEVICES FOR: STANDARD EVAR AND MORE COMPLEX AAAs; REPAIRS OF TAAAs, THE ASCENDING AORTA, THE AORTIC ARCH, AND THE DESCENDING AORTA (TEVAR); NEW DEVICES FOR TREATING LOWER EXTREMITY LESIONS BY ENDO OR OPEN TECHNIQUES; UPDATE ON ENDOANCHORS AND FIXATION DEVICES AND NEW OR IMPROVED DEVICES FOR ENDOVASCULARLY REMOVING CLOT AND OCCLUDING BLOOD VESSELS

Grand Ballroom West, 3rd Floor

SESSION 55 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED DEVICES FOR INFRARENAL AAA AND COMPLEX AAA REPAIR

Moderators: *Eric L.G. Verhoeven, MD, PhD*

Michel S. Makaroun, MD

Rossi M. Silva, MD

7:00 – 7:05 Update On The Polymer O-Ring Based ALTO Endograft (Endologix): Advantages And Limitations
Gianmarco de Donato, MD

7:06 – 7:11 The Adaptive Sealing Ring Polymer Technology Of The ALTO Endograft (Endologix) Is Optimal To Treat Patients With Complex Proximal Neck Anatomy And Narrow Or Tortuous Iliac Arteries: Advantages, Limitations And Results
Piotr Szopinski, MD, PhD

7:12 – 7:17 A Conformable Neck Sealing Ring Endograft (Alto From Endologix) Combined With Sac Embolization Using Shape Memory Polymer Devices Yields Good 1-Year Results
Dipankar Mukherjee, MD

7:18 – 7:23 Rescue Techniques For Late Type 1A Endoleaks After Alto Stent Graft Treatment Of AAA; How To Deal With The Large Barbed Suprarenal Stent
Mazin Foteh, MD

7:24 – 7:29 A New 11 Fr EVAR Device (From Major Medical) Capable Of Delivery From The Upper Extremity: How Does It Work And Why Won't It Be Flimsy Like Other Low Profile Devices
David H. Deaton, MD

7:30 – 7:35 **Panel Discussion**

7:36 – 7:41 5-Year Results Of The Gore Conformable Excluder For EVAR: How Does It Work And Durability In Complex Anatomy (Angulated And Short Necks)
Robert Y. Rhee, MD

7:42 – 7:47 The E-Tegra Device (Artivion) For Infrarenal AAA Treatment: Advantages, Limitations And Results
Michel Reijnen, MD, PhD

7:48 – 7:53 Current Status And Value Of The AFX 2 For The Treatment Of AAAs And Aorto-Iliac Occlusive Disease
Piotr Szopinski, MD, PhD

7:54 – 7:59 AFX (Endologix) And Excluder (Gore) Endografts For AAA Treatment Had Comparable 5-Year Outcomes: However The AFX Graft Was Best With Conical Necks: From A Japanese Multicenter Study (Activseal)
Naoki Fujimura, MD, PhD

- 8:00 – 8:05** 5-Year Results And Advantages Of The TREO (Terumo) Endograft For Standard Infrarenal EVARs: Status In The US
Matthew J. Eagleton, MD

8:06 – 8:11 Panel Discussion

SESSION 56 (Grand Ballroom West, 3rd Floor)

NEW OR UPDATED EVAR DEVICES FOR AAAs, COMPLEX AAAs, TAAAs OR ARCH TEVARs

Moderators: *Christopher J. Kwolek, MD, MBA*
Margaret Tracci, MD, JD

- 8:12 – 8:17** In Choosing Industry Made Endovascular Devices, How Important Is Corporate Reputation, Device Quality, Service By Representatives And Cost
Murray L. Shames, MD
- 8:18 – 8:23** A Novel EVAR Endograft System Dedicated To Prevention Of Type II Endoleaks: How Does It Work And Experience To Date
Wayne W. Zhang, MD
- 8:24 – 8:29** Cook Zenith Fenestrated Endovascular Aneurysm Repair With Distal Inverted Contralateral Iliac Limb: When To Use It: Advantages And Limitations
Clark J. Zeebregts, MD, PhD
- 8:30 – 8:35** Comparison Of Cook And Treo (Terumo) Fenestrated Devices For Juxta- And Pararenal AAAs: Results, Advantages And Limitations Of Both
Sonia Ronchey, MD, PhD
Christopher J. Kwolek, MD, MBA
- 8:36 – 8:41** The Advantages Of The TREO And Fenestrated TREO Endografts (Terumo) For Infrarenal And Complex EVAR Repairs
Vicente Riambau, MD, PhD
- 8:42 – 8:47** What Are The TREO-Fit And Fenestrated TREO Platforms And How Do They Work To Standardize Repairs Of Juxta- And Pararenal AAAs: Advantages And Results
Benjamin W. Starnes, MD
- 8:48 – 8:53** Current Status Of The WeFlow Endografts For Treatment Of Complex AAAs And TAAAs: A Combined Inner Branch And Outer Branch Device: How Does It Work And Promising Results
Wei Guo, MD
- 8:54 – 8:59** New Insights From The 10-Year Results Of The ENGAGE EVAR Registry: What Does It Tell Us About EVAR Durability
Hence J.M. Verhagen, MD, PhD
- 9:00 – 9:06 Panel Discussion**
- 9:06 – 9:19 Break - Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 57 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED DEVICES FOR THORACOABDOMINAL ANEURYSM (TAAA) REPAIRS AND THORACIC AORTIC LESION REPAIRS (TEVAR)

Moderators: *Ross Milner, MD*
Carlos H. Timaran, MD

IMPROVED DEVICES FOR TAAA REPAIRS

- 9:20 – 9:25** Comparative Analysis Of The Results Of Various Off-The-Shelf (OTS) Devices For Treating TAAAs
Michel J. Bosiers, MD

- 9:26 – 9:31** Updated Clinical Experience And Advantages Of The Thoracoflo Graft (Terumo) For The Hybrid Repair Of TAAAs (Proximal TEVAR; Distal Open) How And Why To Preserve IMA Flow And Other Technical Tips
Sebastian E. Debus, MD, PhD (PowerPoint Presentation With Synched Audio)
Sabine H. Wipper, MD, PhD
- 9:32 – 9:37** Clinical Experience With Thoracic Branched Endografts: Which Devices Are Best And What Are The Indications For Their Use
Randy D. Moore, MD
- 9:38 – 9:43** How To Reduce Reinterventions After F/B/EVAR By Improving Branch Stability: Technical Tips
Ciro Ferrer, MD, PhD
- 9:44 – 9:49** Value Of Endo TAAA Repair In Patients With Connective Tissue Disorders: Which Device Or Devices Are Best And Why
Gustavo S. Oderich, MD
- 9:50 – 9:55** T-Branch OTS Endografts (Cook) For The Treatment Of Failed EVAR: Indications, Advantages, Limitations And Clinical Experience
Mauro Gargiulo, Professor
- 9:56–10:01** Duplex Findings From The TAMBE Trial: Why Are They Important And How Will They Improve Results
Jon S. Matsumura, MD
- 10:02–10:07** **Panel Discussion**
IMPROVED DEVICES FOR COMPLEX AAAs, TAAAs AND TEVAR
- 10:08–10:13** What Are Semi Branches In The Artivion Inner Branched Custom-Made Aortic Endograft (E-xtra Design MultiBranch) For Pararenal Aneurysms And How Do They Reduce Aortic Coverage: Advantages, Limitations And Results
Lee Bouwman, MD, PhD
- 10:14–10:19** Comparison Of The Cook t-Branch OTS Endograft Device With The E-nside (Artivion) Multibranched Device For Juxta- And Pararenal AAAs And TAAAs: Advantages And Limitations Of Each
Matteo Orrico, MD
Nicola Mangialardi, MD
- 10:20–10:25** Real-World Experience With The TAMBE Device (Gore) For The Treatment Of TAAAs: Advantages, Limitations And Results
James F. McKinsey, MD
- 10:26–10:31** Gore TAMBE Endograft For The Treatment Of Complex AAAs And TAAAs: Indications, Advantages, Limitations And Technical Tips
Cherrie Z. Abraham, MD
- 10:32–10:37** Total Endovascular Aortic Arch Repair Is Complicated But A 3 Retrograde Branch Design Is Safest And Simplest When Reinforced Steerable Sheaths Are Used Entirely Via Transfemoral Access: Which Devices Are Best And Technical Tips
Andres Schanzer, MD
- 10:38–10:43** Valiant Captiva (Medtronic) For TEVAR: Advantages, Limitations And 5-Year Results For Various Aortic Lesions
Jean Pierre Becquemin, MD (PowerPoint Presentation With Synched Audio)
- 10:44–10:52** **Panel Discussion**

SESSION 58 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED DEVICES FOR THE AORTIC ARCH OR NEAR THE ARCH, TAAAs AND TEVAR

Moderators: *Rodney A. White, MD*
Weiguo Fu, MD

- 10:52–10:57** Current Status In The US Of The Relay Branched Endovascular Graft (Terumo) For Endo Repair Of Aortic Arch Lesions: How Many Branches Can And Should Be Revascularized: Advantages, Limitations And Clinical Experience To Date
Luis A. Sanchez, MD
Eric E. Roselli, MD
- 10:58–11:03** Endovascular Arch Repair With Cook 2 Or 3 Branched Devices For Lesions Involving The Whole Aortic Arch: When Are They Indicated; When Contradicted And Tips For Making Them Work
Mark A. Farber, MD
- 11:04–11:09** Aortic Arch Repair With A Transfemoral, Modular, Off-The-Shelf Design That Avoids Arch Manipulation: How Does It Minimize Cerebral Ischemia
Mathew D. Wooster, MD, MBA
- 11:10–11:15** Updated European Experience With The Gore Single Branch Endograft For The Treatment Of Lesions In Or Near The Aortic Arch: What Makes It Different, Advantages And Results
Michele Antonello, MD, PhD
- 11:16–11:21** New TEVAR Options For Lesions Close To Or Involving The LSA: Advantages And Results With Cook's Custom Single Branch TEVAR Endograft
Tilo Kölbel, MD, PhD
- 11:22–11:27** Preloaded Fenestrated Endografts With A Modified Biport Handle (From Cook): A Way To Make F/EVAR Easier: How Does It Work And Results From An International Multicenter Study
Nikolaos Tsilimparis, MD, PhD
- 11:28–11:33** The Nexus TRE System (Endospan): A New Different Triple Branched Device For Treating Arch Lesions Without Debranching: How Does It Work And Clinical Experience
Said Abisi, MD

IMPROVED DEVICES FOR TEVAR

- 11:34–11:39** Status Of And When And How To Use The Gore Conformable CTAG Endograft With Variable Angulation Control Optimally: Advantages And Limitations
Sukgu M. Han, MD, MS
- 11:40–11:45** Current US Status And Results With The RelayPro NBS Endograft For TEVAR: Advantages And Limitations
Frank R. Arko, MD
- 11:46–11:51** Computational Modeling Is A New Paradigm For Outcomes Improvement In TEVAR
Santi Trimarchi, MD, PhD
- 11:52–12:00** **Panel Discussion**
- 12:00– 1:00** **Break - Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 59 (Grand Ballroom West, 3rd Floor)

UPDATED INFORMATION ON LOWER EXTREMITY PROSTHETIC GRAFTS (SEE ALSO SESSION 28) AND RE-ENTRY DEVICES

Moderators: *Samuel R. Money, MD, MBA*
Mark A. Adelman, MD

PROSTHETIC DRAFTS

- 1:00 – 1:05** Perigraft Seromas After PTFE Lower Extremity And Aortic Arterial Grafts: Frequency, Etiology, When Do They Need To Be Treated And How
Jae S. Cho, MD

- 1:06 – 1:11** Percutaneous (PQ) Transvenous Fem-Pop PTFE Bypasses (From Endologix): Tips To Simplify The Procedure And Avoid Tibial Venous Access: Will It Eliminate Open PTFE FemPop Bypasses
Venkatesh G. Ramaiah, MD
- 1:12 – 1:17** Update On The Tissue Engineered Human Biological Arterial Grafts (Humacyte): 3-Year Clinical Results In Civilian And Military Settings: Indications, Advantages And Unanswered Questions
Todd E. Rasmussen, MD
Charles J. Fox, MD
- 1:18 – 1:23** Heparin Coated PTFE Grafts (Propaten - Gore) vs. Autologous Vein Grafts For Bypasses To Targets Above And Below The Knee: The Heparin Coated Grafts Are Better And Worth The Cost: Based On A Propensity Matched Analysis
David J. Dexter, MD
- 1:24 – 1:29** Does Heparin Bonding To PTFE Grafts Really Make A Difference And Improve Results: Is The Heparin Bonding To Propaten Grafts (Gore) Different Enough To Improve Results
Yann Gouëffic, MD, PhD

RE-ENTRY DEVICES REEXAMINED

- 1:30 – 1:35** Pros And Cons Of Re-Entry Devices In Treating CTOs: Why, Where And When To Use Them: Are They Worth The Cost And Have Other Techniques Like Retrograde Access Largely Replaced Them
Maria Antonella Ruffino, MD
- 1:36 – 1:41** Re-Entry Devices Are Currently Almost Never Necessary: Techniques To Treat Lower Extremity Lesions Successfully Without Them: When Might They Be Needed
Ali Amin, MD, RVT
- 1:42 – 1:47** Improving Endoleak Detection And Accurately Defining Their Source With Contrast Enhanced Sonography: Equipment Needed And How To Do It
Thanila A. Macedo, MD
- 1:48 – 1:54** **Panel Discussion**

SESSION 60 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED ENDOVASCULAR DEVICES FOR LOWER EXTREMITY TREATMENTS: ATHERECTOMY, STENTS, DCBs, ACCESSORIES, ETC. (SEE ALSO SESSIONS 23-27)

Moderators: *Maciej L. Dryjski, MD, PhD*
Sateesh C. Babu, MD

ATHERECTOMY AND LITHOTRIPSY RELATED TOPICS

- 1:54 – 1:59** Atherectomy In Patients With CLTI And Diabetes For In-Stent Restenosis (ISR): When Is It Helpful; How Durable Is It: Which Devices Are The Best
Ignacio Escotto, MD
- 2:00 – 2:05** Managing Complex Lower Extremity Disease: Experience With The Revolution Atherectomy System (From Rex Medical): Advantages And Experience
Robert E. Beasley, MD

STENT-GRAFT RELATED TOPICS

- 2:06 – 2:11** Outcomes Of The Viabahn Endografts (Gore) To Treat Fem-Pop Occlusive Disease; Data From The INSIGHT Individual Participant Or Patient Data Meta-Analysis
Michel Reijnen, MD, PhD

- 2:12 – 2:17** Long-Term Comparative Data For The Gore VBX Balloon Expandable Covered Stents (vs. Bare Metal Stents) To Treat Iliac Occlusive Disease: Advantages And Limitations Of VBX: From The FORWARD RCT
Andrew Holden, MBChB
- 2:18 – 2:23** **Panel Discussion**
NEW STENT AND BIORESORBABLE STENT RELATED TOPICS
- 2:24 – 2:29** Xact Carotid Stent (Abbott) With A Short-Transcarotid Access Delivery System For TCAR Procedures: Advantages And Results
Peter L. Faries, MD
- 2:30 – 2:35** Why The Zilver PTX DES (Cook) Is A Durable Effective Treatment For Long FemPop Lesions: Based On Worldwide Trials And Experience: DES Choice (Zilver PTX And Eluvia – Boston Scientific) Can Impact Patient Well Being: 3-Year Results From The REAL-DES Trial
Charles J. Bailey, MD
- 2:36 – 2:41** Early Experience With A New Bioresorbable Stent Scaffold (Efemoral From Efemoral Medical) To Treat FemPop Disease
Ramon L. Varcoe, MBBS, MS, PhD, MMed
Andrew Holden, MBChB
- 2:42 – 2:47** 3-Year Results With Another Drug Eluting Bioresorbable Stent (Motiv From REVA) To Treat BTK Lesions: How Is This Device Different, Advantages And Limitations
Michel J. Bosiers, MD
- 2:48 – 2:53** New 3-Year Results In >1000 Patients From The Lutonix SAFE Registry Demonstrate The Advantages Of The Lutonix DCB (BD) In Specific Patient Subgroups
Peter A. Schneider, MD
- PERCUTANEOUS FEMPOP BYPASS**
- 2:54 – 2:59** A Novel Device For Percutaneous FemPop Bypass With End To Side Sutureless Clampless Anastomosis In 3 Minutes: How Does It Work And Early Results
Steven Kum, MD
- 3:00 – 3:06** **Panel Discussion**
- 3:06 – 3:18** **Break - Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 61 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED ENDOVASCULAR DEVICE COMBINATIONS FOR LOWER EXTREMITY AND COMPLEX TEVAR TREATMENTS: ANGIOPLASTY BALLOON IMPROVEMENTS

Moderators: *Richard J. Powell, MD*
Dennis R. Gable, MD

- 3:18 – 3:23** Intravascular Lithotripsy (IVL) In Tibial Arteries: Updates From The Shockwave BTK II And Javelin Trials: New Technology Is Available
Andrew Holden, MBChB
- 3:24 – 3:29** Improved Endovascular Device Combinations For Complex TEVARs Involving The Arch And Visceral Segments
Giovanni Pratesi, MD
Carlo Pratesi, MD
- 3:30 – 3:35** Update On The Tack Device (From Philips): Value And Limitations Resulting In An FDA Class I Recall: Can They Be Overcome
Patrick J. Geraghty, MD

- 3:36 – 3:41** The Serranator® Balloon Catheter (From Cagent Vascular) For Vessel Prep In Lower Extremity Arteries (From The PRELUDE And PRELUDE BTK Trials): Clinical Experience And Current Status
Steven Kum, MD
Andrew Holden, MBChB
- 3:42 – 3:47** The Ultrascore Scoring Balloons (From BD) For PTA: How Does It Work: Advantages, Clinical Experience And Current Status
Robert E. Beasley, MD
- 3:48 – 3:53** Rotational Atherectomy With The Rotarex Device (BD): Advantages And Meta-Analysis Results In The Treatment Of Stent Occlusion And In-Stent Restenosis (ISR)
Michael K. W. Lichtenberg, MD
- 3:54 – 3:59** High-Pressure PTA Balloons: How Can They Help With Standard PTA And Deep Vein Arterialization (DVA): What Is The Evidence
Steven Kum, MD
- 4:00 – 4:05** Is LimFlow DVA A Durable Treatment: What Happens When The Arteriovenous Connection Thromboses: Are New Arterial Connections Recruited: After What Interval
Richard J. Powell, MD
- 4:06 – 4:12** **Panel Discussion**

SESSION 62 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED DEVICES AND TECHNIQUES TO PREVENT OR TREAT ENDOLEAKS OR DEVICE MIGRATION: ENDOANCHORS, ETC.

Moderators: *William D. Jordan Jr., MD*
David H. Deaton, MD

- 4:12 – 4:17** Long-Term Results Of Heli-FX Endoanchors: (Medtronic) Fixation To Prevent And Treat EVAR Complications Including Type 1A Endoleaks: From The Global ANCHOR Registry: Can Virtual Techniques Predict The Need For Endoanchors
Jean-Paul de Vries, MD, PhD
William D. Jordan Jr., MD
- 4:18 – 4:23** Endoanchors (Heli-FX – Medtronic) Offer Durable Protection Of EVAR Proximal Seal Zones In Patients With Hostile Neck Anatomy: What Is The Evidence And How Durable Is The Seal
Apostolos K. Tassiopoulos, MD
- 4:24 – 4:29** Progress With The VESTECK Catheter-Based Endosuturing Technology For EVAR And TEVAR Fixation: How Does It Work: How Is It Different From Endoanchors: Advantages And Successful Clinical Results
Dainis K. Krievins, MD
Sean P. Lyden, MD
David H. Deaton, MD
- 4:30 – 4:35** VESTECK: An EVAR Proximal Neck Fixation Device: Advantages And Clinical Experience To Date
Venkatesh G. Ramaiah, MD
- 4:36 – 4:41** A New Device (Aortoseal From Endoron) To Improve Aortic Endograft Seal And Fixation: How Does It Work, When Is It Indicated And What Are Its Advantages: Experience To Date
Ross Milner, MD
- 4:42 – 4:47** Update On The Novelrad Percutaneous Endovascular Suturing Device: How Does It Work: Advantages And Clinical Experience To Date
Elchanan Bruckheimer, MBBS
- 4:48 – 4:54** **Panel Discussion**

SESSION 63 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED ENDOVASCULAR DEVICES FOR CLOT REMOVAL OR EMBOLIZATION (SEE ALSO SESSION 30)

Moderators: *Patrick E. Muck, MD*
Frank R. Arko, MD

CLOT REMOVING DEVICES

- 4:55 – 5:00** Increased Procedural Efficacy And Decreased Cost Are Associated With Use Of Computed-Assisted Vacuum Thrombectomy (Penumbra Indigo And Lightning Flash) To Treat ALI: Is Open Thrombectomy Ever Required
Charles J. Bailey, MD
Maria Antonella Ruffino, MD
- 5:01 – 5:06** Endovascular Arterial Thrombo-Embolectomy Devices: What's The Difference Between Them: Artix, Jeti, Penumbra, AngioJet, Pounce, Etc.: What's Coming Down The Road
Loay S. Kabbani, MD, MHSA
- 5:07 – 5:12** Artix All-In-One Endovascular Thrombectomy System (From Stryker-Inari) Provides Mechanical Extraction And Aspiration: Advantages And Clinical Experience For Treating ALI
Yana Etkin, MD
Anahita Dua, MD, MS, MBA
- 5:13 – 5:18** New Endovascular Thrombectomy Devices: Prodigy, Symphony And Vesalio: How Do They Work And What Are Their Advantages Over Other Endo Clot Removing Technologies
Venkatesh G. Ramaiah, MD
- 5:19 – 5:24** Novel Thrombus Aspiration System (Prodigy From TRUVIC Medical) For Removing Arterial And Venous Clots: How Does It Work, Advantages And Results
David J. Dexter, MD
- 5:25 – 5:30** **Panel Discussion**
- 5:31 – 5:36** Comparison Of Endovascular Thrombectomy Devices For Acute Mesenteric Ischemia: Indications, Contraindications, Which Device Works Best And Results: When Is Open Treatment Necessary
Marco V. Usai, MD

ENDOVASCULAR OCCLUSIVE DEVICES

- 5:37 – 5:42** FluidX: A New Conformable Liquid Occlusive Agent: What Makes It Different, Indications, Advantages And Precautions
Andrew Holden, MBChB
- 5:43 – 5:48** Fibered And Non-Fibered Coil Embolism Technology: Which Type Of Coils Are Best For Different Indications: When Are Liquid Agents Best
Frank R. Arko, MD
- 5:49 – 5:54** How Can Shape Memory Polymer Plug Embolization Devices Be Used To Improve Results After TEVAR For Degenerative Aneurysms And TBADs By False Lumen Obliteration
Virendra I. Patel, MD, MPH
Andrew Holden, MBChB
- 5:55 – 5:59** **Panel Discussion**
- End of Program H**

PROGRAM I (SESSIONS 64-73)

SUPERFICIAL VENOUS DISEASE AND VENOUS ULCERS

Trianon Ballroom, 3rd Floor

SESSION 64 (Trianon Ballroom, 3rd Floor)

VENOUS CLINICAL EXAMINATION

Moderators: *Jose I. Almeida, MD, RPVI, RVT*

Raghu Kolluri, MD

Lowell S. Kabnick, MD

- 6:50 – 6:53** Introduction To VEITH Venous Venous Venous
Jose I. Almeida, MD, RPVI, RVT
- 6:54 – 6:59** Structural vs. Functional Venous Hypertension: Its Importance In Selecting Patients For Interventions
Raghu Kolluri, MD
- 7:00 – 7:05** Lower Extremity Edema Workup
Maxim Shaydakov, MD, PhD
- 7:06 – 7:11** POCIT – Point Of Care Infrared Thermography
Steve Elias, MD
- 7:12 – 7:17** When Should You Duplex Both Lower Extremity And Pelvic Veins
Jan M. Sloves, RVT
- 7:18 – 7:23** Thermography And Venous Duplex: Are They Equally Important
Dale Maharaj, FACS
- 7:24 – 7:29** Cellular Senescence Is The Key To Understanding Venous Disease
Sarah Onida, MD, PhD
Alun H. Davies, MA, DM, DSc (Presenter)
- 7:30 – 7:35** Venous Disorders As An Occupational Disease: A Systematic Review On Epidemiology, Pathophysiology, And Modification Strategies
Tobias Hirsch, MD
- 7:36 – 7:41** What Is An Ideal Vein Center
Omar L. Esponda, MD
- 7:42 – 7:47** **Panel Discussion**

SESSION 65 (Trianon Ballroom, 3rd Floor)

IMPORTANT PAPERS, ABOUT YOU, AND PREVENTION

Moderators: *Alun H. Davies, MA, DM, DSc*

Ruth L. Bush, MD, MPH

- 7:48 – 7:53** From An Expert Witness: How Do You Protect Yourself Against This Litigious Society
Mark Welch, FRCS
- 7:54 – 7:59** You And Medical Entrepreneurship: Do You Have What It Takes
John Chuback, MD
- 8:00 – 8:05** Summary (2025) Of Important Venous And Lymphatic Articles – International Angiology – Editor's Choice
Armando Mansilha, MD, PhD
- 8:06 – 8:11** Summary (2025) Of Important Articles: Journal of Phlebology: Editor's Choice
Alun H. Davies, MA, DM, DSc
- 8:12 – 8:17** Summary (2025) Of Important Articles: Journal of Vascular Surgery Venous And Lymphatic Disorders: Editor's Choice
Ruth L. Bush, MD, MPH
- 8:18 – 8:23** Can We Prevent Varicose Vein/Venous Insufficiency Recurrence
Yung-Wei Chi, DO
- 8:24 – 8:29** Is There Any Correlation Between USA And China Venous Guidelines
Jinsong Wang, MD
- 8:30 – 8:35** Latin American Consensus On Superficial And Perforating Venous Mapping
Oscar H. Bottini, MD
- 8:36 – 8:41** The Length Of Treated Great Saphenous Vein As A Marker Of Post-Procedural Improvement In Clinical And Patient Reported Outcomes
Windsor Ting, MD

8:42 – 8:47 Panel Discussion

SESSION 66 (Trianon Ballroom, 3rd Floor)

SUPERFICIAL VEIN TREATMENT STRATEGIES I

Moderators: *Kursat A. Bozkurt, MD*
Jinsong Wang, MD

8:48 – 8:53 Update On Minimally Invasive Therapy On Varicose Veins In China

Jinsong Wang, MD

8:54 – 8:59 During Saphenous Ablation And Or Phlebectomy, Where And When Do You Have To Worry About Saphenous, Sural, And Peroneal Nerves

Jean Luc Gerard, MD

9:00 – 9:05 Inflammatory Cascade That Contributes To The Formation Of Varicose Veins

Janna Bentley, MD

9:06 – 9:11 Venous Ulcer Guidelines: AVF Update

Alisha Oropallo, MD

9:12 – 9:17 1940nm Wavelength Laser: A Series Of 1000 Cases And New Perspectives

Claudine M. Hamel-Desnos, MD

9:18 – 9:23 Thrombus Extension After Cyanoacrylate Closure vs. Endovenous Glue Induced Thrombosis: What Is The Difference And Treatment

Nuttawut Sermsathanasawadi, MD, PhD

9:24 – 9:29 Simultaneous ASV Ablation For Recurrence Prevention In Patients Undergoing GSV Treatment: 2-Year Results Of The Synchronous Trial

Tobias Hirsch, MD

9:30 – 9:35 Effects Of Truncal Ablation On Pregnancy

Kursat A. Bozkurt, MD

9:36 – 9:41 Saphenous Ablation And Prophylactic Anticoagulation: Why, When, How Long

Glenn Jacobowitz, MD

9:42 – 9:47 Panel Discussion

SESSION 67 (Trianon Ballroom, 3rd Floor)

SUPERFICIAL VEIN TREATMENT STRATEGIES II

Moderators: *Lowell S. Kabnick, MD*
Kathleen J. Ozsvath, MD

9:48 – 9:53 What Did The DIAGRAVES Study Tell Us (The French Society of Phlebology)

Claudine M. Hamel-Desnos, MD

9:54 – 9:59 Update On Living Meta-Analysis Of Non-Compounded Polidacanol 1% Endovenous Microfoam (Varithena) Or Thermal Ablation

Lowell S. Kabnick, MD

10:00–10:05 New Evidence For The Importance Of Incompetent Perforating Veins

Mark S. Whiteley, MS

10:06–10:11 SVT Treatment During Pregnancy: Treatment Choices

Kathleen J. Ozsvath, MD

10:12–10:17 Foam Or Phlebectomy: Which Is Better For Varicose Veins

Alun H. Davies, MA, DM, DSc

10:18–10:23 Is It Time To Stop The FIRE

Sergio Giancesini, MD, PhD

10:24–10:29 Clinical Outcomes Following Treatment Of The SSV: An AVLS Registry Study

Sherry D. Scovell, MD

10:30–10:35 Is It Necessary To Combine Endovenous Thermal Ablation And Foam For The Treatment Of Large Diameter Truncal Veins

Andriy O. Nykonenko, MD, PhD

10:36–10:41 Anticoagulation Strategy During GSV Ablation Using Modified Caprini Varicose Vein Modified Score
Ayman Fakhry, MD

10:42–10:47 **Panel Discussion**

SESSION 68 (Trianon Ballroom, 3rd Floor)

SUPERFICIAL VEIN TREATMENT STRATEGIES III

Moderators: *Manj S. Gohel, MD*

Aleksandra Jaworucka-Kaczorowska, MD, PhD

10:48–10:53 When Is It OK To Ablate The Truncal Leg Veins With Chronic Iliofemoral Outflow Obstruction
Houman Jalaie, MD, PhD

10:54–10:59 SVT Medical Management In 2025: Is There A Role For Surgical Intervention And When
Manj S. Gohel, MD

11:00–11:05 International Practice Patterns In The Treatment Of Pelvic-Origin Lower Extremity Varicose Veins In Women
Neil M. Khilnani, MD

11:06–11:11 Factors Associated With Recanalization And Reintervention Following Below-Knee Polidocanol Endovenous Microfoam Ablation For Great Saphenous And Small Saphenous Veins
Anil P. Hingorani, MD

11:12–11:17 ARTE (Ablation Related Thrombus Extension) – A New Term To Describe EHIT, EGIT, EFIT, EMIT, EHifult
Peter F. Lawrence, MD

11:18–11:23 Open Surgical And Endovenous Treatment Of The Lateral Marginal Vein
Peter Gloviczki, MD, PhD

11:24–11:29 Venclose Multicenter Clinical Study
Erin H. Murphy, MD

11:30–11:35 Physician Compounded Foam Comparing Different Manufacturing Techniques: Is Reproducibility And Standardization Possible
Matthieu M.J. Josnin, MD

11:36–11:41 Management Of Labial And Vulvar Veins: Phlebectomy And Or Sclerotherapy: Tips And Tricks
Aleksandra Jaworucka-Kaczorowska, MD, PhD

11:42–11:47 Is It Safe To Ablate The GSV With A History Of DVT/ DVR: Evidence-Based
Mikel Sadek, MD

11:48–11:53 Tandem Vein Tumescant Technique For Improving Results Of Saphenous And Tributary Veins With Polidocanol 1% Endovenous Microfoam
Natalie A. Marks-Ascher, MD, RPVI, RVT

11:54–11:59 **Panel Discussion**

12:00– 1:00 **Lunch Break - Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 69 (Trianon Ballroom, 3rd Floor)

SUPERFICIAL VEIN TREATMENT STRATEGIES IV

Moderators: *Lowell S. Kabnick, MD*

Jose I. Almeida, MD, RPVI, RVT

1:01 – 1:06 Klippel-Trenaunay Syndrome In Adults: A Staged Approach
Mark S. Whiteley, MS

1:07 – 1:12 Venous Thrombosis After Foam: What To Do
Kerstin S. Schick, MD

1:13 – 1:18 Venous Ulcer Healing In Morbidly Obese Patients: What Is The Best Therapy
Mark H. Meissner, MD

1:19 – 1:24 The Impact Of Accurate Recognition Of GSV Terminal And Pre Terminal Reflux For Varicose Veins Recurrence
Ayman Fakhry, MD

- 1:25 – 1:30** How To Properly Evaluate Patients With Venous Disorders
Omar L. Esponda, MD
- 1:31 – 1:36** Venous Issues And Treatment Of The Elderly: What Must Be Done And When
Kerstin S. Schick, MD
- 1:37 – 1:42** **Panel Discussion**

SESSION 70 (Trianon Ballroom, 3rd Floor)

SUPERFICIAL VEIN TREATMENT STRATEGIES V

Moderators: *Lowell S. Kabnick, MD*

Jose I. Almeida, MD, RPVI, RVT

- 1:43 – 1:48** Vein Step: A Prospective, Observational, International Study To Assess Effectiveness Of Conservative Treatments In Chronic Venous Disease
Jorge H. Ulloa, MD
- 1:49 – 1:54** Which Saphenous Vein Recanalization Should Be Treated And By What Method: Evidence Bases
Jose I. Almeida, MD, RPVI, RVT
- 1:55 – 2:00** Findings Of A Single Arm Systematic Review Of 1% Polidocanol Microfoam
Lowell S. Kabnick, MD
- 2:01 – 2:06** TOTEM Trial: Total Endovenous Laser Ablation
Luca Palombi, MD
- 2:07 – 2:12** Comparative Analysis Of VenaBlock And VenaSeal In Treating Chronic Venous Insufficiency
Kursat A. Bozkurt, MD
- 2:13 – 2:18** New Superficial Venous Devices: Pre FDA Approval
Lowell S. Kabnick, MD
- 2:19 – 2:24** Differences In Industrial Sclerosing Foams And Its Clinical Implications
Jorge H. Ulloa, MD
- 2:25 – 2:30** **Panel Discussion**

SESSION 71 (Trianon Ballroom, 3rd Floor)

SUPERFICIAL VEIN TREATMENT STRATEGIES VI

Moderators: *Victor M. Canata, MD, PhD*

Armando Mansilha, MD, PhD

- 2:31 – 2:36** Venous Lesions Of The Face
Lina M. Vargas, MD, RPVI
- 2:37 – 2:42** Ablative Risks Prior To And After Flying: What To Do For Patients
Sarah Onida, MD, PhD
Alun H. Davies, MA, DM, DSc (Presenter)
- 2:43 – 2:48** Physician Compounded Foam For Truncal Vein Disease: When And Where
Satish Vayuvegula, MD, MS
- 2:49 – 2:54** Anticoagulation After Venous Intervention: Agents And Timing
Armando Mansilha, MD, PhD
- 2:55 – 3:00** Truncal Ablation Plus Foam Sclerotherapy Is Not Superior To Staged Tributary Treatment
Tomasz Urbanek, MD
- 3:01 – 3:06** Tips And Tricks For Ultrasound Guided Foam Sclerotherapy: Varicose Veins
Alvaro Orrego, MD
- 3:07 – 3:12** Total Endovenous Ablation: Introducing The Porcupine Technique And Its Transformative Potential
Victor M. Canata, MD, PhD
- 3:13 – 3:18** How To Avoid Complications From Sclerotherapy
Jean Luc Gerard, MD
- 3:19 – 3:24** Comparison Of Laser And Chemical Sclerosant vs. Sclerosant: What Is The Evidence
Ravul Jindal, FRCS

- 3:25 – 3:30** Quick Case 1: Ask The Panel Or Audience What Would You Do (Cosmetic)
Edward G. Mackay, MD
- 3:31 – 3:36** Quick Case 2: Ask The Panel Or Audience What Would You Do (Cosmetic)
Lina M. Vargas, MD, RPVI
- 3:37 – 3:42** **Panel Discussion**

SESSION 72 (Trianon Ballroom, 3rd Floor)

SUPERFICIAL VEIN TREATMENT STRATEGIES VII

Moderators: *Rashad A. Bishara, MD, RPVI, MSc*

Steve Elias, MD

- 3:43 – 3:48** Mechanical Varicose Vein Excision: Advantages
Steve Elias, MD
- 3:49 – 3:54** When Evaluating Superficial Disease, When And How Do You Look For Deep Venous Obstruction
Gloria Salazar, MD
- 3:55 – 4:00** Guidelines For Management Of Actual Or Suspected Inadvertent Intra-Arterial Injection Of Sclerosants
Ravul Jindal, FRCS
- 4:01 – 4:06** When Not To Ablate The GSV In Patients With Femoropopliteal PTS
Rashad A. Bishara, MD, RPVI, MSc
- 4:07 – 4:12** Body Mass Index And CEAP Clinical Severity Score
Oscar H. Bottini, MD
- 4:13 – 4:18** Treatment Of Varicose Ulcers By Cyanoacrylate: ETUVVE Study
Nicolas Neaume, MD
- 4:19 – 4:24** Morbid Obesity: A Contraindication To Superficial Vein Treatment
Andrea T. Obi, MD
- 4:25 – 4:30** Sausage Foam Sclerotherapy: A Comprehensive Exploration Of Tips, Tricks, And The Nuances Of This Technique
Victor M. Canata, MD, PhD
- 4:31 – 4:36** Comparative Early Outcomes Following Primary Radiofrequency Ablation And Polidocanol Microfoam Ablation Of Symptomatic, Incompetent Small Saphenous Veins
Juan Carlos Jimenez, MD, MBA
- 4:37 – 4:42** Retrospective Study Of Hypersensitivity Reactions In Patients Undergoing Cyanoacrylate In Superficial Veins: What To Avoid
Julianne Stoughton, MD
- 4:43 – 4:48** Treatment Of Reticular Veins With EVLA: Is It Possible
Luca Palombi, MD
- 4:49 – 4:54** **Panel Discussion**

SESSION 73 (Trianon Ballroom, 3rd Floor)

VENOUS ULCERS

Moderators: *Manj S. Gohel, MD*

Yuri A. Casseres, MD, MSc

- 4:55 – 5:00** A Prospective Trial Of Cyanoacrylate Ablation In Venous Ulceration: VenaSeal Spectrum Study
Manj S. Gohel, MD
- 5:01 – 5:06** Hyperbaric Oxygen And Venous Ulcers: Evidence
Yuri A. Casseres, MD, MSc
- 5:07 – 5:12** Calf Muscle Dysfunction In Venous Leg Ulcer
Nuttawut Sermsathanasawadi, MD, PhD
- 5:13 – 5:18** Risks And Contraindications Of Medical Compression Treatment For Venous Ulcers: A Critical Appraisal
Tomasz Urbanek, MD
- 5:19 – 5:24** Compression, Oxygen, And Humidification – Improves Venous Wound Healing And Reduces Venous Ulcer Recurrence
Kathleen J. Ozsvath, MD

- 5:25 – 5:30** Why Venous Leg Ulcers Have Difficulty Healing
Joseph D. Raffetto, MD
- 5:31 – 5:36** Does Ultrasound Guided Foam Sclerotherapy Affect Venous Leg Ulcer Healing: A Multicenter Randomized Study
Rashad A. Bishara, MD, RPVI, MSc
- 5:37 – 5:42** Skin Substitutes To Promote Venous Leg Ulcer Healing: What Is The Evidence
Yuri A. Casseres, MD, MSc
- 5:43 – 5:48** Treatment Of Venous Leg Ulcers Goes Beyond The Obvious
Alvaro Orrego, MD
- 5:49 – 5:54** Endovenous Ablation For Venous Leg Ulcers: Cochrane Review
Joseph D. Raffetto, MD
- 5:55 – 6:00** **Panel Discussion**
End of Program I

PROGRAM J (SESSIONS 74-78)

MULTIDISCIPLINARY STROKE PREVENTION AND TREATMENT

Americas Hall 1 North, 3rd Floor

SESSION 74 (Americas Hall 1 North, 3rd Floor)

LATEST TRIAGE AND CHANGES FOR ACUTE STROKE

Moderators: *Allan L. Brook, MD*
Joshua A. Hirsch, MD

- 7:45 – 7:50** Introduction
Allan L. Brook, MD
- 7:51 – 7:58** Evidence Of Acute Stroke Care And What Gaps Are Left To Fill
Rafael A. Ortiz, MD
- 7:59 – 8:06** Developing Stroke Network In Brazil: Translation Of Scientific Evidence To Public Policy
Carlos Clayton Macedo de Freitas, MD, PhD
- 8:07 – 8:14** Should LVO Patients Go Directly To The Angio Suite, Is There Evidence
Reade A. De Leacy, MBBS
- 8:15 – 8:22** We Know What To Do With LVO – What About The Rest (MEVO/DEVO)
Ansaar T. Rai, MD
- 8:23 – 8:30** Imaging Pearls That Save Time
Lawrence N. Tanenbaum, MD
- 8:31 – 8:38** Low NIHSS And What Is My Algorithm To Proceed With Thrombectomy
James Milburn, MD
- 8:39 – 8:46** Atherosclerosis: Intracranial Stenosis/Occlusion Can Lead To Significant Morbidity: Should They Be Treated
David S. Liebeskind, MD, MBA

SESSION 75 (Americas Hall 1 North, 3rd Floor)

ACCESS AND DEVICES FOR STROKE AND BEYOND

Moderators: *Chirag D. Gandhi, MD*
Sudhakar R. Satti, MD

- 8:47 – 8:54** Radial And Ulnar Anatomy/Access; Complication Management
Sudhakar R. Satti, MD
- 8:55 – 9:02** Direct Carotid Access: Is It Time For This Time-Saving Approach
Ajay K. Wakhloo, MD, PhD
- 9:03 – 9:10** Devices: Clarifying The Latest Catheter Benefits And What Separates Them
Adnan H. Siddiqui, MD, PhD

SESSION 76 (Americas Hall 1 North, 3rd Floor)

INTRACRANIAL HEMORRHAGE, CAUSES AND TREATMENTS

Moderators: *Deepak Khatri, MD*
David Gordon, MD

- 9:11 – 9:18** Subdural Algorithm: Treat Everyone Percutaneously And Save The World, Or Is There Real Data
Chirag D. Gandhi, MD
- 9:19 – 9:26** SDH: Particles, Glue, Onyx, Or My Magic Potion And Why
J Mocco, MD, MS
- 9:27 – 9:34** A Neiman Fellow Analyzes How The No Surprises Act Interests With MT 4 ELVO Stroke
Joshua A. Hirsch, MD
- 9:35 – 9:42** Is There Any Imaging To Distinguish Intracranial Athero
Richard L. Zampolin, MD

SESSION 77 (Americas Hall 1 North, 3rd Floor)

HEADACHES: THE NEUROINTERVENTIONAL TOOLBOX OPENED

Moderators: *Peter K. Nelson, MD*
Allan L. Brook, MD

- 9:43 – 9:50** Intracranial Venous Stenosis And Intracranial Pressure Therapies
Athos Patsalides, MD, MPH
- 9:51 – 9:58** Diagnosis Of Intracranial Increase In Pressure Or Low Pressure Headaches: My Pearls
Amanda Baker, MD
- 9:59–10:06** It Started As A Headache, What Is The Next Generation Going To Offer Neuro-Oncology
Allan L. Brook, MD
- 10:07–10:14** Are There Enough NIRs, Or Do We Need AI And Robots To Train Better Doctors
Aquilla S. Turk, DO
- 10:15–10:22** SDH And MMA Embolization: What Is The Standard Of Care
Colin P. Derdeyn, MD
- 10:23–10:30** Headaches Imaged: Headaches Treated: Latest Literature
Deepak Khatri, MD
- 10:31–10:38** Pulsatile Tinnitus: Cause And Treatment Options In Our Suite
Seon-Kyu Lee, MD, PhD
- 10:39–10:46** Papa Shares Generation Of Pearls: What Would I Tell My Greatest Prodigy
Jeffrey Farkas, MD
- 10:47–10:54** Intracranial Stenting: Lessons Learned On Large Aneurysms Adopted To MEVO And DEVO
Peter K. Nelson, MD
- 10:55–11:02** Imagine, Image, Best Literature Of 2025
Neil Haranahalli, MD

SESSION 78 (Americas Hall 1 North, 3rd Floor)

CAROTID ARTERY THERAPY STARS AND LATEST TRENDS

Moderators: *Thomas G. Brott, MD*
Don Heck, MD

- 11:03–11:10** Carotid Blowout: Evidence And Treatment Options
Guilherme Dabus, MD
- 11:11–11:18** TCAR, CEA, And Now CAS: Why I Choose Not To Treat
Anne L. Abbott, MD, PhD
- 11:19–11:26** CAS vs. TCAR vs. CEA: They Cannot Be Equal And Why Treatment Saves Lives
Don Heck, MD

- 11:27–11:34** TCAR Is Better Than True Percutaneous Carotid Stenting: Myth Or Reality
Peter A. Schneider, MD
- 11:35–11:40** CEA Done Through A Mirco-Incision vs. TCAR: Why Do So Few Perform This
Enrico Ascher, MD
- 11:41–11:48** Carotid Artery Stenting: The Comeback Technology Will Save Time And Money: Does It Match The Evidence
William A. Gray, MD
- 11:49–11:56** Stroke And Carotid Literature That Changed The World And Why
Oleg Otlivanchik, MD, PhD
- 11:57–12:15** **Panel Discussion**
End of Program J
- 12:00– 1:00** **Lunch Available - Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

PROGRAM K (SESSIONS 79–84)

AIMsymposium AT VEITHsymposium: TOPICS OF INTEREST TO INTERVENTIONAL RADIOLOGISTS
Americas Hall 1 South, 3rd Floor

SESSION 79 (Americas Hall 1 South, 3rd Floor)

CONTROVERSIES IN PORTAL HYPERTENSION – PART 1

Moderators: *Ziv J. Haskal, MD*
Matthew S. Johnson, MD

- 7:40 – 7:50** Opening Remarks
Jacob Cynamon, MD
- 7:50 – 8:00** The Various Causes Of Portal Hypertension: Differential Diagnosis
Brett E. Fortune, MD, MSc
- 8:00 – 8:10** Medical Management Of Portal Hypertension
Brett E. Fortune, MD, MSc
- 8:10 – 8:20** Indications For Percutaneous Or Transvenous Biopsies In 2025
Kristina R. Chacko, MD
- 8:20 – 8:30** Transjugular Or Transfemoral Liver Biopsies: How To Choose
Jacob Cynamon, MD
- 8:30 – 8:40** BRTO Or TIPS: How To Choose
Anuj Malhotra, MD
- 8:40 – 8:50** BRTO In Its Various Forms: Technical Considerations
Ziv J. Haskal, MD
- 8:50 – 9:00** Management Of Ectopic Varices
Wael E. Saad, MD
- 9:00 – 9:10** Management Of Ascites: Medical Management Or Early TIPS
Ziv J. Haskal, MD
- 9:10 – 9:20** **Panel Discussion**

SESSION 80 (Americas Hall 1 South, 3rd Floor)

CONTROVERSIES AND CASE PRESENTATIONS IN PORTAL HYPERTENSION

Moderators: *Jacob Cynamon, MD*
Wael E. Saad, MD

- 9:20 – 9:30** Pre TIPS Evaluation And Medical Management
Robert S. Brown, Jr., MD, MPH
- 9:30 – 9:40** TIPS Without ICE: No Problem
F. Scott Nowakowski, MD
- 9:40 – 9:50** TIPS Without ICE: Consider Rescheduling
Dylan Suttle, MD
- 9:50–10:00** When And How To Create A Small Caliber TIPS
Kei Yamada, MD

- 10:00–10:10** Gastric Sleeve Surgery And Portal Vein Thrombosis: Pathophysiology And Management
Rahul S. Patel, MD
- 10:10–10:20** Medical Management Of Acute And Chronic Portal Vein Thrombosis
Maria Teresa De Sancho, MD, MSc
- 10:20–10:30** Intervention For Acute And Chronic Portal Vein Thrombosis
Bartley Thornburg, MD
- 10:30–10:40** **Panel Discussion**
- 10:40–11:10** **Break - Visit Exhibits And Exhibits (2nd and 3rd Floors)**

SESSION 81 (Americas Hall 1 South, 3rd Floor)

CONTROVERSIES IN PORTAL HYPERTENSION - PART 2

Moderators: *Bartley Thornburg, MD*
Kei Yamada, MD

- 11:10–11:20** Difficult TIPS: Overcoming Technical Challenges
Rahul S. Patel, MD
- 11:20–11:30** Additional Tips And Tricks For Routine And Difficult TIPS
Jacob Cynamon, MD
- 11:30–11:40** Hepatic Encephalopathy Post TIPS: Etiology And Management
Arun B. Jesudian, MD
- 11:40–11:50** Management Of Early And Late TIPS Complications
Matthew S. Johnson, MD
- 11:50–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break - Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 82 (Americas Hall 1 South, 3rd Floor)

UPDATES ON LIVER CANCER THERAPY – HCC AND LIVER METASTASES

Moderators: *Jeff H. Geschwind, MD*
Joshua L. Weintraub, MD

- 1:00 – 1:10** Staging System For HCC And Treatment Recommendation
Jeff H. Geschwind, MD
- 1:10 – 1:20** Surgical Management Of HCC: Resection vs. Transplantation
Milan Kinkhabwala, MD
- 1:20 – 1:30** TACE For HCC: Is It Still The Gold Standard
Jeff H. Geschwind, MD
- 1:30 – 1:40** Percutaneous Ablative Treatments For HCC And Value Of Pre Ablation Fiducial Markings
Hooman Yarmohammadi, MD
- 1:40 – 1:50** Radioembolotherapy For HCC: Curative, Palliative Or Both
Matthew S. Johnson, MD
- 1:50 – 2:00** Novel Image-Guided Therapies For Liver Cancer: Histotripsy
Mikhail T. Silk, MD
- 2:00 – 2:10** Systemic Therapy For HCC (Including Immunotherapy For Dummies)
Andreas Kaubisch, MD
- 2:10 – 2:20** Combination Therapies: How Are They Affecting Patient Management
Joshua L. Weintraub, MD
- 2:20 – 2:30** **Panel Discussion**

SESSION 83 (Americas Hall 1 South, 3rd Floor)

METASTATIC LIVER CANCER

Moderators: *Resmi A. Charalel, MD, MPH*
Andreas Kaubisch, MD

- 2:30 – 2:40** What Are The Guidelines Of Patients With Colorectal Liver Metastases
Matthew S. Johnson, MD
- 2:40 – 2:50** Systemic Therapy For Patients With Colorectal Liver Metastases
Resmi A. Charalel, MD, MPH
- 2:50 – 3:00** Image-Guided Ablative Therapy For Colorectal Liver Metastasis
Constantinos T. Sofocleous, MD, PhD
- 3:00 – 3:10** Transarterial Therapies For Colorectal Liver Metastases
Resmi A. Charalel, MD, MPH
- 3:10 – 3:20** Technical Innovations In Transarterial Therapies For Liver Cancer
Joshua Cornman-Homonoff, MD
- 3:20 – 3:30** **Panel Discussion**
- 3:30 – 3:50** **Break - Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 84 (Americas Hall 1 South, 3rd Floor)

PANCREATIC CANCER

Moderators: *Matthew S. Johnson, MD*
Kapil Wattamwar, MD

- 3:50 – 4:00** Surgical Management: Robotic And Open Surgical Approaches
Sarah Bellemare, MD
- 4:00 – 4:10** Role Of Radiation Therapy: SBRT And MR Linac
Rafi Kabarriti, MD
- 4:10 – 4:20** Clinical Trials In Pancreas Cancer: IRE, RenovoRX And Others
Ripal T. Gandhi, MD
- 4:20 – 4:30** Interventional Oncology Care Changing Trials
David C. Madoff, MD
- 4:30 – 4:40** IR Management Of Surgical Complications
Jonathan Susman, MD
- 4:40 – 4:50** Advances In MSK Embolizations
Yosef Golowa, MD
- 4:50 – 5:00** PAE: Techniques And Outcomes
Aaron M. Fischman, MD
- 5:00 – 5:10** **Panel Discussion**

CONCURRENT HANDS-ON WORKSHOPS

- 5:10 – 6:00** 1. TIPS/BRTO/TRANSVENOUS BIOPSIES

Panelist(s): Ziv J. Haskal, MD
Jacob Cynamon, MD
Dylan Suttle, MD
Wael E. Saad, MD
Bartley Thornburg, MD
Rahul S. Patel, MD
Kapil Wattamwar, MD
Kei Yamada, MD

- 5:10 – 6:00** 2. EMBOLIZATION – COILS/PLUGS/PARTICLES/ LIQUID/RADIOEMBOLIZATION

Panelist(s): Jeff H. Geschwind, MD
Matthew S. Johnson, MD
Mikhail T. Silk, MD
Joshua Cornman-Homonoff, MD
Ripal T. Gandhi, MD
David C. Madoff, MD
Yosef Golowa, MD
Aaron M. Fischman, MD
Resmi A. Charalel, MD, MPH

End of Program K

FRIDAY, NOVEMBER 21, 2025

6:00 A.M. General Registration – Rhinelander Gallery, 2nd Floor
6:00 A.M. Faculty Registration – Gramercy Suite West, 2nd Floor
6:15 A.M. Continental Breakfast – Rhinelander Gallery, 2nd Floor

CONCURRENT FRIDAY PROGRAMS

PROGRAM L (SESSIONS 85-92)

Progress In The Prevention And Treatment Of Spinal Cord Ischemia (SCI) With TAAAs And Complex Aortic Aneurysm Repairs; New Developments In Carotid Artery Disease And Its Treatment: Mesh Covered Stents And TCAR, Cognitive Changes, Timing Of Treatment, Medical Treatment, Update On Carotid Trials, Treatment Of Asymptomatic Carotid Stenosis (ACs), String Sign, Carotid Clot, Significance Of MRI Lesions, Carotid Controversies And More Carotid Topics; Other New Endovascular Treatment Concepts, Techniques; Update On Percutaneous Access Closure Devices And Wound Care

Location: Grand Ballroom East, 3rd Floor

PROGRAM M (SESSIONS 93-100)

New Developments In The Treatment Of Popliteal Disease; Advances In Treating Arterial And Graft Infections; Advances In Vascular Imaging And Guidance; Augmented Reality And Artificial Intelligence; Recorded Live Complex Endovascular Cases From Münster, Germany; New Developments In Thoracic Outlet Syndrome Management; Advances In Medical, Drug, Anticoagulant And Rare Vascular Disease Treatment; And Advances In The Treatment Of Vascular Trauma

Location: Grand Ballroom West, 3rd Floor

PROGRAM N (SESSIONS 101-111)

Deep Venous Disease

Location: Trianon Ballroom, 3rd Floor

PROGRAM L (SESSIONS 85-92)

PROGRESS IN THE PREVENTION AND TREATMENT OF SPINAL CORD ISCHEMIA (SCI) WITH TAAAs AND COMPLEX AORTIC ANEURYSM REPAIRS; NEW DEVELOPMENTS IN CAROTID ARTERY DISEASE AND ITS TREATMENT: MESH COVERED STENTS AND TCAR, COGNITIVE CHANGES, TIMING OF TREATMENT, MEDICAL TREATMENT, UPDATE ON CAROTID TRIALS, TREATMENT OF ASYMPTOMATIC CAROTID STENOSIS (ACS), STRING SIGN, CAROTID CLOT, SIGNIFICANCE OF MRI LESIONS, CAROTID CONTROVERSIES AND MORE CAROTID TOPICS; OTHER NEW ENDOVASCULAR TREATMENT CONCEPTS, TECHNIQUES; UPDATE ON PERCUTANEOUS ACCESS CLOSURE DEVICES AND WOUND CARE

Grand Ballroom East, 3rd Floor

SESSION 85 (Grand Ballroom East, 3rd Floor)

PROGRESS IN THE PREVENTION AND TREATMENT OF SPINAL CORD ISCHEMIA (SCI) ASSOCIATED WITH THE TREATMENT OF THORACIC, THORACOABDOMINAL AND COMPLEX ABDOMINAL ANEURYSMS

Moderators: *Germano C.G. Melissano, MD*

Christian D. Etz, MD, PhD

Adam Beck, MD

- 6:40 – 6:45** How MRI Can Help Guide Treatment To Prevent SCI And Determine SCI Prognosis After Thoracic Aortic Aneurysm And TAAA Repairs (Endo And Open)
Hamdy Awad, MD
- 6:46 – 6:51** How To Measure Blood Flow To The Spinal Cord: How Can It Help In The Prediction And Prevention Of SCI After TAAA Repair
Bijan Modarai, PhD
- 6:52 – 6:57** Prediction Of SCI With AI: What Factors Are Evaluated And How Accurate Is It: Should It Be An Indication For CSF Drainage
Kak Khee Yeung, MD, PhD
- 6:58 – 7:03** Update On Value Of MEPs: How Can They Guide Treatment To Decrease SCI With Endo And Open TAAA Repairs
Geert Willem H. Schurink, MD, PhD
Michael J. Jacobs, MD
- 7:04 – 7:09** Extra Anatomic Bypasses To Preserve Segmental Spinal Artery Flow And Protect Against SCI With Endo TAAA Repairs: When And How To Do Them
Sukgu M. Han, MD, MS
- 7:10 – 7:15** Prevention Of SCI During Endo Repair Of TAAAs By Adding An Additional Branch To Revascularize The "Adamkiewicz Artery": How To Identify The Artery And Do The Procedure
Waclaw B. Kuczmik, MD, PhD
- 7:16 – 7:21** Current Strategies To Minimize SCI With TAAA Repairs (Endo And Open) By Improving The Intraspinal Collateral Arterial Network: Status Of Intercostal Embolization As Preconditioning To Prevent Ischemia (MIS2ACE): Update On Progress Of The PAPA-ARTIS RCT
Christian D. Etz, MD, PhD
- 7:22 – 7:27** With The Extensive Single Center Clinical Experience With Intercostal Coil Embolization (MIS2ACE) To Prevent SCI With Endo TAAA Repair Do We Still Need An RCT: When And How To Do The Procedure
Daniela Branzan, MD
Andrej Schmidt, MD
- 7:28 – 7:33** Why Cerebrospinal Fluid (CSF) Drainage To Decrease SCI With TAAA Repair Is Not A Benign Procedure: When To Use It And When Not
Gustavo S. Oderich, MD
- 7:34 – 7:39** Changes In Protocols To Prevent SCI During Open And Endo TAAA Repairs Including The Role Of CSF Drainage: What Is Known, What Is Unknown And What Remains Controversial
Germano C.G. Melissano, MD
Roberto L.V. Chiesa, MD
- 7:40 – 7:45** What Does The US Aortic Research Consortium (ARC) Tell Us About SCI And CSF Drainage: Decreased Prophylactic Use Of The Latter Seems Beneficial Except For A Few High-Risk Patients: Therapeutic Use Continues To Have Value
Adam Beck, MD
- 7:46 – 7:54** **Panel Discussion**

SESSION 86 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN THE TREATMENT OF CAROTID STENOSIS: UPDATE ON MESH COVERED STENTS AND TCAR (TRANSCERVICAL CAROTID ARTERY REVASCULARIZATION)

Moderators: *Marc L. Schermerhorn, MD*
D. Christopher C. Metzger, MD
Bruce A. Perler, MD, MBA

MESH COVERED STENTS

- 7:54 – 7:59** Long-Term Results Of Micromesh Stents Show Their Value In Carotid Artery Stenting (CAS): What Are The Differences In The 3 Micromesh Stents And Do They Matter
D. Christopher C. Metzger, MD
Max Amor, MD
- 8:00 – 8:05** Progress And Updated Clinical Trials With The CGuard And CGuard Prime MicroMesh Covered Stents (From InspireMD): Are They Making A Positive Difference And Are There Thrombotic Or ISR Downsides: Should They Become First Line Therapy For All CAS And TCAR Procedures
Piotr Musialek, MD, DPhil
- 8:06 – 8:11** How To Optimize Carotid Stenting Using A Double Mesh Covered Stent (CGuard From InspireMD) And TCAR With Flow Reversal: Device Details And Results
Patrick J. Geraghty, MD
- 8:12 – 8:17** Latest Real-World Results Of More Than 2,000 Patients Treated With The Roadsaver (Terumo) Dual-Layer Micromesh Covered Carotid Stent
Stefan Müller-Hülsbeck, MD

TCAR RELATED TOPICS

- 8:18 – 8:23** Comparative Safety And Efficacy Of TCAR vs. TFCAS vs. CEA: What Is The Effect Of Anemia, Uncontrolled Hypertension, Recent MI, Weekend Effect And Arch Type: Which Procedure Is Best And When: How Will An Individual Treatment Plan Help
Mahmoud B. Malas, MD, MHS
- 8:24 – 8:29** **DEBATE:** Comparative Contemporary Performance And Risks Of TCAR And CEA, Show Them To Be Superior To Transfemoral CAS (TFCAS) For The Treatment Of Carotid Artery Stenosis
Marc L. Schermerhorn, MD
- 8:30 – 8:35** **DEBATE:** Not So: Contemporary Data Show That TFCAS Can Be Performed At Very Low Stroke Rates And Is The Best Treatment For Most Patients Requiring Treatment For Carotid Stenosis: The Operator's Experience And Skill Are Critical
Klaus D. Mathias, MD (PowerPoint Presentation With Synched Audio)
- 8:36 – 8:42** **Panel Discussion**
- 8:42 – 8:47** IVL (Shockwave) For Treating Symptomatic Patients With Heavily Calcified Carotid Stenoses By TCAR And TFCAS: Technical Tips And Results
Peter L. Faries, MD
- 8:48 – 8:53** The Effect Of Calcium Burden (Circumference, Thickness, Length) On The Early And Late Outcomes Of TCAR: How Best To Optimize The Treatment For Each Of These
Ali F. AbuRahma, MD
Zach AbuRahma, DO
- 8:54 – 8:59** How To Manage Safely Heavily Calcified Carotid Lesions With TCAR And Without IVL (Shockwave)
Michael C. Stoner, MD
- 9:00 – 9:05** **DEBATE:** Why We Do NOT Need An RCT Comparing TCAR With Other Treatments: Real-World Data Prove Its Safety, Efficacy, And Superiority As A Treatment For Carotid Stenosis
Charles J. Bailey, MD
- 9:06 – 9:11** **DEBATE:** Not So: TCAR Results To Date May Not Be As Good As They Seem: Why We Still Need An RCT Comparing TCAR With CEA To Treat Carotid Stenosis
Bruce A. Perler, MD, MBA

- 9:12 – 9:17** Why We Need An RCT Comparing TCAR With TFCAS, Transradial CAS And Best Medical Treatment For Asymptomatic And Symptomatic Carotid Stenosis
Michael H. Wholey, MD, MBA
- 9:18 – 9:23** **Panel Discussion**
- 9:24 – 9:34** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 87 (Grand Ballroom East, 3rd Floor)

MORE CAROTID HOT TOPICS RELATED TO TCAR, CAS AND EFFECTS OF INTERVENTIONS ON COGNITIVE FUNCTION

Moderators: *Thomas G. Brott, MD*
Mahmoud B. Malas, MD, MHS
Michael B. Silva, Jr., MD

- 9:35 – 9:40** Carotid Dissections With TCAR: Causes; How Often; How Morbid; How To Avoid; How To Fix
Richard J. Powell, MD
- 9:41 – 9:46** **DEBATE:** The Role For TFCAS In The Era Of TCAR Is Minimal: What Is It
Ashraf Mansour, MD
- 9:47 – 9:52** **DEBATE:** Not So: There Is Still A Major Role For TFCAS: What Is It: How Much Does Operator Experience And Skill Matter With TFCAS
D. Christopher C. Metzger, MD
- 9:53 – 9:58** How Patient Selection And Operator Skill May Influence Carotid Trial Results With TCAR And TFCAS: How May They Overshadow Other Factors And Render Trials Misleading
Gary M. Ansel, MD (PowerPoint Presentation With Synched Audio)
- 9:59–10:04** TCAR With Flow Reversal Combined With The New Mesh Covered Stent (CGuard From InspireMD) Is The Best Invasive Treatment For Carotid Stenosis: What Are The Results And Are There Downsides Or Limitations
Ralf R. Kolvenbach, MD
- 10:05–10:10** CGuard Micronet-Covered Stents (From InspireMD) Trap Plaque Particles Between The Stent And Vessel Wall (Plaque Sequestration): When Is It Valuable With High-Risk Lesions Other Than The Carotids
Piotr Musialek, MD, DPhil

CAROTID STENOSIS AND COGNITIVE FUNCTION

- 10:11–10:16** **DEBATE:** Invasive Treatment Of Asymptomatic Carotid Stenosis (ACS) Improves Cognitive Function
Wei Zhou, MD
- 10:17–10:22** **DEBATE:** Not So: A Systematic Review Shows NO Benefit In Cognitive Function From Invasive Treatment Of Carotid Stenosis
Gianluca Faggioli, MD
- 10:23–10:30** **Panel Discussion**

SESSION 88 (Grand Ballroom East, 3rd Floor)

MORE CAROTID RELATED NEW TOPICS RELATED TO GUIDELINES, TCAR, CAS, CEA, NEW DEVICES, MESH COVERED STENTS, DEALING WITH DISTAL (HIGH) CAROTID LESIONS, MINI-INCISION CEA AND TREATMENT OF POST-PROCEDURAL STROKES

Moderators: *Wei Zhou, MD*
Jacques Busquet, MD
Frank J. Veith, MD

- 10:30–10:35** Update On International Guidelines For Asymptomatic Carotid Disease: How They Differ And Why
Ali F. AbuRahma, MD

- 10:36–10:41** Trends In Use Of CEA, CAS, And TCAR Before And After Medicare's Expansion Of Reimbursement For Carotid Stenting: Why Medicare's Recent Expansion Of Reimbursement For Carotid Stenting Was Factually Unjustified
Caitlin W. Hicks, MD, MS
- 10:42–10:47** Current Optimal Strategies To Maximize Embolic Protection During TFCAS
D. Christopher C. Metzger, MD
- 10:48–10:53** The Role Of Intravascular Lithotripsy (IVL) And Next Generation Stents In TFCAS And TCAR
Adnan H. Siddiqui, MD, PhD

PERCUTANEOUS TCAR

- 10:54–10:59** Percutaneous TCAR Is Possible: Technical Aspects Of How This Can Be Accomplished Safely
Wesley S. Moore, MD
- 11:00–11:05** A System For Percutaneous TCAR With Reversal Of Flow Protection: How Does It Work And Clinical Experience To Date
Wayne W. Zhang, MD
- 11:06–11:14** **Panel Discussion**
- 11:15–11:20** Expanding The Use Of TCAR For Patients With Anatomic Or Plaque Related Limitations
Misty D. Humphries, MD, MAS
- 11:21–11:26** CEA vs. TCAR In A Single Center Propensity Matched Study: 30-Day Outcomes Of The Two Treatments Are Similar: Why Is TCAR Mortality Higher At 2 Years
Zach AbuRahma, DO
Ali F. AbuRahma, MD
- 11:27–11:32** Transradial CAS Using Novel Low-Profile Double-Mesh Stents (Roadsaver - Terumo): Results And Technical Tips
Andrea Kahlberg, MD
Germano C.G. Melissano, MD (Presenter)
- 11:33–11:38** Maneuvers And Technical Tips To Make Open Treatment Of High Carotid Lesions Relatively Simple And Safe
Richard J. Powell, MD
- 11:39–11:44** What Are The Various Duplex Ultrasound Criteria For Determining High Grade (>80%) Carotid Artery Stenosis: Which Is Most Accurate: How Often Are They Misleading: Confirmatory Imaging Should Precede Any Invasive Procedure
R. Eugene Zierler, MD, RPVI
- 11:45–11:50** Current Best Treatment For Strokes Apparent During Or Right After CEA, CAS Or TCAR: Best Diagnostic Modalities And Treatments: Who Should Be Involved And What Skills Are Needed
Adnan H. Siddiqui, MD, PhD
- 11:51–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break - Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 89 (Grand Ballroom East, 3rd Floor)

MORE HOT CAROTID TOPICS: UPDATES ON KEY CAROTID RCTs AND TREATMENT OF ASYMPTOMATIC CAROTID STENOSIS (ACS) AND POST-RADIATION STENOSIS

Moderators: *Frank J. Veith, MD*
Wesley S. Moore, MD
Glenn M. LaMuraglia, MD
Barry T. Katzen, MD

UPDATE ON CAROTID RCTs

- 1:00 – 1:05** CAS vs. CEA: Why The Debate Will Never End: Bias And Self Interest Overwhelms Facts And Logic And Often Influences How Good Trials And Even RCTs Are Misinterpreted
Francesco Setacci, MD
Carlo Setacci, MD
- 1:06 – 1:11** When Invasively Treating Asymptomatic Carotid Stenosis (ACS) Patients >75, Should CEA Be Preferred Over TFCAS: Has Anything Changed Or Are The Data From ACT1 And CREST RCTs Showing Comparable Outcomes For The Two Treatments Still Applicable
Jon S. Matsumura, MD
- 1:12 – 1:17** First Game Changing Results From CREST 2: CEA vs. Best Medical Treatment (BMT) And CAS vs. BMT For ACS: Some 4-Year RESULTS TO DATE Show . . .
Brajesh K. Lal, MD
Thomas G. Brott, MD
- 1:18 – 1:23** First Game Changing Results From CREST 2: Do They Resolve The Controversy Conclusively Or Are Further Studies Needed
Thomas G. Brott, MD
Brajesh K. Lal, MD
- 1:24 – 1:29** ACST-2 Final Results: This RCT Found That CEA And CAS For ACS Had Comparable Stroke/Death Rates For 10 Years And Implied That Both Invasive Treatments Were Superior To Now Obsolete BMT: Why This Conclusion Is No Longer Applicable
Richard Bulbulia, MA, MD
Alison Halliday, MS
- 1:30 – 1:35** The 2nd European Carotid Surgery Trial (ECST-2): Current Status; 2-Year Results Report And Its Flaws: What It Tells Us And What It Doesn't About BMT vs. Invasive Therapy
Kosmas I. Paraskevas, MD
- 1:36 – 1:46** **Panel Discussion**

OTHER HOT CAROTID RELATED TOPICS

- 1:47 – 1:52** Optimal Current Management Of Carotid Stenosis After Radiation Therapy For Cancer - Symptomatic And Asymptomatic: What Is The Pathology: How Is It Best Treated And How Results Differ From Standard Carotid Stenosis
Peter L. Faries, MD
- 1:53 – 1:58** Management Options With A Carotid String Sign Or Near Occlusion: Why Are They Controversial: Current Optimal Treatment In Symptomatic And Asymptomatic Patients
Christos D. Liapis, MD
- 1:59 – 2:04** Optimal Management Of Asymptomatic Carotid Stenosis With Coexistent Unruptured Intracerebral Aneurysm: Based On A Multicenter Study
Jean-Baptiste Ricco, MD, PhD
- 2:05 – 2:10** Photoacoustic Imaging (With Laser And Ultrasound Derived Information) To Assess Carotid Plaque Vulnerability: How Does It Work And Does It Help
Marc R.H.M. van Sambeek, MD, PhD
- 2:11 – 2:16** How Can AI Identify And Characterize Vulnerable Carotid Plaque Using A Multi-Modality Approach – How Is This Helpful In Guiding Treatment
Jimmy Davaine, MD, PhD
Jean Pierre Becquemin, MD
- 2:17 – 2:23** **Panel Discussion**

SESSION 90 (Grand Ballroom East, 3rd Floor)

MORE HOT CAROTID TOPICS: TREATMENT IN 2025 OF EXTRACRANIAL CAROTID INFECTIONS AND ANEURYSMS, RECURRENT STENOSIS, WEBS, ETC.

Moderators: *Keith D. Calligaro, MD*
William A. Gray, MD
Ali F. AbuRahma, MD

- 2:24 – 2:29** Treatment Of Carotid Artery Infections Complicating Open Or Interventional Treatments: Optimal Techniques And Outcomes: When Is A Bypass Necessary And When Is It Not
Heron E. Rodriguez, MD
- 2:30 – 2:35** Current Optimal Treatment Of Extracranial Carotid Aneurysms: When Endo, When Open: Technical Tips
Peter L. Faries, MD
- 2:36 – 2:41** Most Recurrent Carotid Stenosis (After CEA And CAS) Is Benign: When Is Intervention Justified And What Intervention Should Be Used
Ashraf Mansour, MD
- 2:42 – 2:47** In-Stent Stenosis After CAS: How Can It Be Predicted: When Is It Threatening And How Is It Best Managed
Jacques Busquet, MD
- 2:48 – 2:53** Update On Carotid Webs: Diagnosis, Symptoms/ Morbidity And Optimal Current Treatment: Medical, Endo Or Open
Clayton J. Brinster, MD
- 2:54 – 2:59** Coronary Calcium Scores May Stratify Distinct Phenotypes Of Carotid Artery Stenosis: How Should This Influence Management
Thomas S. Maldonado, MD
- 3:00 – 3:05** Because Drug Eluting Balloons Are Associated With Microembolization, They Can Only Be Used For Treating Carotid Stent Recurrent Stenosis With Reversal Of Flow Cerebral Protection
Wesley S. Moore, MD
- 3:06 – 3:11** Neuroguard 3-In-1 Carotid Stent System (Contego Medical) With Integrated Balloon, Stent And Distal Filter: Updated 2-Year Results From The PERFORMANCE II Trial And Advantages Including Preventing Particulate Emboli Released During Presumed Flow Reversal Protected CAS From Reaching The Brain (Or Distal Filter)
William A. Gray, MD
Sean P. Lyden, MD
- 3:12 – 3:19** **Panel Discussion**
- 3:19 – 3:30** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 91 (Grand Ballroom East, 3rd Floor)

MORE HOT AND CONTROVERSIAL CAROTID TOPICS

Moderators: *Mahmoud B. Malas, MD, MHS*
George L. Berdejo, BA, RVT
Michael H. Wholey, MD, MBA

- 3:30 – 3:35** Cervical Carotid Artery Open Approaches For TAVR And TCAR: Technical Tips, Complications And How To Avoid Them
Mauro Gargiulo, Professor
Gianluca Faggioli, MD
- 3:36 – 3:41** With Tandem Carotid Lesions In The Neck And Supra-Aortic Trunks, How Should Acutely Symptomatic Patients Be Managed: What About Asymptomatic Patients With Such Lesions: Controversies And Optimal Strategy
W. Darrin Clouse, MD

- 3:42 – 3:47** Minimal Incision CEA (MICE) vs. TCAR: Technical Tips For MICE, Cost Effectiveness, Advantages And Limitations Of Both
Enrico Ascher, MD
- 3:48 – 3:53** Surprisingly A Bovine Aortic Arch Does NOT Confer Increased Stroke Risk With TFCAS: From A Large VQI Study
Heepeel Chang, MD
- 3:54 – 3:59** Asymptomatic Patients With A Carotid Lesion That Cannot Be Serially Followed Or The Severity Of Which Cannot Be Assessed: When Is It A Valid Indication For Carotid Intervention: Why Not Just BMT For All
Reese A. Wain, MD
- 4:00 – 4:05** TCAR Is Safe In Recently Symptomatic Patients And Those With Contralateral Carotid Occlusions: Why TCAR Should Be The Procedure Of Choice In These Conditions
Mahmoud B. Malas, MD, MHS
Peter A. Schneider, MD
- 4:06 – 4:11** When A Duplex Scan Detects Subclavian Steal, Symptomatic Or Asymptomatic, What Is The Natural History And How Should It Be Managed
Ali F. AbuRahma, MD
Zach AbuRahma, DO
- 4:12 – 4:17** Floating Clot At The Carotid Bifurcation Is A Prime Indication For Flow Reversal Technology During Treatment Of Carotid Stenosis: How Can Flow Reversal Best Be Achieved In This Setting
Mark A. Adelman, MD (Presenter) (PowerPoint Presentation With Synched Audio)
Juan C. Parodi, MD
- 4:18 – 4:23** Techniques For Dealing With Challenging Carotid Lesions: How Does TCAR Facilitate Treatment When Nothing Else Could Work
Joseph J. Ricotta II, MD, MS
- 4:24 – 4:30** **Panel Discussion**

SESSION 92 (Grand Ballroom East, 3rd Floor)

NEW CONCEPTS AND NEW DEVELOPMENTS IN PERCUTANEOUS ACCESS CLOSURE AND WOUND CARE

Moderators: *Zvonimir Krajcer, MD*
Zach AbuRahma, DO
Kenneth Ouriel, MD, MBA

PROGRESS IN PERCUTANEOUS ACCESS AND CLOSURE

- 4:30 – 4:35** New Devices (Including PerQseal) For Large Bore Arterial And Venous Closure Devices: Advantages And Limitations Of Each And How To Avoid Complications
Zvonimir Krajcer, MD
- 4:36 – 4:41** How To Prevent And Treat Complication Of Large Bore Arterial Access: Comparative Analysis Of Manta, Prostar XL And Perclose ProGlide Devices
Michael J. Singh, MD
- 4:42 – 4:47** Closure Techniques And Devices For Percutaneous Brachial And Axillary Access: What's Different, What Works, Results And Complications
W. Anthony Lee, MD (PowerPoint Presentation With Synched Audio)
- 4:48 – 4:53** When And How To Use Fascial Suture Technique To Control Percutaneous Large Vessel Access: Technical Tips
Tal M. Hörer, MD, PhD
Thomas Larzon, MD, PhD

PROGRESS IN WOUND CARE

- 4:54 – 4:59** The Value Of Local Oxygen Therapy Combined With Compression And Humidification (AOTI) And Low Frequency Ultrasound Stimulation To Enhance Non-Specific And Venous Wound Healing
Joann M. Lohr, MD
- 5:00 – 5:05** A New Technology (From AOTI) Combining Local Oxygen Therapy With Cycled Compression And Humidification Enhances Healing Of Diabetic Wounds And Ischemic Ulcers After Revascularization
Anil P. Hingorani, MD
Enrico Ascher, MD
- 5:06 – 5:11** Optimal Treatment For Deep Groin Infection After Prosthetic Bypasses From The Common Femoral Artery: How To Save The Graft, The Patient And The Extremity
Hosam F. El Sayed, MD
- 5:12 – 5:17** Advantages Of Having A Wound Care Center In A Vascular Surgery Practice: How To Finance It
Robert B. McLafferty, MD, MBA
- 5:18 – 5:25** **Panel Discussion**
- 5:26 – 5:27** **End of Program L**

PROGRAM M (SESSIONS 93-100)

NEW DEVELOPMENTS IN THE TREATMENT OF POPLITEAL DISEASE; ADVANCES IN TREATING ARTERIAL AND GRAFT INFECTIONS; ADVANCES IN VASCULAR IMAGING AND GUIDANCE; AUGMENTED REALITY AND ARTIFICIAL INTELLIGENCE; RECORDED LIVE COMPLEX ENDOVASCULAR CASES FROM MÜNSTER, GERMANY; NEW DEVELOPMENTS IN THORACIC OUTLET SYNDROME MANAGEMENT; ADVANCES IN MEDICAL, DRUG, ANTICOAGULANT AND RARE VASCULAR DISEASE TREATMENT; AND ADVANCES IN THE TREATMENT OF VASCULAR TRAUMA
Grand Ballroom West, 3rd Floor

SESSION 93 (Grand Ballroom West, 3rd Floor)

POPLITEAL DISEASE TOPICS RELATED TO ANEURYSM TREATMENT, ENTRAPMENTS, ADVENTITIAL CYSTIC DISEASE AND TRAUMA

Moderators: *Jason T. Lee, MD*

Russell H. Samson, MD, RVT

TREATMENT OF POPLITEAL ANEURYSMS AND ADVENTITIAL CYSTIC DISEASE

- 6:52 – 6:57** Small Asymptomatic Popliteal Aneurysms: What Factors Determine Whether They Should Be Treated Invasively Or Observed: If Invasively, When Endo When Open
Enrico Ascher, MD
Natalie A. Marks-Ascher, MD, RPVI, RVT
Anil P. Hingorani, MD
- 6:58 – 7:03** Given A Patient With CLTI And A Popliteal Aneurysm: How To Assess And How To Treat: Endo vs. Open
Jos C. van den Berg, MD, PhD
- 7:04 – 7:09** Advances In The Treatment Of Popliteal Artery Aneurysm And Adventitial Cystic Disease (Endo vs. Open): What Treatments Are Currently Best And Long-Term Results
Irwin V. Mohan, MBBS, MD

- 7:10 – 7:15** With Popliteal Artery Aneurysms, Why After 20 Years Of Selective Endograft Treatment Do I Now Favor Open Repair In Most Patients: Which Ones Still Get An Endograft
Martin R. Back, MD
- 7:16 – 7:21** Repair Of Popliteal Artery Aneurysms With Bare Metal Stents: Which Stent Is Best: Proof That It Works And That It Can Be Done Successfully And Effectively As An Outpatient Procedure
Sam S. Ahn, MD, MBA

ENTRAPMENTS AND TRAUMA

- 7:22 – 7:27** Updates And New Concepts In The Diagnosis And Treatment Of Popliteal Entrapments
Katherine A. Gallagher, MD
- 7:28 – 7:33** Dynamic MRI To Assess Popliteal Artery Entrapment Syndrome: How Can It Influence Diagnosis And Treatment
Jos C. van den Berg, MD, PhD
- 7:34 – 7:39** Functional Popliteal Entrapment In Athletes: How Best To Diagnose And Treat: How To Know What Structure Needs To Be Addressed To Achieve Arterial Decompression: Is Recurrence Ever A Problem
Jason T. Lee, MD
- 7:40 – 7:45** Optimal Surgical Approach And Graft For Popliteal Artery Injuries: How Best To Treat Associated Popliteal Venous Injuries: Best Venous Graft
Charles J. Fox, MD
- 7:46 – 7:56** **Panel Discussion**

SESSION 94 (Grand Ballroom West, 3rd Floor)

NEW DEVELOPMENTS IN TREATING ARTERIAL (INCLUDING AORTIC) GRAFT AND ENDOGRAFT INFECTIONS

Moderators: *Keith D. Calligaro, MD*
Manju Kalra, MBBS

- 7:56 – 8:01** Current Concepts In Treatment Of Aortic Graft And Endograft Infections, Including EVAR, F/EVAR, TAAA And Arch Endografts: From The GRANDPA Registry
Anders Wanhainen, MD, PhD
- 8:02 – 8:07** New Developments In The Treatment Of Aortic Graft Infection After EVAR And Open Repair: What Is The Best Current Treatment And Mid-Term Results: From A Multicenter Study
Jean-Paul de Vries, MD, PhD
- 8:08 – 8:13** Support For The Graft Preservation Concept For Treating Prosthetic Aortic Graft Infections From A European Multicenter Study (VASGRA): All Or Part Of The Infected Graft May Be Preserved: Under What Circumstances
Zoran Rancic, MD, PhD
- 8:14 – 8:19** Current Concepts In The Management Of Endograft Infections After EVAR: When And How Can The Endograft Be Preserved
Audra A. Duncan, MD
- 8:20 – 8:25** Rifampin-Soaked Dacron Or Cryopreserved Aorto-Iliac Conduits: When Is Each The Best Treatment For Infected Aortic Grafts Or EVARs: How Do Differences In Failure Rates For The 2 Grafts Influence Their Choice And Need For Surveillance
Randall DeMartino, MD
Manju Kalra, MBBS

- 8:26 – 8:31** Update On Rifampin Soaked Endografts To Treat Mycotic AAAs: How To Prepare Them: When To Use Them And When Not: When Are They A Stand-Alone Treatment And When Are They A Life Saving Measure Requiring Further Definitive Treatment
Guillermo A. Escobar, MD
- 8:32 – 8:37** **Panel Discussion**
- 8:38 – 8:43** Improvements In The NAIS Procedure (Graft Removal And In-Line Deep Vein Reconstruction) For Infected Aortic Grafts: How To Make The Operation Easier And Faster: When Is It Indicated And When Not
John F. Eidt, MD
- 8:44 – 8:49** For Many Infected Prosthetic Arterial/Aortic Grafts, Endografts And Mycotic Aneurysms Less Than The Current Standard Radical Graft Excisional Treatment Is Best: Details And Examples Of This Less Radical Treatment
Martin Malina, MD, PhD
- 8:50 – 8:55** The Role Of Percutaneous CT-Guided Drainage And Antibiotics Irrigation For Endograft Infections: How To Do It And Real-World Results
Tal M. Hörer, MD, PhD
- 8:56 – 9:01** New Developments In The Surgical Treatment For Infected Thoracic Aortic Graft And Endografts, With Or Without Aorto-Esophageal Fistulas: Technical Tips And Current Results In A Committed Center
Germano C.G. Melissano, MD
Andrea Kahlberg, MD
Roberto L.V. Chiesa, MD
- 9:02 – 9:07** Infected Axillary Artery Prosthetic Graft Stumps: How Best To Deal With Them Without Total Graft Excision
Sateesh C. Babu, MD
- 9:08 – 9:13** Arterial Graft Infections Can Be Treated With Local Antibiotic Beads To Downgrade Infection Virulence And Allow For Graft Preservation: How To Do It And When Does It Work
Michael C. Stoner, MD
- 9:14 – 9:20** **Panel Discussion**
- 9:20 – 9:34** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 95 (Grand Ballroom West, 3rd Floor)

PROGRESS IN VASCULAR IMAGING AND GUIDANCE FOR ENDOVASCULAR TREATMENTS; DECREASING RADIATION EXPOSURE OR CONTRAST TOXICITY

Moderators: *Jacob Cynamon, MD*

Jan M.M. Heyligers, MD, PhD

- 9:34 – 9:39** Skills That Vascular Surgeons/Specialists Must Have To Improve Imaging And Decrease Radiation Exposure Include Control Of Gantry Angle Projections, All Image Settings, Columination, Contrast Dilution, Mechanical Injection Pressure And Flow Rates, Frame Rates, Cone Beam CT, Fusion Setup And More
Martin Malina, MD, PhD
- 9:40 – 9:45** The Value Of CO2 Contrast Angiography: Indications, Contraindications, Precautions, Value: Vascular Beds Where It Can Be Used And Where It Cannot Be: How To Do It Simply And Effectively
Sigrid Nikol, MD
- 9:46 – 9:51** What Conditions Can Cause Increased 18F FDG (Fluorodeoxyglucose) Uptake In Positron Emission CT: How Reliable Is It In Diagnosing Aortic And EVAR Graft Infection And Predicting AAA Rupture
Clark J. Zeebregts, MD, PhD

- 9:52 – 9:57** How To Pick The Best Hybrid OR/Suite For Your Institution: Advantages, Disadvantages, Accessories And Determinants Of Cost Of The Three Main Systems (GE, Siemens, Philips)
Bjoern D. Suckow, MD
- 9:58–10:03** Experience With A New Better Setup For A Hybrid OR/Suite: Features, Advantage And Cost: Who Supplies It And What Components Make A Difference For Standard And Advanced Procedures
Stephan Haulon, MD
- 10:04–10:09** Simple And Not So Simple Radiation Protection Techniques And Devices: What's Here And What's On The Horizon
Ripal T. Gandhi, MD
- 10:10–10:15** Radiation Hazards To The Pregnant Surgeon/Specialist: What Practice Modifications And Techniques Are Needed To Minimize Them
Venita R. Chandra, MD
- 10:16–10:21** Myths And New Facts About Decreasing Radiation Exposure: Lead Caps, Glasses And Most Light Weight Gowns, Etc. Don't Help; What Methods And Devices Do Help
Melissa L. Kirkwood, MD

VASCULAR HOLOGRAPHY

- 10:22–10:27** Holographic Guidance Of Endovascular Procedures (With Augmented Reality Goggles And No Screen): How Does It Work And Clinical Experience: What Is Possible And What Is Not
Claude Mialhe, MD
- 10:28–10:33** Update On The ARCUS System Of Augmented Reality (Derived From A Contrast CT) And Its Value In Vascular And Endovascular Procedures: How Does It Work And Experience To Date
Jan M.M. Heyligers, MD, PhD
- 10:34–10:40** **Panel Discussion**

SESSION 96 (Grand Ballroom West, 3rd Floor)

NEW INNOVATIVE ADVANCED TECHNIQUES FOR COMPLEX ENDOVASCULAR AORTIC REPAIRS

Moderators: *Gustavo S. Oderich, MD*

Carlos H. Timaran, MD

Grace C. Mulatti, MD, PhD

- 10:40–10:46** FEM-SMART, Femoral Staggered Multi-Branch Aneurysm Repair Technique
Jong H. Park, MD, PhD
- 10:46–10:50** **Discussion**
- 10:50–10:56** Single Femoral TAMBE Technique To Avoid Upper Extremity Access
Sukgu M. Han, MD, MS
- 10:56–11:00** **Discussion**
- 11:00–11:06** BIS2T, Bifurcated In-Stent In Situ Stent-Graft Technique To Incorporate Two Target Vessels From A Single Directional Branch
Gustavo Paludetto Oliveira, PhD
- 11:06–11:10** **Discussion**
- 11:10–11:16** EndoHub Concept: A Solution To Solve Gutter Leaks With Parallel Grafts And First-In-Man Applications
Pierre S. Galvagni, MD, PhD
- 11:16–11:20** **Discussion**
- 11:20–11:26** Thoracic Branch Endoprosthesis (TBE®) + In Situ Fenestration For Zone 0 Arch Repair
Jorge A. Miranda, MD
- 11:26–11:30** **Discussion**

11:30–11:36 Thoracic Branch Endoprosthesis (TBE®) + Modified Fenestration For Zone 0/1 Arch Repair
George C. Pontikis, MD

11:36–11:40 **Discussion**

11:40–12:00 **Panel Discussion**

12:00– 1:00 **Lunch Break - Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 97 (Grand Ballroom West, 3rd Floor)

CHALLENGING RECORDED LIVE CASES FROM MÜNSTER, GERMANY

Moderators: *Martin J. Austermann, MD*
Giovanni B. Torsello, MD
Marco V. Usai, MD

1:00 – 1:37 Recorded Cases Showing Different Endovascular Techniques For Repair Of Late EVAR Failures
Martin J. Austermann, MD
Marco V. Usai, MD

SESSION 98 (Grand Ballroom West, 3rd Floor)

NEW DEVELOPMENTS IN THE TREATMENT OF THORACIC OUTLET SYNDROMES (TOSs)

Moderators: *Michael J. Singh, MD*
Mark A. Adelman, MD

1:38 – 1:43 How MRI Provides Improved Imaging For Vascular TOS And Influences Treatment
Robert A. Morgan, MD

1:44 – 1:49 How Anterior Scalene And Pectoralis Minor Blocks Can Simplify The Diagnostic Dilemma With Neurogenic TOS: What Agent To Use, Technique And How It Directs Treatment
Michael J. Singh, MD

1:50 – 1:55 Neurogenic TOS: When And How To Use Botox Treatment: When Is Surgical Treatment Necessary And How Best To Do Them
Jason T. Lee, MD

1:56 – 2:01 What's New In The Management Of Vascular And Neurogenic TOSs In Athletes
Hugh A. Gelabert, MD

2:02 – 2:07 Arterial And Venous TOS Disorders In Overhead Throwing Athletes: What Are These Disorders And How Should They Best Be Treated
Margaret Tracci, MD, JD

2:08 – 2:13 Arterial TOS In Patients With Connective Tissue Disorders: How The Latter Influences The Vascular Pathology And Should Change Treatment Strategies
Michael J. Singh, MD

2:14 – 2:19 Minimally Invasive Transaxillary First Rib Resection For TOS Under Local And Regional Anesthesia: How To Do It Safely: What Are The Limitations
Francesco Spinelli, MD

2:20 – 2:25 Robotic Approach To Thoracic Outlet Decompression: Equipment Required And How To Do It: Advantages, Limitations And Results
Katherine A. Teter, MD

2:26 – 2:31 For Venous TOS An Anterior Infraclavicular Approach With Resection Of The Anterior Third Of The First Rib Provides Access To The Vein And Relieves Its Compression: Technique, Limitations And Results
Keith D. Calligaro, MD
Matthew J. Dougherty, MD

2:32 – 2:38 **Panel Discussion**

2:38 – 2:48 **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 99 (Grand Ballroom West, 3rd Floor)

MEDICAL AND ADJUNCTIVE (DRUG AND CELL) TREATMENTS IN VASCULAR PATIENTS; A NEW CONCEPT; VASCULAR DISEASES; VASCULAR PROCEDURES TO FACILITATE OTHER SURGERIES

Moderators: *Natalie A. Marks-Ascher, MD, RPVI, RVT*
Karan Garg, MD

NEW DEVELOPMENTS IN MEDICAL MANAGEMENT

- 2:48 – 2:53** Lowering LDL-C And Controlling Elevated Blood Pressure And Lipoprotein Little A [Lp(a)] Can Lower Cardiovascular Risk 80%: What To Do If Patients Can't Tolerate A Statin Dose: Ezetimibe (Zetia), A PCSK9 Inhibitor, Inclisiran, Bempedoic Acid (Nexletol), Etc.
Richard Bulbulia, MA, MD
- 2:54 – 2:59** Current Optimal Antiplatelet And Anticoagulation Treatment For Various Vascular Procedures In Various Vascular Beds: What Newer Drugs And DOACs Are Useful And What Is The Optimal Timing Of Treatment
Peter Henke, MD
- 3:00 – 3:05** Update On Autologous Cell And Gene Therapy For Chronic Limb Threatening Ischemia (CLTI): Do They Really Work And Future Prospects
Carlo Setacci, MD
- 3:06 – 3:11** Why A New Oral PCSK9 Inhibitor (AZD0780) Will Be A Game Changer In Lipid Management And Lowering The Morbidity Of Atherosclerosis: Implications Of Its Different Mode Of Action
Richard Bulbulia, MA, MD

A NEW CONCEPT ABOUT OTHER USES FOR AN ENDOVASCULAR DEVICE

- 3:12 – 3:17** New Uses For The WavelinQ EndoAVF Device: Turning Veins Into Arteries: How It Can Be Used To Treat CLTI And ESRD: How Does It Work And Clinical Experience
Chris Delaney, MD

UPDATE ON TREATMENT OF RARE VASCULAR DISEASES AND NEW TREATMENTS

- 3:18 – 3:23** Optimal Current Management Of Takayasu's Disease Involving The Supra-Aortic Branches: Technical Details For Open Surgical Management And What Is The Role For Endo Treatment With Bare Or Covered Stents In 2025
Kellie R. Brown, MD (PowerPoint Presentation With Synched Audio)
- 3:24 – 3:29** Twenty Years Of Large Blood Vessel Management In The Treatment Of Retroperitoneal Sarcomas: Lessons Learned And Why A Vascular Surgeon Is Critical To Successful Treatment
Elizabeth L. George, MD, MS
- 3:30 – 3:35** Nutritional Science: How Can It Transform Peripheral Arterial Disease Outcomes
Chris Delaney, MD
- 3:36 – 3:42** **Panel Discussion**

SESSION 100 (Grand Ballroom West, 3rd Floor)

ADVANCES IN THE ENDO AND OPEN TREATMENT OF VASCULAR TRAUMA

Moderators: *Todd E. Rasmussen, MD*
Gilbert R. Upchurch, MD

- 3:42 – 3:47** Patients With Head Injury, Solid Organ Injury And Vascular Trauma: When, How And Sequence Of Repair: When And How To Use Heparin For Endo And Open Vascular Procedures
Elina Quiroga, MD, MPH

- 3:48 – 3:53** Update On Resuscitative Endovascular Balloon Occlusion Of The Aorta (REBOA): When Is It A Valuable Procedure And When Is It Not: Limitations And Precautions
Joseph J. DuBose, MD (PowerPoint Presentation With Synched Audio)
- 3:54 – 3:59** Emergency Management Of Major Arterial And Venous Injuries During Interventional Cardiology Procedures: Diagnosis, Technical Tips, And Outcomes
Pasqualino Sirignano, MD, PhD
Francesco Speziale, MD
- 4:00 – 4:05** Vascular Injuries After Blunt Abdominal Trauma: Diagnosis And Management: When Endo, When Open Treatment
Dittmar Böckler, MD
- 4:06 – 4:11** New Developments In The Endovascular Management Of Vascular Injuries: How Can A Hybrid Suite Be Helpful
Ravi R. Rajani, MD
- 4:12 – 4:17** New Developments In The Diagnosis And Treatment Of Penetrating And Blunt Carotid Artery Injuries: The Evolving Role Of Endovascular Treatments
Erica L. Mitchell, MD, MEd
- 4:18 – 4:23** **Panel Discussion**
UPDATES ON PEDIATRIC VASCULAR TRAUMA AND BLUNT THORACIC AORTIC INJURY (BTAI)
- 4:24 – 4:29** Evolving Techniques In Pediatric Vascular And Endovascular Trauma Surgery: What Special Precautions Are Needed: How To Deal With Arterial Spasm: When And How Can Endovascular Grafts Be Used
Dawn M. Coleman, MD
- 4:30 – 4:35** Blunt Thoracic Aortic Injury (BTAI) In Pediatric Patients: When And How Should We Intervene: Lessons From The Aortic Trauma Foundation Registry
Elina Quiroga, MD, MPH
- 4:36 – 4:41** Long-Term Outcomes Following TEVAR For BTAI: Late Complications Are Extremely Rare
Rabih A. Chaer, MD
- 4:42 – 4:47** Thoracic Aortic Pseudo-Coarctation After BTAI: What Is It: How Does It Produce Distal Organ Ischemia: How Should It Be Diagnosed And Treated Emergently By TEVAR: Technical Tips
Erica L. Mitchell, MD, MEd
- 4:48 – 5:00** **Panel Discussion**
End of Program M

PROGRAM N (SESSIONS 101-111)

DEEP VENOUS DISEASE

Trianon Ballroom, 3rd Floor

SESSION 101 (Trianon Ballroom, 3rd Floor)

DEEP VENOUS PHYSIOLOGY, IMAGING AND NIVLS

Moderators: *Jose I. Almeida, MD, RPVI, RVT*

Lowell S. Kabnick, MD

- 7:30 – 7:34** Introduction To The Deep System
Lowell S. Kabnick, MD
- 7:35 – 7:40** JURY-2 Trial Results
Brajesh K. Lal, MD
- 7:41 – 7:46** Iliocaval Duplex Ultrasound With Image Optimization
Jan M. Sloves, RVT
- 7:47 – 7:52** Flow Dynamics Of Different Stenting Configurations Of The Iliac Vein Confluence
Steven D. Abramowitz, MD

- 7:53 – 7:58** Hemodynamic Characteristics Of Patients With Non-Thrombotic Iliac Vein Lesions And Deep Venous Thrombosis
Carlos Alberto Figueroa, PhD
- 7:59 – 8:04** Is 50% Stenosis The Cutpoint For Stenting
Mark H. Meissner, MD
- 8:05 – 8:10** Proper IVUS Interpretation For NIVL
Paul J. Gagne, MD
- 8:11 – 8:16** Endovascular Management Of NIVL: Guidance From Multidisciplinary Consensus
Kush R. Desai, MD
Steve Elias, MD (Presenter)
- 8:17 – 8:22** **Panel Discussion**

SESSION 102 (Trianon Ballroom, 3rd Floor)

VENOUS STENT ISSUES

Moderators: *Jose I. Almeida, MD, RPVI, RVT*
Alun H. Davies, MA, DM, DSc

- 8:23 – 8:28** Inflow Improvement Techniques For PTS Patients
Jose I. Almeida, MD, RPVI, RVT
- 8:29 – 8:34** Why Lack Of Equipoise To Do RCTs In The Deep Venous Stenting Space
Alun H. Davies, MA, DM, DSc
- 8:35 – 8:40** Prospective Randomized Analysis: Necessity Of Clopidogrel After Iliac Vein Stenting
Anil P. Hingorani, MD
- 8:41 – 8:46** Obesity Paradox Reflected In Outcomes After Iliac Vein Stenting: A Subset Analysis From The ABRE Trial
Erin H. Murphy, MD
- 8:47 – 8:52** 8-Year Follow Up On The Venovo Venous Stent
Michael K.W. Lichtenberg, MD
- 8:53 – 8:58** Overview Of The First Prospective, Multicenter, Study To Evaluate The Treatment Of Symptomatic Inferior Vena Cava (IVC) Obstruction With Or Without Combined Iliofemoral Obstruction
Kush R. Desai, MD
Steven D. Abramowitz, MD (Presenter)
- 8:59 – 9:04** Zilver Vena Stent Trial: Long-Term Follow-Up
Paul J. Gagne, MD
- 9:05 – 9:10** Revcore/Venacore For Occluded Stents/Veins
Jose I. Almeida, MD, RPVI, RVT
- 9:11 – 9:16** **Panel Discussion**

SESSION 103 (Trianon Ballroom, 3rd Floor)

FEMORO-ILIOCAVAL CHRONIC TOTAL OCCLUSIONS, RECANALIZATION TECHNIQUES AND OTHER CONSIDERATIONS

Moderators: *Anil P. Hingorani, MD*
Houman Jalaie, MD, PhD

- 9:17 – 9:22** Aspirin Plus Rivaroxaban vs. Rivaroxaban Alone For Stent Patency In PTS: Multicenter, Randomized, Open Label ARIVA Trial
Houman Jalaie, MD, PhD
- 9:23 – 9:28** Imaging Required For Safe Central Venous Recanalization
Marcelo Guimaraes, MD, MBA
- 9:29 – 9:34** Preclinical Data On Sirolimus Coated Balloons In Deep Veins: Results From The vSTRIDE Trial
Andrea T. Obi, MD
- 9:35 – 9:40** Safety And Efficacy Of Iliac Vein Stenting For 4312 NIVL In The OBL
Anil P. Hingorani, MD
- 9:41 – 9:46** Long-Term Results In Iliocaval Recanalization: A Retrospective Analysis On A 20-Year Experience
Marzia Lugli, MD

- 9:47 – 9:52** Endovenectomy Of Common Femoral Vein: When And How
Houman Jalaie, MD, PhD
- 9:53 – 9:58** Complex And Chronic IVC-Iliac Vein Endovascular Reconstructions
Marcelo Guimaraes, MD, MBA
- 9:59–10:04** **Panel Discussion**

SESSION 104 (Trianon Ballroom, 3rd Floor)

VENOUS THROMBOSIS SCIENCE AND TREATMENT STRATEGIES

Moderators: *Peter Henke, MD*

Thomas W. Wakefield, MD

- 10:05–10:10** Thrombus Age In DVT: Imaging Pearls
Iris Baumgartner, MD
- 10:11–10:16** Venous Thromboembolism In The Context Of Chronic Venous Disease
Thomas W. Wakefield, MD
- 10:17–10:22** What's New In Experimental Deep Vein Thrombus Resolution
Peter Henke, MD
- 10:23–10:28** Venous Insufficiency In The Patient With Congenital Heart Disease
Andrea T. Obi, MD
- 10:29–10:34** Hypercoagulable Work Up, Thrombophilia Testing, And Duration Of Anticoagulation
Rachel Rosovsky, MD, MPH
- 10:35–10:40** VTE Treatment In The Patient With PAD
Andrea T. Obi, MD
- 10:41–10:46** Factor XI Inhibitors: What Are They
Timothy K. Liem, MD, MBA
- 10:47–10:52** Inflammation, Selectins And Venous Thrombosis
Thomas W. Wakefield, MD
- 10:53–10:58** SVT Treatment Options: DOAC, LMWH, Nothing
Steve Elias, MD
- 10:59–11:04** **Panel Discussion**

SESSION 105 (Trianon Ballroom, 3rd Floor)

THROMBUS REMOVAL THROMBECTOMY DEVICES AND OTHER ISSUES TO CONSIDER

Moderators: *Alan M. Dietzek, MD, RPVI*

Patrick E. Muck, MD

- 11:05–11:10** Are Lytic Based Thrombectomy Devices Still Relevant In 2025
Nicolas J. Mouawad, MD, MPH, MBA
- 11:11–11:16** Clinical Outcomes In The CLOUT Registry, The Design Of The DEFIANCE Trial And Benefits Of The ClotTriever System
Steven D. Abramowitz, MD
- 11:17–11:22** How My Approach To DVT Treatment Has Evolved Over The Past 30 Years
Alan M. Dietzek, MD, RPVI
- 11:23–11:28** Mechanical Thrombectomy For The Management Of Post-Thrombotic Syndrome Venous Obstructions
Nicolas J. Mouawad, MD, MPH, MBA
- 11:29–11:34** Ichor Device: Next-Gen Fogarty For Venous Thrombectomy
Edward J. Arous, MD, MPH
- 11:35–11:40** Computer Aided (AI) Vacuum Thrombectomy (CAVT) For Lower Extremity Deep Venous Thrombosis: How Beneficial Is It
Adam C. Reichard, MD
- 11:41–11:46** Aspirex: 36-Month Update From A Multicenter Clinical Study
Patrick E. Muck, MD

- 11:47–11:52** DVT Different Treatments For Different Perspectives
Rebeca Reachi Lugo, MD
- 11:53–11:58** **Panel Discussion**
- 11:59– 1:03** **Lunch Break - Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 106 (Trianon Ballroom, 3rd Floor)

PELVIC VEIN DISORDERS

Moderators: *Cynthia K. Shortell, MD*
Julianne Stoughton, MD

- 1:04 – 1:09** When Is A Left Renal Vein Compression Hemodynamically Significant: Clues Offered By Duplex Ultrasound
Kathleen D. Gibson, MD
- 1:10 – 1:15** Treatment Algorithm For Left Renal Vein Compression
Cynthia K. Shortell, MD
- 1:16 – 1:21** Treatment Of Nutcracker Syndrome With Ovarian Vein Transposition
Bernadette Aulivola, MD
- 1:22 – 1:27** Outcomes Of Left Renal Vein Stenting In Patients With Nutcracker Syndrome
Rabih A. Chaer, MD
- 1:28 – 1:33** Open Surgical And Endovascular Treatment Of Nutcracker Syndrome: Do We Have The Answer Now
Manju Kalra, MBBS
- 1:34 – 1:39** Management Of Symptomatic Vulvar Varices With And Without Pelvic Symptoms
Julianne Stoughton, MD
- 1:40 – 1:45** Iliac Vein Stenting Or Embolizing An Ovarian Vein(s) For Pelvic Pain: How Much Improvement Should One Expect
Mark H. Meissner, MD
- 1:46 – 1:51** RCT Of Pelvic Venous Embolization vs. Sham Procedure For Venous Origin Chronic Pelvic Pain In Women
Neil M. Khilnani, MD
- 1:52 – 1:57** Sclerotherapy Injections For Treatment Of Pelvic Escape Points
Aleksandra Jaworucka-Kaczorowska, MD, PhD
- 1:58 – 2:03** Successful Wallstent Exclusion Of Iliofemoral Venous Aneurysms: A New Treatment Paradigm
Arjun Jayaraj, MD
- 2:04 – 2:09** **Panel Discussion**

SESSION 107 (Trianon Ballroom, 3rd Floor)

VALVES AND MORE VENOUS THROMBOSIS

Moderators: *Paul J. Gagne, MD*
Jorge H. Ulloa, MD

- 2:10 – 2:15** Current Status Of Prosthetic Deep Venous Valves: Experience To Date And What's On The Horizon
Jorge H. Ulloa, MD
- 2:16 – 2:21** When Deep Venous Reflux Repair Is Not Effective: What Next
Marzia Lugli, MD
- 2:22 – 2:27** Long-Term Results Of The SAVVE Trial: A Bioprosthetic Valve
David J. Dexter, MD
- 2:28 – 2:33** Deep Vein Valve Devices: What Outcome Measures Should Be Used
Fedor Lurie, MD, PhD
- 2:34 – 2:39** Percutaneous Vein Valve - An Elusive Solution: Lessons Learned From Recent Trials
Paul J. Gagne, MD
- 2:40 – 2:45** Ambulatory Venous Pressure Measurement Via Column Interruption Duration
Seshadri Raju, MD

2:46 – 2:51 Panel Discussion

SESSION 108 (Trianon Ballroom, 3rd Floor)

IVC FILTERS

Moderators: *Rabih A. Chaer, MD*
Anil P. Hingorani, MD

- 2:52 – 2:57** Rethinking Filters: The Latest Evidence From The Cook IVC Filter Study
Rabih A. Chaer, MD
- 2:58 – 3:03** Long-Term Mortality Of Trapease Filter vs. Greenfield Filter: 20-Year Results Of A RCT
Anil P. Hingorani, MD
- 3:04 – 3:09** Denali Filter Experience
Eric Hager, MD
- 3:10 – 3:15** IVC Filter Retrieval: Basic And Advanced
Ripal T. Gandhi, MD
- 3:16 – 3:21** The Root Cause Of Venous Phasicity Is Not From The Abdominal Thoracic Pump But Due To Vena Cava Distortion During Respiration
Seshadri Raju, MD
- 3:22 – 3:27** Surgical Removal Of IVC Filters: When, How
Stefan C. K  nel-Pierre, MD
- 3:28 – 3:33 Panel Discussion**

SESSION 109 (Trianon Ballroom, 3rd Floor)

THORACIC VENOUS OBSTRUCTION AND ISSUES WITH STENTS IN YOUNG PATIENTS

Moderators: *William A. Marston, MD*
Glenn Jacobowitz, MD

- 3:34 – 3:39** Open Surgical And Endovascular Treatment Of Superior Vena Cava Syndrome
Manju Kalra, MBBS
- 3:40 – 3:45** Outcome Of Venous Stents In Adolescents, Teenagers, And Pregnancy
Mahmood Razavi, MD
- 3:46 – 3:51** Acute Iliofemoral DVT In Adolescents And Young Adults And Whether They Should Undergo Stenting For May-Thurner At The Time Of DVT Intervention
William A. Marston, MD
- 3:52 – 3:57** Common Iliac Vein Stenting And Subsequent Pregnancy – Durability And Need For Anticoagulation
Glenn Jacobowitz, MD
- 3:58 – 4:03 Panel Discussion**

SESSION 110 (Trianon Ballroom, 3rd Floor)

OTHER VENOUS ISSUES IMPORTANT TO VASCULAR SURGEONS

Moderators: *Peter Gloviczki, MD, PhD*
Monika L. Gloviczki, MD, PhD

- 4:04 – 4:09** Tips And Tricks For Optimal Management Of Primary And Secondary IVC Tumors
Jill J. Colglazier, MD
- 4:10 – 4:15** Migration Of Iliac And Renal Vein Stents: T-Stent Might Be A Solution To The Problem
Peter Gloviczki, MD, PhD
- 4:16 – 4:21** Management Of Venous Thoracic Outlet Syndrome
Robert J. Beaulieu, MD, MSE
- 4:22 – 4:27** Mesenteric Vein Thrombosis: What Is The Best Strategy, Do We Need To Be More Aggressive
Mark G. Davies, MD
- 4:28 – 4:33** What Is Iatrogenic May-Turner Syndrome And Why Is It On The Rise
Joann M. Lohr, MD
- 4:34 – 4:39** Relationship Of Obstruction And Deep Vein Reflux
Mikel Sadek, MD

FRIDAY/SATURDAY SESSIONS 110–111

- 4:40 – 4:45** Utility Of Venoactive Compounds In Post-Thrombotic Syndrome: A Systematic Review
Monika L. Gloviczki, MD, PhD
- 4:46 – 4:51** **Panel Discussion**

SESSION 111 (Trianon Ballroom, 3rd Floor)

LYMPHEDEMA AND THE SWOLLEN LEG

Moderators: *Thomas F. O'Donnell, Jr., MD*
Thomas S. Maldonado, MD

- 4:52 – 4:57** Computed Tomography Scanning In The Diagnosis Of Lower Extremity Phlebolymphe-
dema
Arjun Jayaraj, MD
- 4:58 – 5:03** Changing Views In The Anatomy And Pathophysiology Of Lymphedema
Thomas F. O'Donnell, Jr., MD
- 5:04 – 5:09** Cutaneous Manifestations Of Lymphedema
Steven M. Dean, DO
- 5:10 – 5:15** Treatment Effectiveness Of A Non-Pneumatic Compression Device vs. An Advanced Pneumatic Compression Device For Lower Extremity Lymphedema Swelling (TEAYS Study)
Thomas S. Maldonado, MD
- 5:16 – 5:21** Is Pneumatic Compression For Lymphedema A Lot Of Hot Air: A Systematic Review
Thomas F. O'Donnell, Jr., MD
- 5:22 – 5:27** Update On Pharmacological Treatment For Lymphedema
Monika L. Gloviczki, MD, PhD
- 5:28 – 5:33** Single Center Data On Treatment Of SVT With Ablation Plus Anticoagulation
Raghu Kolluri, MD
- 5:34 – 5:39** The New Recana System For The Endovascular Treatment Of Venous In-Stent Restenosis And Native Vessel Obstructions
William A. Marston, MD
- 5:39 – 5:44** **Panel Discussion**
- End of Program N**

SATURDAY, NOVEMBER 22, 2025

- 6:00 A.M.** General Registration — Rhinelander Gallery, 2nd Floor
- 6:00 A.M.** Faculty Registration — Gramercy Suite East, 2nd Floor
- 6:15 A.M.** Continental Breakfast — Grandballroom Foyer, 3rd Floor

CONCURRENT SATURDAY PROGRAMS

PROGRAM O (SESSIONS 112-115)

Topics Too Important To Miss In General And In The Treatment Of Lower Extremity, Aortic Or Carotid Disease

Location: Grand Ballroom East, 3rd Floor

PROGRAM P (SESSIONS 116-121)

Improving Outcomes In Hemodialysis Access

Location: Grand Ballroom West, 3rd Floor

PROGRAM O (SESSIONS 112-115)

TOPICS TOO IMPORTANT TO MISS IN GENERAL AND IN THE TREATMENT OF LOWER EXTREMITY, AORTIC OR CAROTID DISEASE

Grand Ballroom East, 3rd Floor

Grand Ballroom East, 3rd Floor

SESSION 112 (Grand Ballroom East, 3rd Floor)

LOWER EXTREMITY TOPICS TOO IMPORTANT TO MISS

Moderators: *Vikram S. Kashyap, MD*
Venita R. Chandra, MD
Peter A. Schneider, MD

- 7:00 – 7:05** How To Do Bypass Surgery To Heavily Non-Compressible Calcified Target Arteries
Enrico Ascher, MD
Frank J. Veith, MD
- 7:06 – 7:11** Antegrade Via The SFA vs. Pedal Access: Technical Tips And When To Use Each
Todd Berland, MD
Karan Garg, MD
- 7:12 – 7:17** When Is Primary Amputation The Best Treatment For Patients With CLTI: It Is Currently Very Rare But There Are Valid Indications
Christopher J. Abularrage, MD
- 7:18 – 7:23** A Comparison Of Directional Atherectomy Followed By DCB vs. PTA Followed By DCB To Treat Long Calcified FemPop Lesions: From The TOTAL REALITY Pooled Analysis
Venita R. Chandra, MD
- 7:24 – 7:29** Comparison Of Atherectomy And DCB Treatment With Open Surgery For Symptomatic Deep Femoral Artery Lesions: When Is Each Indicated
Giovanni B. Torsello, MD
Thomas Zeller, MD
- 7:30 – 7:35** In Patients Requiring Endovascular Intervention For FemPop Disease What Lesion Characteristics Should Determine Whether DCB Or DES Treatment Is Best
Naoki Fujimura, MD, PhD
- 7:36 – 7:41** **Panel Discussion**
- 7:42 – 7:47** Why Dementia In Patients With CLTI Is Important To Evaluate: How Should It Influence Treatment And Will It Change Outcomes
Salvatore Scali, MD
- 7:48 – 7:53** With Prograde CFA Punctures, How To Easily Get The Guidewire Down The SFA Rather Than The Deep Femoral
Ali Amin, MD, RVT
- 7:54 – 7:59** Aggressive Interventions Including Atherectomy In Claudicants Leads To More Harm Than Good
Dipankar Mukherjee, MD
- 8:00 – 8:05** Open Treatment First For CLTI In The Era Of BEST-CLI: When Is It Best: It's Not Just For Patients With Good Ipsilateral Great Saphenous Veins
Yana Etkin, MD
- 8:06 – 8:11** The Importance Of Establishing In Line Flow To A Wound To Achieve Healing In Patients With CLTI
Osamu Iida, MD, PhD (PowerPoint Presentation With Synched Audio)
- 8:12 – 8:17** Adventitial Drug Delivery With The BullFrog Device (From Mercator MedSystems) And The Spur Device (From Reflow): How Do They Work And How Will We Know They Improve Results
William A. Gray, MD
- 8:18 – 8:26** **Panel Discussion**

SESSION 113 (Grand Ballroom East, 3rd Floor)

MORE LOWER EXTREMITY TOPICS TOO IMPORTANT TO MISS

Moderators: *William A. Gray, MD*
Jeffrey J. Siracuse, MD, MBA

- 8:26 – 8:31** Axillo-Unifemoral And Axillo-Bifemoral Bypasses Have Equal Patency For More Than A Year: Why The Bilateral Procedure Should Only Be Used When Bilateral Ischemia Exists
Jeffrey J. Siracuse, MD, MBA
- 8:32 – 8:37** Technical Tips For Performing BK Popliteal To Distal Leg Or Foot Artery Bypasses: Advantages And Results
Francesco Spinelli, MD
- 8:38 – 8:43** Treatment Of Dissections After PTA Of Lower Extremity Lesions: What Techniques Are Available: When Is Treatment Necessary And When Is It Not
Jos C. van den Berg, MD, PhD
- 8:44 – 8:49** Successful Bypasses To Foot Arteries And Their Branches Allowed Limb Salvage In What Were Thought To Be 'No Option For Treatment' CLTI Patients
Enrico Ascher, MD
Frank J. Veith, MD
- 8:50 – 8:55** Value Of Intravascular Lithotripsy (Shockwave-J&J) For Treatment Of Calcified BTK Lesions Causing CLTI: Results Of The BTK-PAD II Study
Venita R. Chandra, MD
- 8:56 – 9:01** **Panel Discussion**
- 9:02 – 9:07** Endovascular vs. Open Repair Of Popliteal Aneurysms: Indications And Contraindications For Each: Comparable Long-Term (5 Years) Durability Can Be Achieved: From The VISION Database
Philip P. Goodney, MD, MS
- 9:08 – 9:13** Outcomes Of Greater Saphenous Vein (GSV) Bypasses In The Setting Of Traumatic Injuries: Do They Differ From Those Of GSV Bypasses For Occlusive Disease And If So Why
Alik Farber, MD, MBA
- 9:14 – 9:19** Technical Tips For Overcoming Recoil After PTA In BTK Interventions: When And How To Do It
Jos C. van den Berg, MD, PhD
- 9:20 – 9:25** Novel Uses Of Selective Superficial Venous Arterialization To Achieve Lower Limb Salvage: Techniques, Indications, Precautions And Results
Patrick J. Geraghty, MD
- 9:26 – 9:31** Duplex Ultrasound For Diagnosis Of Failing Stents Placed For Arterial Occlusive Disease: Why Is It Important And How Often Should It Be Done After Treatment In Claudicants; In CLTI Patients
Keith D. Calligaro, MD
- 9:32 – 9:38** **Panel Discussion**
- 9:38 – 9:48** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 114 (Grand Ballroom East, 3rd Floor)

AORTIC TOPICS TOO IMPORTANT TO MISS

Moderators: *David J. Minion, MD*

Jessica P. Simons, MD, MPH

Kenneth Ouriel, MD, MBA

- 9:48 – 9:53** Chimney EVAR Is A Dependable And Durable (Over 2 Years) Way To Treat Pararenal AAAs: Endografts To Use And Technical Tips To Minimize Type 1A Endoleaks
Felice Pecoraro, MD
- 9:54 – 9:59** How To Minimize Gutter Type 1A Endoleaks With Chimney EVAR (Ch/EVAR): How Does The "Eye Of The Tiger" Technique And A Standard Protocol Help; How To Treat Them When They Occur
David J. Minion, MD

- 10:00–10:05** Management Of Congenital AAAs In Infants With And Without Rupture: What Is The Best Graft And Long-Term Prognosis
Anders Wanhainen, MD, PhD
- 10:06–10:11** The Aortyx Aortic Patch: A More Compliant Way Than TEVAR To Seal Aortic Entry Tears With TBADs: A New Endovascular Approach: How Does It Work: Improved Delivery System And Progress To Date
Vicente Rimbau, MD, PhD (PowerPoint Presentation With Synched Audio)
- 10:12–10:17** New Concepts Regarding Type 2 Endoleaks After EVAR And F/B/EVAR: How Are They Different: Which Ones Are Dangerous And Need To Be Treated And Which Ones Can Be Observed: How Best To Treat
Jessica P. Simons, MD, MPH
- 10:18–10:23** The Alto Endograft (Endologix) Is As Good Or Better Than F/EVAR For Some Short Necked Juxtarenal AAAs: From 5-Year Results Of The UK-COMPASS Trial
Vijay M. Gadhvi, BSc, MB, BS, MSc
- 10:24–10:29** Balloon Expandable vs. Self-Expandable Covered Stent To Treat Aorto-Iliac Occlusive Disease (AIOD): Advantages And Limitations Of Each And When Is Each Proven To Be The Best Treatment: A Systematic Review And Meta-Analysis
Gian Franco Veraldi, Professor
- 10:30–10:40** **Panel Discussion**

SESSION 115 (Grand Ballroom East, 3rd Floor)

AORTIC AND CAROTID TOPICS TOO IMPORTANT TO MISS

Moderators: *Frank J. Veith, MD*
Enrico Ascher, MD
Mark A. Adelman, MD

AORTIC RELATED TOPICS

- 10:41–10:46** RCT Comparing CO₂ vs. Saline Flushing For Stroke Prevention With TEVAR: Do We Really Need CO₂: From The INTERCEPT Multicenter Study
Richard G.J. Gibbs, FRCS
- 10:47–10:52** Successful Factors For Improving Aortic Remodeling After TBAD Treatment With TEVAR And Bare Stent Extension (Petticoat Technique)
Kenichi Hashizume, MD, PhD
- 10:53–10:58** AAA Ruptures Are Not Always A Catastrophic Event: What Is The Best Treatment For Ruptured Aneurysms, Catastrophic And Non Catastrophic In 2025
Felice Pecoraro, MD
- 10:59–11:04** Balloon Optimized Molding For Better Deployment And Sealing Of Alto (From Endologix) Low Profile Endografts For EVAR: How To Do It And How It Helps Prevent Endoleaks And Migration
David J. Minion, MD
- 11:05–11:10** AI Based Auto Image Analysis Systems To Evaluate Aortic And Carotid CT Scans To Determine Lesion Progression And Aneurysm Risk Factors: Will It Work And Current Status
Ravi K. Veeraswamy, MD
- 11:11–11:16** First Clinical Results With A Repositionable Fenestrated And Branched Device To Treat Complex Aortic Aneurysms: How Does This Innovative New Endograft Work
Edwaldo E.D.N. Joviliano, MD, PhD
- 11:17–11:25** **Panel Discussion**

CAROTID RELATED TOPICS

- 11:26–11:31** TCAR Is Safe In Symptomatic And Other High Risk Patients And Technical Tips To Make TCAR Safe With Adverse Anatomy
Jeffrey Jim, MD, MPH
- 11:32–11:37** Open Surgical Rescue For Carotid Stent Complications And Failures: When Is It Necessary And Techniques For Performing It Safely
Jorge Rey, MD
- 11:38–11:43** Endovascular Emergency Treatment Of Carotid Blowout From Head And Neck Cancer Or Carotid Patch Infections: Planning, Preparation And Technical Tips Are Essential
Michael B. Silva, Jr., MD
- 11:44–11:49** The Importance Of Transcarotid Access For TAVRs: The Role Of Vascular Surgeons: Technical Tips And Advantages
Gregg S. Landis, MD
- 11:50–11:55** Impact Of Antiplatelet Regimens On CAS Outcomes: Plavix Alone May Be As Safe As Plavix And Aspirin (DAPT) But Not Aspirin Alone; What Is The Optimal Timing And Dosage: What About Resistance To Plavix
Marc L. Schermerhorn, MD
- 11:56–12:01** The Importance Of Plavix Resistance With TFCAS And TCAR: How To Detect It, How Common Is It; Does It Matter And What To Do About It
Thomas S. Maldonado, MD
- 12:02–12:10** **Panel Discussion**
End of Program O

VEITH Symposium continues with the A-V Access Program in the Grand Ballroom West, 3rd Floor.

PROGRAM P (SESSIONS 116–121)

IMPROVING OUTCOMES IN HEMODIALYSIS ACCESS

Grand Ballroom West, 3rd Floor

SESSION 116 (Grand Ballroom West, 3rd Floor)

IMPORTANT ISSUES IN HEMODIALYSIS ACCESS

Moderators: *Larry A. Scher, MD*
Anton N. Sidawy, MD, MPH

- 8:00 – 8:05** Introduction
Larry A. Scher, MD
Anton N. Sidawy, MD, MPH
- 8:06 – 8:13** The Importance Of Talking To Your Patients About Dialysis Options
Dori R. Schatell, MS
- 8:14 – 8:21** Health Literacy In Patients With Chronic Kidney Disease
Deborah Brouwer-Maier, RN, CNN
- 8:22 – 8:29** Have KDOQI Guideline Revisions Changed Clinical Practice
Charmaine Lok, MD
- 8:30 – 8:37** Point Of Care Ultrasound For Assessing AV Fistula Maturation And Facilitating Safe Cannulation In Outpatient Hemodialysis
George N. Coritsidis, MD
- 8:38 – 8:45** Evolving Algorithms Of Care In AV Access Creation And Maintenance
Rashid Sharaf, MD
- 8:46 – 8:53** Deep Learning Analysis Of Blood Flow Sounds To Detect AV Fistula Stenosis
Herrick Wun, MD
- 8:54 – 9:04** **Panel Discussion**

- 9:05 – 9:12** Volumetric Access Flow: Challenges And Pitfalls
George L. Berdejo, BA, RVT
- 9:13 – 9:20** Clinical Applications Of Volume Flow Measurement In Hemodialysis Access
Robert Shahverdyan, MD
- 9:21 – 9:28** Predicting Mortality Risk In Dialysis: Assessment Of Risk Factors Using Traditional And Advanced Modeling Techniques
Peter Kotanko, MD
- 9:29 – 9:36** Does Preoperative Exercise Or Heat Therapy Improve AV Fistula Remodeling And Reduce Hemodialysis Access Induced Hand Ischemia
Salvatore Scali, MD
- 9:37 – 9:44** Strengths And Weaknesses Of Using VQI And Other Administrative Data Bases To Assess Hemodialysis Access Outcomes
Jeffrey J. Siracuse, MD, MBA
- 9:45 – 9:52** AV Access Revision Using The Viabahn® Endoprosthesis: Post-Market Registry Results
Daniel Patel, MD
- 9:53–10:03** **Panel Discussion**
- 10:04–10:25** **Break – Visit Exhibits And Pavilions (3rd Floors)**

SESSION 117 (Grand Ballroom West, 3rd Floor)

MORE IMPORTANT ISSUES IN HEMODIALYSIS ACCESS

Moderators: *Haimanot (Monnie) Wasse, MD, MPH*
Evan C. Lipsitz, MD, MBA

- 10:26–10:33** Helping Patients Overcome Needle Fear
Dori R. Schatell, MS
- 10:34–10:41** Management Of Infiltration Injuries
Deborah Brouwer-Maier, RN, CNN
- 10:42–10:49** Establishing Protocols For Precertification For Dialysis Access Interventions
Russell H. Samson, MD, RVT
- 10:50–10:57** Tips And Tricks To Achieve Long-Term Dialysis Access Patency
John F. Lucas III, MD
- 10:58–11:05** Management Of Life And Limb-Threatening Complications In The Outpatient Dialysis Center
Neghae Mawla, MD
- 11:06–11:16** **Panel Discussion**

SESSION 118 (Grand Ballroom West, 3rd Floor)

MINISYMPOSIUM: MANAGEMENT OF THE COMPLEX HEMODIALYSIS PATIENT

Moderators: *Larry A. Scher, MD*
Yana Etkin, MD

- 11:17–11:24** Hemodialysis Access In Patients With Chronic Hypotension
Surendra Shenoy, MD, PhD
- 11:25–11:32** Management Of Patients With Recurrent Access Thrombosis
Theodore F. Saad, MD
- 11:33–11:40** Strategies For Access Placement In Patients With Chronic Congestive Heart Failure
John R. Ross, Sr., MD
- 11:41–11:48** Choosing The Optimal Access In Obese Patients
William Jennings, MD
- 11:49–11:59** **Panel Discussion**
- 12:00– 1:00** **Lunch Break - Mercury Rotunda & Ballroom (3rd Floor)**

SESSION 119 (Grand Ballroom West, 3rd Floor)

POLITICAL, ECONOMIC AND LEGAL ISSUES IN HEMODIALYSIS ACCESS

Moderators: *Larry A. Scher, MD*
Anton N. Sidawy, MD, MPH

- 1:00 – 1:07** Potential Impact Of Federal 'Efficiency' Cuts On Chronic Kidney Disease Patients
Terry Litchfield, MPA
- 1:08 – 1:15** A Futuristic View Of Dialysis Access Innovations
Tim Fitzpatrick, BA
- 1:16 – 1:23** How To Improve Oversight Of New Technologies And Next Generation Dialysis Access Devices
Robert E. Lee, MD
- 1:24 – 1:31** Diagnosis And Management Of Hypercoagulable States In Patients With Recurrent Access Thrombosis
Jeffrey H. Lawson, MD, PhD
- 1:32 – 1:39** Update On CMS Quality Metrics In Hemodialysis Access
Evan C. Lipsitz, MD, MBA
- 1:40 – 1:50** **Panel Discussion**

SESSION 120 (Grand Ballroom West, 3rd Floor)

NOVEL TECHNOLOGIES IN HEMODIALYSIS ACCESS

Moderators: *Haimanot (Monnie) Wasse, MD, MPH*
Clifford M. Sales, MD, MBA

- 1:51 – 1:58** The Rise And Fall And Future Of Endovascular AV Fistulas
Robert Shahverdy, MD
- 1:59 – 2:06** First-In-Human Experience With Amplifi™ For Pre-Fistula Vein Dilatation
Surendra Shenoy, MD, PhD
- 2:07 – 2:14** Sixty Years Of Flying Blind In Hemodialysis: Precision Guided AV Access Has Arrived
Erin Moore, MD
Shannon Beardsley, MD
- 2:15 – 2:22** Extended Applications Of The VasQ Device For Creating Hemodialysis Access
George Blessios, MD, PhD
- 2:23 – 2:30** Is There A Role For Intravascular Lithotripsy In Hemodialysis Access
Alexander Ushinsky, MD
- 2:31 – 2:38** First Results Of The DEScover Randomized Trial Of Drug Eluting Stents vs. PTA In Hemodialysis Access
Leonardo O. Harduin, MD, MSc, PhD
- 2:39 – 2:49** **Panel Discussion**

SESSION 121 (Grand Ballroom West, 3rd Floor)

UPDATE ON CLINICAL CHALLENGES IN HEMODIALYSIS ACCESS

Moderators: *Larry A. Scher, MD*
Surendra Shenoy, MD, PhD

- 2:50 – 2:57** Should Intravenous Heparin Be Used During AV Access Creation
Mohamad A. Hussain, MD, PhD
- 2:58 – 3:05** Is Botulinum Toxin Effective Treatment For Digital Ischemia
Fabiola Aguilera, MD
- 3:06 – 3:13** Desperate Options For Hemodialysis Access: What To Do When All Else Fails
Frank T. Padberg Jr, MD
- 3:14 – 3:21** Strategies For Hemodialysis Access In Patients With Implanted Cardiac Devices
Matthew J. Dougherty, MD
- 3:22 – 3:29** Management Strategies For Cephalic Arch Stenosis
Mark G. Davies, MD

- 3:30 – 3:37** Is Regional Anesthesia The Best Option For Hemodialysis Access
Yana Etkin, MD
- 3:38 – 3:45** Should AV Fistula Aneurysm Repair Include Simultaneous Inflow Or Outflow Revision
John R. Ross, Sr., MD
- 3:46 – 3:55** **Panel Discussion**
End of Program P

VEITHSYMPOSIUM ON DEMAND

www.veithondemand.com



**VIEW THE
ENTIRE 2025
VEITHSYMPOSIUM
ONLINE**

Purchase all the Talks, Slides, and Videos
- fully synchronized - and all the Panels.
This Library or Components thereof can be used
as an Educational Resource or Teaching Tool.

**For more information on how to obtain the
VEITHsymposium Online Library, please call
800-987-9314 (select option 3).**

www.veithsymposium.org

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

A

Anne L. Abbott, MD, PhD
Melbourne, Australia

Dorothy B. Abel, BSBME
Columbia, Maryland

Said Abisi, MD
London, United Kingdom

Cherrie Z. Abraham, MD
Portland, Oregon

Steven D. Abramowitz, MD
Washington, District of Columbia

Christopher J. Abularrage, MD
Baltimore, Maryland

Ali F. AbuRahma, MD
Charleston, West Virginia

Zach AbuRahma, DO
Charleston, West Virginia

Joshua D. Adams, MD
Roanoke, Virginia

Mark A. Adelman, MD
New York, New York

Fabiola Aguilera, MD
Bronx, New York

Sam S. Ahn, MD, MBA
Fort Worth, Texas

Francesco A. Aiello, MD, MBA
Worcester, Massachusetts

Jose I. Almeida, MD, RPVI, RVT
Miami, Florida

Jean-Marc Alsac, MD, PhD
Paris, France

Ali Amin, MD, RVT
Reading, Pennsylvania

Gary M. Ansel, MD
Columbus, Ohio

Michele Antonello, MD, PhD
Padua, Italy

George A. Antoniou, MD, PhD, MSc
Manchester, United Kingdom

Frank R. Arko, MD
Charlotte, North Carolina

Edward J. Arous, MD, MPH
Worcester, Massachusetts

Zachary M. Arthurs, MD
San Antonio, Texas

Enrico Ascher, MD
New York, New York

Bernadette Aulivola, MD
Chicago, Illinois

Martin J. Austermann, MD
Münster, Germany

Hamdy Awad, MD
Upper Arlington, Ohio

Faisal Aziz, MD
Hershey, Pennsylvania

Ali Azizzadeh, MD
Los Angeles, California

Nobuyoshi Azuma, MD
Asahikawa, Hokkaido, Japan

B

Sateesh C. Babu, MD
Valhalla, New York

Martin R. Back, MD
Gainesville, Florida

Charles J. Bailey, MD
Atlanta, Georgia

Amanda Baker, MD
Bronx, New York

Jonathan Bath, MD
Columbia, Missouri

Iris Baumgartner, MD
Bern, Switzerland

Hernan A. Bazan, MD
San Francisco, California

Robert E. Beasley, MD
Miami Beach, Florida

Robert J. Beaulieu, MD, MSE
Ann Arbor, Michigan

Adam Beck, MD
Birmingham, Alabama

Jean Pierre Becquemin, MD
Saint-Clément-de-Rivière, France

Christian A. Behrendt, MD
Hamburg, Germany

Sarah Bellemare, MD
New York, New York

Janna Bentley, MD
British Columbia, Canada

George L. Berdejo, BA, RVT
White Plains, New York

Ramon Berguer, MD, PhD
Ann Arbor, Michigan

Todd Berland, MD
New York, New York

Colin D. Bicknell, MD
London, United Kingdom

Rashad A. Bishara, MD, RPVI, MSc
Cairo, Egypt

Jean Bismuth, MD
Tampa, Florida

James H. Black, III, MD
Baltimore, Maryland

Jan D. Blankensteijn, MD
Amsterdam, The Netherlands

John Blebea, MD, MBA
Saginaw, Michigan

Erwin Blessing, MD
Hamburg, Germany

George Blessios, MD, PhD
Buffalo, New York

Dittmar Böckler, MD
Heidelberg, Germany

Michel J. Bosiers, MD
Bern, Switzerland

Oscar H. Bottini, MD
Buenos Aires, Argentina

Lee Bouwman, MD, PhD
Spaubeek, The Netherlands

Jonathan R. Boyle, MD, MA (Cantab)
Cambridge, United Kingdom

Kursat A. Bozkurt, MD
Istanbul, Turkey

Daniela Branzan, MD
Munich, Germany

Clayton J. Brinster, MD
Chicago, Illinois

Marianne Brodmann, MD
Graz, Austria

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Allan L. Brook, MD

Bronx, New York

Benjamin S. Brooke, MD, PhD

Park City, Utah

Thomas G. Brott, MD

Jacksonville, Florida

Deborah Brouwer-Maier, RN, CNN

Lansdale, Pennsylvania

Kellie R. Brown, MD

Milwaukee, Wisconsin

O. William Brown, MD, JD

Royal Oak, Michigan

Robert S. Brown, Jr., MD, MPH

New York, New York

Elchanan Bruckheimer, MBBS

Petah-Tikva, Israel

Richard Bulbulia, MA, MD

Oxford, United Kingdom

Ruth L. Bush, MD, MPH

Galveston, Texas

Jacques Busquet, MD

Paris, France



Keith D. Calligaro, MD

Philadelphia, Pennsylvania

Victor M. Canata, MD, PhD

Asuncion, Paraguay

Ludovic Canaud, MD, PhD

Montpellier, France

Piergiorgio Cao, MD

Roma, Italy

Laura Capoccia, MD, PhD

Frosinone, Italy

Francis Caputo, MD

Cleveland, Ohio

Yuri A. Casseres, MD, MSc

Oranjestad, Aruba

Neal S. Cayne, MD

New York, New York

Kristina R. Chacko, MD

Bronx, New York

Rabih A. Chaer, MD

Stony Brook, New York

Elliot L. Chaikof, MD, PhD

Boston, Massachusetts

Venita R. Chandra, MD

Stanford, California

Heepeel Chang, MD

Hackensack, New Jersey

Robert W. Chang, MD

San Francisco, California

Resmi A. Charalel, MD, MPH

New York, New York

Zhong Chen, MD

Beijing, China

Yung-Wei Chi, DO

Davis, California

Jae S. Cho, MD

Cleveland, Ohio

John Chuback, MD

Paramus, New Jersey

Daniel G. Clair, MD

Nashville, Tennessee

Timothy W.I. Clark, MD

Philadelphia, Pennsylvania

Rachel E. Clough, PhD

London, United Kingdom

W. Darrin Clouse, MD

Charlottesville, Virginia

Frederic Cochenne, MD, PhD

Paris, France

Dawn M. Coleman, MD

Durham, North Carolina

Jill J. Colglazier, MD

Rochester, Minnesota

Anthony J. Comerota, MD

Alexandria, Virginia

Michael S. Conte, MD

San Francisco, California

George N. Coritsidis, MD

Southold, New York

Joshua Cornman-Homonoff, MD

New Haven, Connecticut

Joseph S. Coselli, MD

Houston, Texas

Victor S. Costache, MD, PhD

Bucuresti, Romania

Frank J. Criado, MD

Baltimore, Maryland

Jack L. Cronenwett, MD

Lebanon, New Hampshire

Jacob Cynamon, MD

New York, New York



Guilherme Dabus, MD

Miami, Florida

Michael D. Dake, MD

Tucson, Arizona

Ronald L. Dalman, MD

Stanford, California

R. Clement Darling III, MD

Albany, New York

Jimmy Davaine, MD, PhD

Nogent Sur Marne, France

Alun H. Davies, MA, DM, DSc

London, United Kingdom

Mark G. Davies, MD

Houston, Texas

Gianmarco de Donato, MD

Siena, Italy

Reade A. De Leacy, MBBS

New York, New York

Maria Teresa De Sancho, MD, MSc

New York, New York

Jean-Paul de Vries, MD, PhD

Groningen, The Netherlands

Steven M. Dean, DO

Columbus, Ohio

David H. Deaton, MD

Philadelphia, Pennsylvania and

Crownsville, Maryland

Sebastian E. Debus, MD, PhD

Hamburg, Germany

Chris Delaney, MD

Bedford Park, Australia

Randall DeMartino, MD

Rochester, Minnesota

Colin P. Derdeyn, MD

Charlottesville, Virginia

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Brian G. DeRubertis, MD

New York, New York

David J. Dexter, MD

Norfolk, Virginia

Nuno V. Dias, MD, PhD

Malmö, Sweden

Alan M. Dietzek, MD, RPVI

Neptune, New Jersey

Hasan H. Dosluoglu, MD

Buffalo, New York

Matthew J. Dougherty, MD

Philadelphia, Pennsylvania

Maciej L. Dryjski, MD, PhD

Buffalo, New York

Anahita Dua, MD, MS, MBA

Boston, Massachusetts

Joseph J. DuBose, MD

Austin, Texas

David M. Dudzinski, MD

Boston, Massachusetts

Audra A. Duncan, MD

London, Ontario, Canada

E

Matthew J. Eagleton, MD

Boston, Massachusetts

John F. Eidt, MD

Dallas, Texas

Hosam F. El Sayed, MD

Norfolk, Virginia

Jens Eldrup-Jorgensen, MD

Portland, Maine

Steve Elias, MD

Englewood, New Jersey

Guillermo A. Escobar, MD

Atlanta, Georgia

Ignacio Escotto, MD

Mexico City, Mexico

Omar L. Esponda, MD

Pineville, North Carolina

Anthony L. Estrera, MD

Houston, Texas

Yana Etkin, MD

New York, New York

Christian D. Etz, MD, PhD

Rostock, Germany

F

Dominique Fabre, MD, PhD

Le Plessis Robinson, France

Gianluca Faggioli, MD

Bologna, Italy

Alex Fairman, MD

Philadelphia, Pennsylvania

Ayman Fakhry, MD

Alexandria, Egypt

Fabrizio Fanelli, MD

Florence, Italy

Alik Farber, MD, MBA

Boston, Massachusetts

Mark A. Farber, MD

Chapel Hill, North Carolina

Peter L. Faries, MD

New York, New York

Jeffrey Farkas, MD

New York, New York

Javairiah Fatima, MD

Danbury, Connecticut

Marcelo Ferreira, MD

Rio de Janeiro, Brazil

Ciro Ferrer, MD, PhD

Rome, Italy

Carlos Alberto Figueroa, PhD

Ann Arbor, Michigan

Aaron M. Fischman, MD

New York, New York

Tim Fitzpatrick, BA

New York, New York

Thomas L. Forbes, MD

Toronto, Ontario, Canada

Brett E. Fortune, MD, MSc

New York, New York

Mazin Foteh, MD

Dallas, Texas

Charles J. Fox, MD

Baltimore, Maryland

Weiguo Fu, MD

Shanghai, China

Naoki Fujimura, MD, PhD

Tokyo, Japan

G

Dennis R. Gable, MD

Dallas, Texas

Vijay M. Gadhvi, BSc, MB, BS, MSc

Essex, United Kingdom

Paul J. Gagne, MD

Darien, Connecticut

Katherine A. Gallagher, MD

Ann Arbor, Michigan

Pierre S. Galvagni, MD, PhD

Florianopolis, Santa Catarina, Brazil

Chirag D. Gandhi, MD

Valhalla, New York

Ripal T. Gandhi, MD

Miami, Florida

Lawrence A. Garcia, MD

Roslyn, New York

Karan Garg, MD

New York, New York

Mauro Gargiulo, Professor

Bologna, Italy

Hugh A. Gelabert, MD

Los Angeles, California

Elizabeth L. George, MD, MS

Palo Alto, California

Patrick J. Geraghty, MD

Saint Louis, Missouri

Jean Luc Gerard, MD

Paris, France

George Geroulakos, MD, PhD

Athens, Greece

Jeff H. Geschwind, MD

Westport, Connecticut

Brian B. Ghoshhajra, MD, MBA

Boston, Massachusetts

Sergio Giancesini, MD, PhD

Ferrara, Italy

Richard G.J. Gibbs, FRCS

London, United Kingdom

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Kathleen D. Gibson, MD

Bellevue, Washington

Jay Giri, MD, MPH

Philadelphia, Pennsylvania

Rocco Giudice, MD

Rome, Italy

Monika L. Gloviczki, MD, PhD

Scottsdale, Arizona

Peter Gloviczki, MD, PhD

Scottsdale, Arizona

Manj S. Gohel, MD

Cambridge, United Kingdom

Jerry Goldstone, MD

Stanford, California

Yosef Golowa, MD

New York, New York

Philip P. Goodney, MD, MS

Lebanon, New Hampshire

David Gordon, MD

Mt. Kisco, New York

Yann Gouëffic, MD, PhD

Paris, France

William A. Gray, MD

Philadelphia, Pennsylvania

Marcelo Guimaraes, MD, MBA

Charleston, South Carolina

Wei Guo, MD

Beijing, China

H

Eric Hager, MD

Pittsburgh, Pennsylvania

Claudine M. Hamel-Desnos, MD

Paris, France

Sukgu M. Han, MD, MS

Los Angeles, California

Neil Haranhalli, MD

Bronx, New York

Leonardo O. Harduin, MD, MSc, PhD

Niterói, Rio de Janeiro, Brazil

Linda M. Harris, MD

Buffalo, New York

Kenichi Hashizume, MD, PhD

Shinjuku, Tokyo, Japan

Ziv J. Haskal, MD

Charlottesville, Virginia

Stephan Haulon, MD

Paris, France

Don Heck, MD

Winston-Salem, North Carolina

Peter Henke, MD

Ann Arbor, Michigan

Jan M.M. Heyligers, MD, PhD

Tilburg, The Netherlands

Caitlin W. Hicks, MD, MS

Baltimore, Maryland

Anil P. Hingorani, MD

Brooklyn, New York

Jade S. Hiramoto, MD

San Francisco, California

Joshua A. Hirsch, MD

Boston, Massachusetts

Tobias Hirsch, MD

Halle, Germany

Kim J. Hodgson, MD

Springfield, Illinois

Tal M. Hörer, MD, PhD

Örebro, Sweden

Andrew Holden, MBChB

Auckland, Australia

Misty D. Humphries, MD, MAS

Sacramento, California

Mohamad A. Hussain, MD, PhD

Boston, Massachusetts

O

Osamu Iida, MD, PhD

Osaka, Japan

Sriram S. Iyer, MD

New York, New York

J

Glenn Jacobowitz, MD

New York, New York

Michael R. Jaff, DO

Delray Beach, Florida

Krishna Jain, MD

Chicago, Illinois

Houman Jalaie, MD, PhD

Aachen, Germany

Aleksandra Jaworucka-

Kaczorowska, MD, PhD

Gorzów Wielkopolski, Poland

Arjun Jayaraj, MD

Jackson, Mississippi

Michael P. Jenkins, MBBS, BSc, MS

London, United Kingdom

William Jennings, MD

Tulsa, Oklahoma

Arun B. Jesudian, MD

New York, New York

Jeffrey Jim, MD, MPHS

Minneapolis, Minnesota

Juan Carlos Jimenez, MD, MBA

Los Angeles, California

Ravul Jindal, FRCS

Chandigarh, India

Matthew S. Johnson, MD

Indianapolis, Indiana

Douglas W. Jones, MD, MS

Worcester, Massachusetts

William D. Jordan Jr., MD

Augusta, Georgia

Matthieu M.J. Josnin, MD

La Roche sur Yon, France

Edwaldo E.D.N. Joviliano, MD, PhD

São Paulo, Brazil

K

Rafi Kabarriti, MD

Bronx, New York

Loay S. Kabbani, MD, MHSA

Detroit, Michigan

Lowell S. Kabnick, MD

Lake Worth Beach, Florida

Andrea Kahlberg, MD

Milano, Italy

Stavros K. Kakkos, MD, PhD

Patras, Greece

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Manju Kalra, MBBS

Rochester, Minnesota

Vikram S. Kashyap, MD

Grand Rapids, Michigan

Piotr M. Kasprzak, MD

Regensburg, Germany

Konstantinos Katsanos, MSc, MD, PhD

Patras, Greece

Athanasios Katsargyris, MD

*Nuremberg, Germany and
Athens, Greece*

Barry T. Katzen, MD

Miami, Florida

Andreas Kaubisch, MD

New York, New York

Stefan C. K  nel-Pierre, MD

Miami, Florida

Deepak Khatri, MD

Bronx, New York

Neil M. Khilnani, MD

New York, New York

Ali B. Khoyneshad, MD, PhD

Bel Air, California

Milan Kinkhabwala, MD

New York, New York

Melissa L. Kirkwood, MD

Dallas, Texas

Tilo K  lbel, MD, PhD

Hamburg, Germany

Raghu Kolluri, MD

Columbus, Ohio

Ralf R. Kolvenbach, MD

Duesseldorf, Germany

Kimihiko Komori, MD, PhD

Nagoya, Japan

Stavros V. Konstantinides, MD

Mainz, Germany

Peter Kotanko, MD

New York, New York

Panos Kougias, MD, MSc

Brooklyn, New York

Zvonimir Krajcer, MD

Houston, Texas

Dainis K. Krievins, MD

Riga, Latvia

Boonprasit Kritpracha, MD

Hat Yai, Songkhla, Thailand

Waclaw B. Kuczmik, MD, PhD

Katowice, Poland

Steven Kum, MD

Singapore

Toru Kuratani, MD, PhD

Osaka, Japan

Christopher J. Kwolek, MD, MBA

Boston, Massachusetts

L

Nicos Labropoulos, PhD

Stony Brook, New York

Mario L. Lachat, MD

Zurich, Switzerland

Brajesh K. Lal, MD

Baltimore, Maryland

Glenn M. LaMuraglia, MD

Boston, Massachusetts

Gregg S. Landis, MD

New Hyde Park, New York

Werner Lang, MD

Erlangen, Germany

Kamphol Laohapensang, MD

Chiang Mai, Thailand

Igor A. Laskowski, MD, PhD

Valhalla, New York

Peter F. Lawrence, MD

Los Angeles, California

Jeffrey H. Lawson, MD, PhD

Durham, North Carolina

Jason T. Lee, MD

Stanford, California

Robert E. Lee, MD

Grosse Pointe Shores, Michigan

Seon-Kyu Lee, MD, PhD

Bronx, New York

W. Anthony Lee, MD

Boca Raton, Florida

Christos D. Liapis, MD

Athens, Greece

Michael K.W. Lichtenberg, MD

Arnsberg, Germany

David S. Liebeskind, MD, MBA

Los Angeles, California

Timothy K. Liem, MD, MBA

Portland, Oregon

Francesco Liistro, MD

Arezzo, Italy

Jes S. Lindholt, MD

Odense, Denmark

Thomas F. Lindsay, MDCM

Toronto, Ontario, Canada

Evan C. Lipsitz, MD, MBA

New York, New York

Terry Litchfield, MPA

Blanchardville, Wisconsin

Armando C. Lobato, MD, PhD

S  o Paulo, Brazil

Ian Loftus, MD

London, United Kingdom

Shang Loh, MD

Philadelphia, Pennsylvania

Joann M. Lohr, MD

Columbia, South Carolina

Charmaine Lok, MD

Toronto, Ontario, Canada

Joseph V. Lombardi, MD, MBA

Pomona, New Jersey

Robert A. Lookstein, MD, MHCDL

New York, New York

Qingsheng Lu, MD

Shanghai, China

John F. Lucas III, MD

Greenwood, Mississippi

Marzia Lugli, MD

Modena, Italy

Alan B. Lumsden, MD

Houston, Texas

Fedor Lurie, MD, PhD

Toledo, Ohio and Ann Arbor Michigan

Sean P. Lyden, MD

Cleveland, Ohio

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

M

Thanila A. Macedo, MD

Houston, Texas

Carlos Clayton Macedo de Freitas, MD, PhD

São Paulo, Brazil

Lindsay Machan, MD

Vancouver, British Columbia, Canada

Edward G. Mackay, MD

St. Petersburg, Florida

Jason N. MacTaggart, MD

Omaha, Nebraska

Mahesh V. Madhavan, MD, MS

New York, New York

David C. Madoff, MD

New Haven, Connecticut

Dale Maharaj, FACS

Port of Spain, Trinidad and Tobago

Michel S. Makaroun, MD

Pittsburgh, Pennsylvania

Mahmoud B. Malas, MD, MHS

San Diego, California

Thomas S. Maldonado, MD

New York, New York

Anuj Malhotra, MD, RPVI

Mineola, New York

Martin Malina, MD, PhD

London, United Kingdom

Nicola Mangialardi, MD

Rome, Italy

Armando Mansilha, MD, PhD

Porto, Portugal

Ashraf Mansour, MD

Grand Rapids, Michigan

Marco G. Manzi, MD

Abano Terme, Italy

Michael L. Marin, MD

New York, New York

Gabriele Maritati, MD

Rome, Italy

Natalie A. Marks-Ascher, MD, RPVI, RVT

Brooklyn, New York

William A. Marston, MD

Chapel Hill, North Carolina

Klaus D. Mathias, MD

Hamburg, Germany

Jon S. Matsumura, MD

Aurora, Colorado

Mark A. Mattos, MD

Flint, Michigan

Neghae Mawla, MD

Dallas, Texas

Steven Maximus, MD

Houston, Texas

David T. McGreevy, MD, PhD

Örebro, Sweden

James F. McKinsey, MD

New York, New York

Robert B. McLafferty, MD, MBA

Portland, Oregon

Barend M.E. Mees, MD, PhD

Maastricht, The Netherlands

Manish Mehta, MD, MPH

Latham, New York

Mark H. Meissner, MD

Seattle, Washington

Germano C.G. Melissano, MD

Milano, Italy

Matthew W. Mell, MD, MS

Sacramento, California

Matthew T. Menard, MD

Boston, Massachusetts

Bernardo C. Mendes, MD

Los Angeles, California

Valerie M. Merkle, PhD

Silver Spring, Maryland

D. Christopher C. Metzger, MD

Columbus, Ohio

Mark W. Mewissen, MD, RVT

Milwaukee, Wisconsin

Claude Mialhe, MD

Le Tholonet, France

James Milburn, MD

New Orleans, Louisiana

Joseph L. Mills, MD

Houston, Texas

Ross Milner, MD

Chicago, Illinois

David J. Minion, MD

Lexington, Kentucky

Jorge A. Miranda, MD

Houston, Texas

Erica L. Mitchell, MD, MED

Memphis, Tennessee

J Mocco, MD, MS

New York, New York

Bijan Modarai, PhD

London, United Kingdom

Irwin V. Mohan, MBBS, MD

Sydney, Australia

Frans L. Moll, MD, PhD

Utrecht, The Netherlands

Samuel R. Money, MD, MBA

New Orleans, Louisiana

Peter Monteleone, MD

Austin, Texas

Miguel F. Montero-Baker, MD

Houston, Texas

Robert A. Montgomery, MD, DPhil

New York, New York

Erin Moore, MD

Jacksonville, Florida

Randy D. Moore, MD

Chestermere, Canada

Wesley S. Moore, MD

Los Angeles, California

Robert A. Morgan, MD

London, United Kingdom

John Moriarty, MD

Los Angeles, California

Nicolas J. Mouawad, MD, MPH, MBA

Bay City, Michigan

Patrick E. Muck, MD

Cincinnati, Ohio

Stefan Müller-Hülsbeck, MD

Flensburg, Germany

Dipankar Mukherjee, MD

Falls Church, Virginia

Grace C. Mulatti, MD, PhD

São Paulo, Brazil

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Erin H. Murphy, MD
Charlotte, North Carolina

Piotr Musialek, MD, DPhil
Krakow, Poland

Firas F. Mussa, MD
Houston, Texas

Pramook Mutirangura, FRCS
Bangkok, Thailand (EDINBURGH)

Piotr Myrcha, MD
Warsaw, Poland

N

Yuliia Nahaliuk, MD
Kiev, Ukraine

Nicolas Neaume, MD
Toulouse, France

Peter K. Nelson, MD
New York, New York

Richard F. Neville, MD
Fairfax, Virginia

Christoph A. Nienaber, MD, PhD
London, United Kingdom

Sigrid Nikol, MD
Hamburg, Germany

Samy S. Nitecki, MD
Haifa, Israel

Katariina M. Noronen, MD, PhD
Helsinki, Finland

F. Scott Nowakowski, MD
New York, New York

Furuzan Numan, MD
Istanbul, Turkey

Andriy O. Nykonenko, MD, PhD
Zaporizhzhia, Ukraine

O

Thomas F. O'Donnell, Jr., MD
Boston, Massachusetts

Andrea T. Obi, MD
Ann Arbor, Michigan

Paulo E. Ocke Reis, MD, PhD
Niterói, Rio de Janeiro, Brazil

Gustavo S. Oderich, MD
Houston, Texas

Sarah Onida, MD, PhD
London, United Kingdom

Alisha Oropallo, MD
New York, New York

Alvaro Orrego, MD
Vina del Mar, Chile

Matteo Orrico, MD
Rome, Italy

Rafael A. Ortiz, MD
White Plains, New York

Oleg Otlivanchik, MD, PhD
Bronx, New York

Kenneth Ouriel, MD, MBA
New York, New York

Kathleen J. Ozsvath, MD
Troy, New York

P

Frank T. Padberg Jr, MD
Newark, New Jersey

Luca Palombi, MD
Mestre Venezia, Italy

Gustavo Paludetto Oliveira, PhD
Brasilia, Brazil

Jean M. Panneton, MD
Norfolk, Virginia

Rajiv Parakh, MBBS, MS
Gurgaon, India

Kosmas I. Paraskevas, MD
Athens, Greece

Sahil A. Parikh, MD
New York, New York

Jong H. Park, MD, PhD
São Paulo, Brazil

Juan C. Parodi, MD
Buenos Aires, Argentina

Daniel Patel, MD
Daytona Beach, Florida

Rahul S. Patel, MD
New York, New York

Virendra I. Patel, MD, MPH
New York, New York

Lorenzo Patrone, MD
Florence, Italy

Athos Patsalides, MD, MPH
Manhasset, New York

Felice Pecoraro, MD
Palermo, Italy

Bruce A. Perler, MD, MBA
Baltimore, Maryland

Jennifer L. Perri, MD, MBA
Hartford, Connecticut

Ivo Petrov, MD, PhD
Sofia, Bulgaria

Michele Piazza, MD
Padova, Italy

George C. Pontikis, MD
Chicago, Illinois

Matthew Popplewell, MD
Edgmond, United Kingdom

Richard J. Powell, MD
Lebanon, New Hampshire

Giovanni Pratesi, MD
Genoa, Italy

Ourania Preventza, MD
San Antonio, Texas

Robert M. Proczka, MD, PhD
Warsaw, Poland

Q

Elina Quiroga, MD, MPH
Seattle, Washington

R

Joseph D. Raffetto, MD
West Roxbury, Massachusetts

Ansaar T. Rai, MD
Morgantown, West Virginia

Ravi R. Rajani, MD
Atlanta, Georgia

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Seshadri Raju, MD
Jackson, Mississippi

Venkatesh G. Ramaiah, MD
Scottsdale, Arizona

Zoran Rancic, MD, PhD
Lachen, Switzerland

Todd E. Rasmussen, MD
Rochester, Minnesota

Animesh Rathore, MD
Norfolk, Virginia

Mahmood Razavi, MD
Orange, California

Rebeca Reachy Lugo, MD
San Luis Potosi, Mexico

Adam C. Reichard, MD
Cincinnati, Ohio

Michel Reijnen, MD, PhD
Arnhem, The Netherlands

Timothy A. Resch, MD, PhD
Copenhagen, Denmark

Jorge Rey, MD
Miami, Florida

Robert Y. Rhee, MD
Brooklyn, New York

Vicente Riambau, MD, PhD
Barcelona, Spain

Jean-Baptiste Ricco, MD, PhD
Poitiers, France

Götz M. Richter, MD, PhD
Stuttgart, Germany

Joseph J. Ricotta II, MD, MS
Boca Raton, Florida

Celia Riga, MD
London, United Kingdom

William P. Robinson, MD
Springfield, Illinois

Caron B. Rockman, MD
Hackensack, New Jersey

Sean P. Roddy, MD
Albany, New York

Heron E. Rodriguez, MD
Chicago, Illinois

Sonia Ronchey, MD, PhD
Rome, Italy

Kenneth Rosenfield, MD
Boston, Massachusetts

Rachel Rosovsky, MD, MPH
Boston, Massachusetts

John R. Ross, Sr., MD
Orangeburg, South Carolina

Vincent L. Rowe, MD
Los Angeles, California

Maria Antonella Ruffino, MD
Lugano, Switzerland

Gloria Salazar, MD
Chapel Hill, North Carolina

Clifford M. Sales, MD, MBA
Livingston, New Jersey

Russell H. Samson, MD, RVT
Sarasota, Florida

Luis A. Sanchez, MD
St. Louis, Missouri

Wilhelm Sandmann, MD
Duesseldorf, Germany

Timur P. Sarac, MD
St. Pete Beach, Florida

Pierre G. Sarradon, MD
Toulon, France

Sudhakar R. Satti, MD
Newark, Delaware

Salvatore Scali, MD
Gainesville, Florida

Robert M. Schainfeld, DO
Boston, Massachusetts

Andres Schanzer, MD
Worcester, Massachusetts

Dori R. Schatell, MS
Catonsville, Maryland

Dierk Scheinert, MD
Leipzig, Germany

Larry A. Scher, MD
Bronx, New York

Marc L. Schermerhorn, MD
Boston, Massachusetts

Kerstin S. Schick, MD
Munich, Germany

Andrej Schmidt, MD
Leipzig, Germany

Darren B. Schneider, MD
Philadelphia, Pennsylvania

Peter A. Schneider, MD
San Francisco, California

Andrew H. Schulick, MD, MBA
Bethesda, Maryland

Geert Willem H. Schurink, MD, PhD
Maastricht, The Netherlands

Sherry D. Scovell, MD
Boston, Massachusetts

Eric A. Secemsky, MD, MSc
Boston, Massachusetts

Nuttawut Sermsathanasawadi, MD, PhD
Bangkok, Thailand

Carlo Setacci, MD
Siena, Italy

Francesco Setacci, MD
Catania, Italy

Julien G. Sfeir, MD
Beirut, Lebanon

Robert Shahverdyan, MD
Hamburg, Germany

Sherene Shalhub, MD, MPH
Portland, Oregon

Murray L. Shames, MD
Tampa, Florida

Rashid Sharaf, MD
San Antonio, Texas

Aditya Sharma, MD
Charlotte, North Carolina

Palma M. Shaw, MD, MBA, RPVI
Syracuse, New York

S

Theodore F. Saad, MD
Newark, Delaware

Wael E. Saad, MD
Salt Lake City, Utah

Mikel Sadek, MD
New York, New York

Hazim J. Safi, MD
Houston, Texas

Natzi Sakalihasan, MD, PhD
Sart Tilman, Liege, Belgium

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Maxim Shaydakov, MD, PhD
York, Pennsylvania

Malachi Sheahan, MD
New Orleans, Louisiana

Surendra Shenoy, MD, PhD
St. Louis, Missouri

Cynthia K. Shortell, MD
Durham, North Carolina

Chang Shu, MD
*Beijing, China and
Chang Sha, Hunan Province, China*

Anton N. Sidawy, MD, MPH
Washington, District of Columbia

Adnan H. Siddiqui, MD, PhD
Buffalo, New York

Horst Sievert, MD
Frankfurt, Germany

Mikhail T. Silk, MD
New York, New York

Henrik Sillesen, MD, DMSc
Copenhagen, Denmark

Rossi M. Silva, MD
Rio de Janeiro, Brazil

Michael B. Silva, Jr., MD
Galveston, Texas

Jessica P. Simons, MD, MPH
Worcester, Massachusetts

Michael J. Singh, MD
Pittsburgh, Pennsylvania

Niten Singh, MD
Seattle, Washington

Jeffrey J. Siracuse, MD, MBA
Boston, Massachusetts

Pasqualino Sirignano, MD, PhD
Rome, Italy

Jan M. Sloves, RVT
New York, New York

Christopher J. Smolock, MD
New York, New York

Constantinos T. Sofocleous, MD, PhD
New York, New York

Francesco Speziale, MD
Rome, Italy

Francesco Spinelli, MD
Rome, Italy

Lars Stangenberg, MD, PhD
Boston, Massachusetts

James C. Stanley, MD
Ann Arbor, Michigan

Benjamin W. Starnes, MD
Seattle, Washington

Johnny Steuer, MD, PhD
Stockholm, Sweden

Scott L. Stevens, MD
Knoxville, Tennessee

David H. Stone, MD
Hanover, New Hampshire

Patrick A. Stone, MD
Nashville, Tennessee

Michael C. Stoner, MD
Rochester, New York

Martin Storck, MD, PhD
Karlsruhe, Germany

Julianne Stoughton, MD
Boston, Massachusetts

Bjoern D. Suckow, MD
Lebanon, New Hampshire

Sherif A.H. Sultan, MD, PhD
Galway, Ireland

Jonathan Susman, MD
New York, New York

Dylan Suttle, MD
Greensboro, North Carolina

Wilson Y. Szeto, MD
Philadelphia, Pennsylvania

Piotr Szopinski, MD, PhD
Warsaw, Poland

T

Michael G. Tal, MD, MBA
Tel Aviv, Israel

Lawrence N. Tanenbaum, MD
Riverside, Connecticut

Apostolos K. Tassiopoulos, MD
Stony Brook, New York

Gunnar Tepe, MD
Rosenheim, Germany

Katherine A. Teter, MD
Hackensack, New Jersey

Bartley Thornburg, MD
Chicago, Illinois

Bryan W. Tillman, MD, PhD
Columbus, Ohio

Carlos H. Timaran, MD
Dallas, Texas

Giovanni Tinelli, MD, PhD
Rome, Italy

Windsor Ting, MD
New York, New York

Giovanni B. Torsello, MD
Münster, Germany

Margaret Tracci, MD, JD
Charlottesville, Virginia

Santi Trimarchi, MD, PhD
Milano, Italy

Patrick Troy, MD
Hartford, Connecticut

Yamume Tshomba, MD
Roma, Italy

Nikolaos Tsilimparis, MD, PhD
Munich, Germany

Aquilla S. Turk, DO
Greenville, South Carolina

U

Jorge H. Ulloa, MD
Bogota, Colombia

Gilbert R. Upchurch, MD
Gainesville, Florida

Tomasz Urbanek, MD
Katowice, Poland, Europe

Marco V. Usai, MD
Münster, Germany

Alexander Ushinsky, MD
Saint Louis, Missouri

V

Claude D. Vaislic, MD
Le Chesnay, France

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Domenico Valenti, PhD

London, United Kingdom

S. Rao Vallabhaneni, MD

Liverpool, United Kingdom

Jos C. van den Berg, MD, PhD

Lugano, Switzerland

Joost van Herwaarden, MD, PhD

Utrecht, The Netherlands

Isabelle Van Herzele, MD, PhD

Ghent, Belgium

Marc R.H.M. van Sambeek, MD,

Eindhoven, The Netherlands **PhD**

Ramon L. Varcoe, MBBS, MS, PhD,

Sydney, Australia **MMed**

Lina M. Vargas, MD, RPVI

Windermere, Florida

Satish Vayuvegula, MD, MS

Coppell, Texas

Ravi K. Veeraswamy, MD

Charleston, South Carolina

Frank J. Veith, MD

Cleveland, Ohio and

New York, New York

Maarit Venermo, MD, PhD

Helsinki, Finland

Gian Franco Veraldi, Professor

Verona, Italy

Hence J.M. Verhagen, MD, PhD

Rotterdam, The Netherlands

Eric L.G. Verhoeven, MD, PhD

Nuremberg, Germany

Todd R. Vogel, MD, MPH

Columbia, Missouri

Arno von Ristow, MD, PhD

Rio de Janeiro, Brazil

W

Reese A. Wain, MD

Old Westbury, New York

Thomas W. Wakefield, MD

Ann Arbor, Michigan

Ajay K. Wakhloo, MD, PhD

Boston, Massachusetts

Ron Waksman, MD

Washington, District of Columbia

Craig M. Walker, MD

Houma, Louisiana

Grace J. Wang, MD, MSCE

Philadelphia, Pennsylvania

Jinsong Wang, MD

Guangzhou, China

Anders Wanhainen, MD, PhD

Uppsala, Sweden

Haimanot (Monnie) Wasse, MD,

Chicago, Illinois **MPH**

Kapil Wattamwar, MD

Bronx, New York

Fred A. Weaver, MD, MMM

Los Angeles, California

Ido Weinberg, MD, MSc

Boston, Massachusetts

Mitchell D. Weinberg, MD

Staten Island, New York

Joshua L. Weintraub, MD

New York, New York

Mark Welch, FRCS

Manchester, United Kingdom

Rodney A. White, MD

Long Beach, California

Mark S. Whiteley, MS

Guildford, United Kingdom

Michael H. Wholey, MD, MBA

San Antonio, Texas

David M. Williams, MD

Ann Arbor, Michigan

Willem Wisselink, MD

Chicago, Illinois

Mathew D. Wooster, MD, MBA

Charleston, South Carolina

I-Hui Wu, MD, PhD

Taipei, Taiwan

Herrick Wun, MD

New York, New York

Y

Wayne F. Yakes, MD

Englewood, Colorado

Kei Yamada, MD

Boston, Massachusetts

Hooman Yarmohammadi, MD

New York, New York

Kak Khee Yeung, MD, PhD

Amsterdam, The Netherlands

Z

Richard L. Zampolin, MD

New York, New York

Christopher K. Zarins, MD

Stanford, California

Hany M. Zayed, MD

London, United Kingdom

Clark J. Zeebregts, MD, PhD

Groningen, The Netherlands

Sara L. Zettervall, MD

Seattle, Washington

Wayne W. Zhang, MD

Seattle, Washington

Wei Zhou, MD

Tucson, Arizona

R. Eugene Zierler, MD, RPVI

Seattle, Washington

REGISTRATION

Tuesday, November 18 - Saturday, November 22, 2025
New York Hilton-Midtown

FULL REGISTRATION (TUESDAY - SATURDAY)

Tuition

Tuition includes access to any Thursday and Saturday Only Component.

Registration fee includes breakfast, lunch and breaks

Physicians (excluding Fellows/Trainees and Residents) **\$1449**

US 2nd-Year Fellows in an RRC-approved 2-Year Vascular Fellowship **Complimentary**
OR 5th-Year Vascular Resident in an approved Vascular Surgery Residency as of November 2025 **AND** Canadian Vascular Surgery Fellows in Training. **(Tuition is provided through an Educational Grant by W.L. Gore & Associates Inc.)** Letter of verification from Chief of Service must be obtained prior to registration and sent by email to registrar@veithsymposium.org. The letter must include the start and end dates of vascular fellowship.

PGY-6 Fellows & PGY-4 Residents **Complimentary**
 Complimentary tuition is available but limited. Contact admin@veithsymposium.org for more details.

Non-US Fellows and Residents (Trainees) **\$729**
 Letter of verification from Chief of Service must be obtained prior to registration and emailed to registrar@veithsymposium.org.

Non-Finishing U.S. Fellows/Residents, Nurses, Technologists **\$679**

Medical Students **\$529**
 (Letter of verification from Dean must be obtained prior to registration and emailed to registrar@veithsymposium.org.)

Allied Health Care Professionals, Venture Capitalists, and All Others **\$979**

Venous Venous and More Venous® Workshop **\$25**
 Wednesday, November 19, 2025 from 1:00 P.M. - 6:00 P.M.,
 (This is a non-CME Activity.)

THURSDAY ONLY - NOVEMBER 20, 2025

AIMsymposium at VEITHsymposium **\$349**

7:50 A.M. to 6:20 P.M.

Tuition includes access to any VEITHsymposium Thursday Sessions.

Multidisciplinary Stroke Prevention and Treatment **\$349**

7:45 A.M. to 12:10 P.M.

Tuition includes access to any VEITHsymposium Thursday Sessions.

FRIDAY ONLY - NOVEMBER 21, 2025

VEITHsymposium Fellows & Residents Career Development Program

8:00 A.M. to 5:00 P.M.

(This is a non-CME Activity.)

Potential Employer/Recruiter **\$500**

(For Employers/Recruiters not registered at VEITHsymposium)

Tuition includes access to VEITHsymposium Friday Sessions.

SATURDAY ONLY COMPONENTS - NOVEMBER 22, 2025

VEITHsymposium (Miscellaneous Topics) **\$349**

7:00 A.M. - 12:30 P.M.

Tuition includes access to any Saturday Only Component.

Hemodialysis Access (Physicians only) **\$349**

8:00 A.M. - 4:00 P.M.

Tuition includes access to any Saturday Only Component.

Hemodialysis Access (Non-Physicians) **\$150**

8:00 A.M. - 4:00 P.M.

(This rate is not available to industry personnel.)

Tuition includes access to Hemodialysis Access Only.

Cancellation Policy: There is a \$95 cancellation fee if canceled in writing by October 19, 2025. No refunds will be made thereafter.

Online: www.veithsymposium.org/registration

Phone: 800-987-9314, (select option 1) with payment information

Mail: Please make checks payable to the Cleveland Clinic Educational Foundation and print and mail your receipt to:

The Cleveland Clinic Educational Foundation

Attn: EKCC157

P.O. Box 931653

Cleveland, OH 44193-1082

Please notify registrar@veithsymposium.org if sending by overnight mail or courier service.

Email: registrar@veithsymposium.org

Checks must be received by October 31, 2025

REGISTER ONLINE AT

WWW.VEITHSYMPOSIUM.ORG/REGISTRATION



Connecting The **Vascular** Community

SAVE THE DATE

Tuesday - Saturday, November 17-21, 2026

VASCULAR ENDOVASCULAR ISSUES TECHNIQUES HORIZONS

Symposium Chairman

Frank J. Veith, MD

Executive Co-Chairman

Enrico Ascher, MD

Symposium Co-Chairmen

Kenneth Ouriel, MD, MBA

Sean P. Lyden, MD

Sponsored by



www.VEITHsymposium.org



Cleveland Clinic

THE CLEVELAND CLINIC EDUCATIONAL FOUNDATION

PO BOX 931653

CLEVELAND, OH 44193-1082

AGAIN THIS YEAR

- Associate Faculty Global Podium Presentations Program - Wednesday - Friday, November 19-21, 2025
- The Frank J. Veith International Society Associate Faculty Global Podium Presentations Program at VEITHsymposium - Wednesday - Friday, November 19-21, 2025
- World Federation of Vascular Surgery at VEITHsymposium - Wednesday, November 19, 2025
- International Society for Women Vascular Surgeons - Wednesday, November 19, 2025
- AIMsymposium at VEITHsymposium - Thursday, November 20, 2025
- J. Leonel Villavicencio Latin-American Program at VEITHsymposium - Thursday - Friday, November 20-21, 2025
- Vascular Fellows & Residents Career Development Program - Friday, November 21, 2025
- VVVs @ Vs® - Venous Venous and More Venous® Workshop at VEITHsymposium - Wednesday, November 19, 2025
- Point - Counterpoint: Controversies in Modern Venous Disease - Wednesday, November 19, 2025
- Physicians as Industry Employees - Wednesday, November 19, 2025
- Multidisciplinary Stroke Prevention and Treatment - Thursday, November 20, 2025

VEITH[®] SYMPOSIUM

Connecting The **Vascular** Community
www.veithsymposium.org

Tuesday - Saturday
November 18-22, 2025

Download The VEITHsymposium
App To Stay Up To Date



iOS and Android

VEITHsymposium is Compliant with the MedTech Europe Code of Ethical Business Practice.